var title_f27_18_27936="Mycosis fungoides blood";
var content_f27_18_27936=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F70592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F70592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    S&eacute;zary cells within peripheral blood",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    S&eacute;zary cells within peripheral blood. Note the cerebriform nuclear convolution.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Armitage JO, Mauch PM, Harris NL, et al. Non-Hodgkin Lymphomas, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27936=[""].join("\n");
var outline_f27_18_27936=null;
var title_f27_18_27937="Necrotizing scleritis in RA";
var content_f27_18_27937=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Necrotizing scleritis in rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 401px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotizing scleritis in a patient with rheumatoid arthritis has resulted in extreme scleral thinning with prolapse of the underlying uvea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27937=[""].join("\n");
var outline_f27_18_27937=null;
var title_f27_18_27938="HR and BP response in tilt table test";
var content_f27_18_27938=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F56293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F56293&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 571px\">",
"   <div class=\"ttl\">",
"    Heart rate and blood pressure patterns observed in head-up tilt table testing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 551px; height: 348px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are the heart rate and blood pressure responses seen during tilt table testing in patients with various etiologies of syncope, including autonomic failure, neurally mediated syncope, and postural tachycardia syndrome (POTS). The absence of an appropriate reflex-induced increase in heart rate as the blood pressure falls is a useful clue to the presence of autonomic failure. During neurally mediated syncope, parasympathetic (vagal) activity increases as blood pressure declines, slowing the heart. With POTS, tilt table testing typically reproduces the clinical symptoms in association with a heart rate increase &ge;30 beats/min or a maximum heart rate &ge;120 beats/min within the first 10 minutes; these changes are not associated with hypotension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27938=[""].join("\n");
var outline_f27_18_27938=null;
var title_f27_18_27939="Aflibercept (ophthalmic): Drug information";
var content_f27_18_27939=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Aflibercept (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/44/25283?source=see_link\">",
"    see \"Aflibercept (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14933691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Eylea&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F14933694\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent;",
"     </li>",
"     <li>",
"      Vascular Endothelial Growth Factor (VEGF) Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F14933724\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Age-related macular degeneration (AMD):",
"     </b>",
"     Intravitreal injection: 2 mg (0.05 mL) every 4 weeks for 3 months then every 8 weeks thereafter",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Macular edema following central retinal vein occlusion (CRVO):",
"     </b>",
"     Intravitreal injection: 2 mg (0.05 mL) every 4 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F14933725\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F14933726\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F14933727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling (has not been studied); however, no adjustment expected due to minimal systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F14933740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, intravitreal [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Eylea&trade;: 40 mg/mL (0.05 mL) [derived from or manufactured using Chinese hamster ovary cells]",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F14933728\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For ophthalmic intravitreal injection only. Remove contents from vial using a 5 micron, 19-gauge   1",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch filter needle (supplied) attached to a 1 mL syringe (supplied). Discard filter needle and replace with a sterile 30 gauge",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     inch needle (supplied) for intravitreal injection procedure (do not use filter needle for intravitreal injection). Depress plunger to expel excess air and medication (plunger tip should align with the 0.05 mL marking on syringe). Adequate anesthesia and a topical broad-spectrum antimicrobial agent should be administered prior to the procedure.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F14933697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of neovascular (wet) age-related macular degeneration (AMD); treatment of macular edema following central retinal vein occlusion (CRVO)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F14933688\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Aflibercept may be confused with Ziv-aflibercept",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F14933705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Ocular: Conjunctival hemorrhage (12% to 25%), eye pain (9% to 13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Injection site pain (3%), injection site hemorrhage (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Intraocular pressure increased (5% to 8%), cataract (7%), vitreous detachment (6%), vitreous floaters (5% to 6%), conjunctival hyperemia (4% to 5%), corneal erosion (4% to 5%), foreign body sensation (3%), lacrimation increased (3%), retinal pigment epithelium detachment (3%), blurred vision (1% to 2%), retinal pigment epithelium tear (2%), eyelid edema (1%), corneal edema (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Aflibercept antibodies (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Endophthalmitis, hypersensitivity, intraocular inflammation, retinal detachment, retinal tear, thromboembolic events, traumatic cataract",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F14933701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to aflibercept or any component of the formulation; current ocular or periocular infection; active intraocular inflammation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F14933702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Endophthalmitis/retinal detachment: Intravitreous injections may be associated with endophthalmitis and retinal detachments. Proper aseptic injection techniques should be used and patients should be instructed to report any signs of infection (eg, eye pain or redness, photophobia, blurred vision) immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity may present as severe intraocular inflammation; instruct patients to report intraocular inflammation that increases with severity. Rare hypersensitivity reactions (including anaphylaxis) have been associated with another VEGF inhibitor, pegaptanib, occurring within several hours of use; monitor closely. Equipment and appropriate personnel should be available for monitoring and treatment of anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Increased intraocular pressure: Following intravitreal injection, intraocular pressure may increase. Onset is seen within 60 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Thromboembolic events: Risk of thromboembolic events (eg, nonfatal stroke/MI, vascular death) may be increased following intravitreal administration of VEGF inhibitors, including aflibercept.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F14933711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F14933709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F14933698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14933699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14933700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16570449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Eylea Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mg/0.05 mL (0.05 mL): $2220.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F14933730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Intraocular pressure immediately following injection; signs of infection/inflammation (for first week following injection); retinal perfusion; endophthalmitis; visual acuity",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F14933743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Eylea (AU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F14933717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Aflibercept is a recombinant fusion protein that acts as a decoy receptor for vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PIGF). Decoy receptor binding prevents VEGF-A and PIGF from binding and activating endothelial cell receptors, thereby suppressing neovascularization and slowing vision loss.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F14933719\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Low levels are detected in the serum following intravitreal injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: Plasma: 5-6 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Boyer D, Heier J, Brown DM, et al, \"Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion: Six-Month Results of the Phase 3 COPERNICUS Study,\"",
"      <i>",
"       Ophthalmology",
"      </i>",
"      , 2012, 119(5):1024-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?27/18/27939/abstract-text/22440275/pubmed\" id=\"22440275\" target=\"_blank\">",
"        22440275",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      EYLEA Phase 3 Clinical Trials for Wet AMD, Regeneron Pharmaceuticals [data on file, November 2011]",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 86380 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-46BEA4AD38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27939=[""].join("\n");
var outline_f27_18_27939=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933691\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933694\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933724\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933725\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933726\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933727\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933740\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933728\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933697\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933688\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933705\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933701\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933702\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933711\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933709\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933698\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933699\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933700\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16570449\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933730\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933743\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933717\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14933719\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86380\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/86380|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/44/25283?source=related_link\">",
"      Aflibercept (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/18/2342?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?36/41/37524?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27940="Short daily home hemodialysis: The low dialysate volume approach";
var content_f27_18_27940=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Short daily home hemodialysis: The low dialysate volume approach",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Joel D Glickman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27940/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27940/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/18/27940/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H7208619\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of daily home dialysis has increased over the past decade. This increase is driven by increased awareness of better outcomes and quality of life provided by home dialysis and by short daily hemodialysis compared with conventional in-center three times per week hemodialysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This trend has prompted the development of effective hemodialysis equipment that may be used outside of a dialysis center. Although conventional hemodialysis machines have been used for home dialysis, such machines generally employ a high dialysis flow rate. High flow rates potentially increase water and electrical costs often mandating home electrical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    plumbing modifications that render the use of such machine impractical for some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27940/abstract/1\">",
"     1",
"    </a>",
"    ]. This topic reviews the requirements for a home hemodialysis machine and the approach used by NxStage to develop an effective dialysis machine for home use.",
"   </p>",
"   <p>",
"    Issues relating to patient survival and the technical aspects of home hemodialysis, short daily hemodialysis, and nocturnal hemodialysis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=see_link\">",
"     \"Outcomes associated with nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25286?source=see_link\">",
"     \"Organization and elements of a home hemodialysis program\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link\">",
"     \"Technical aspects of nocturnal hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link\">",
"     \"Short daily hemodialysis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link\">",
"     \"Home hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6764688\">",
"    <span class=\"h1\">",
"     REQUIREMENTS OF HOME HEMODIALYSIS MACHINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A home hemodialysis machine should have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Easy to use",
"     </li>",
"     <li>",
"      Require minimal storage space",
"     </li>",
"     <li>",
"      Require no electrical or plumbing modification to the home",
"     </li>",
"     <li>",
"      Are energy and water efficient (ie, not significantly increase water and electricity costs)",
"     </li>",
"     <li>",
"      Are portable for travel",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many home machines that meet some or all of these requirements have been developed or are under development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=see_link&amp;anchor=H8#H8\">",
"     \"Home hemodialysis\", section on 'Home hemodialysis machines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6764751\">",
"    <span class=\"h1\">",
"     FREQUENT LOW VOLUME DIALYSATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to provide effective dialysis with a low dialysate volume, the dialysate must be nearly saturated with uremic solutes such as urea. One home hemodialysis platform that utilizes such an approach is the NxStage home hemodialysis device [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27940/abstract/2\">",
"     2",
"    </a>",
"    ]. Near-saturation of dialysate is achieved by maintaining a very low ratio of dialysate flow rate (QD) to blood flow rate (QB); this ratio",
"    <span class=\"nowrap\">",
"     (QD/QB)",
"    </span>",
"    is termed the flow fraction by NxStage. Utilizing a low flow fraction is in marked contrast to standard hemodialysis platforms that utilize a nearly unlimited supply of dialysate which is generally not as saturated with uremic solutes upon leaving the dialyzer. In conventional hemodialysis, urea clearance increases as either blood flow (QB) or dialysate flow (QD) increases. Although the urea clearance increases as the dialysis flow rate increases, there is a marked decrease in dialysis efficiency (",
"    <a class=\"graphic graphic_figure graphicRef65329 \" href=\"UTD.htm?34/53/35679\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    By contrast, when a low",
"    <span class=\"nowrap\">",
"     QD/QB",
"    </span>",
"    (flow fraction) is utilized, there is much more efficient use of dialysate (urea saturation can theoretically approach 100 percent) (",
"    <a class=\"graphic graphic_figure graphicRef76066 \" href=\"UTD.htm?37/13/38110\">",
"     figure 2",
"    </a>",
"    ) and therefore less dialysate can be used. Under these conditions, urea clearance is approximately equal to the dialysate flow rate. Though the optimal ratio of dialysate to blood flow rate that allows maximum efficiency and a minimum amount of dialysate is in the range of 25 to 33 percent, the use of flow fractions of approximately 40 percent (dialysate urea saturation 90 percent) can achieve target",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    if the volume of dialysate is appropriate (see",
"    <a class=\"local\" href=\"#H7208640\">",
"     'Target Kt/V'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27940/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A decrease in dialysate flow rate (ie, a lower flow fraction) while maintaining the same volume of dialysate results in an increased time on therapy. Given blood flow rates of 400 to 450",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    typical dialysate flow rates are in the range of 100 to 150",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"   </p>",
"   <p>",
"    One consequence of maintaining a fixed, low ratio of dialysate to blood flow rate (flow fraction) is that an increase in the prescribed dialysate volume will result in an increased time on dialysis. (See",
"    <a class=\"local\" href=\"#H7208633\">",
"     'Ultrafiltration'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Similarly, a decrease in blood flow rate dictates a proportionate decrease in dialysate flow rate, or else dialysate urea saturation and",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    will decrease.",
"   </p>",
"   <p>",
"    More importantly, a fixed flow fraction maintains dialysate saturation and delivered",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    regardless of any intradialytic changes in blood flow.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208633\">",
"    <span class=\"h2\">",
"     Ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with conventional hemodialysis or peritoneal dialysis, ultrafiltration is required in order to maintain euvolemia. The ultrafiltration volume generally does not affect the dialysis time of patients who are dialyzed utilizing standard technology (providing the volume remains within hourly ultrafiltration parameters). The ultrafiltration volume increases the dialysis time of patients using the NxStage System One&trade; dialysis device, since these machines fix the ratio of QD (fluid leaving",
"    <span class=\"nowrap\">",
"     dialyzer)/QB.",
"    </span>",
"    The amount of total ultrafiltrate volume per treatment is added to the total dialysate volume per treatment, which increases the total fluid volume leaving the dialyzer (prescribed dialysate volume plus ultrafiltration volume). Since the flow fraction is fixed (as it is with NxStage), the increased volume requires an increase in the treatment time. In some patients, this provides an incentive to limit fluid intake. For example, to ultrafiltrate an extra liter, it might require another 6 to 10 minutes of treatment time, depending on the flow fraction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208640\">",
"    <span class=\"h2\">",
"     Target Kt/V",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urea kinetic modeling has not been validated as a measure of adequate dialysis for more frequent low volume hemodialysis modalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=see_link\">",
"     \"Kt/V and the adequacy of hemodialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best measure of adequacy of more frequent dialysis therapies is unknown, though several have been proposed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27940/abstract/4\">",
"     4",
"    </a>",
"    ]. Dialysis Outcomes Quality Initiative guidelines and recommendations for target standardized",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    per week are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link&amp;anchor=H12#H12\">",
"     \"Short daily hemodialysis\", section on 'Dialysis prescription and dose monitoring'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=see_link&amp;anchor=H30#H30\">",
"     \"Short daily hemodialysis\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208647\">",
"    <span class=\"h2\">",
"     Volume of dialysate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prescribing the appropriate volume of dialysate is conceptually similar to prescribing appropriate dialysate volume in peritoneal dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=see_link&amp;anchor=H11#H11\">",
"     \"Adequacy of peritoneal dialysis\", section on 'Weekly Kt/Vurea'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The volume of distribution of urea (V) is estimated to be equal to body water. Larger patients have larger volumes of distribution of urea (V) and therefore require a higher product of clearance X time (Kt) to achieve the target",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"    The clearance (K) during dialysis is theoretically adjusted by changing either the volume of dialysate or the saturation of urea in the dialysate fluid.",
"   </p>",
"   <p>",
"    Among patients undergoing low volume frequent hemodialysis six days per week, most clinicians target a standardized weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    urea of 2.0 to 2.1, or a per treatment",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    urea of approximately 0.5. As an example, a 70 kg male who has a urea volume of distribution of 35 liters (assuming V is 50 percent of body weight in kilograms), would need to use 17.5 liters of 100 percent saturated dialysate, providing no or only minimal ultrafiltration was required. If",
"    <span class=\"nowrap\">",
"     QD/QB",
"    </span>",
"    is in the range of 25 to 33 percent then saturation is about 90 percent (",
"    <a class=\"graphic graphic_figure graphicRef65329 \" href=\"UTD.htm?34/53/35679\">",
"     figure 1",
"    </a>",
"    ). Thus a 70 Kg male would need 20 liters of fluid to meet the daily",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    goal of",
"    <span class=\"nowrap\">",
"     0.5/treatment",
"    </span>",
"    if there was no ultrafiltration to add to convective urea clearance (20L x 0.9",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    35L = 0.5). In hemodialysis, if dialysate saturation is maximized with a low ratio of dialysate to blood flow rate (low flow fraction), then the only way to increase",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is to increase the volume of dialysate used. If the patient is undergoing frequent low volume hemodialysis using a system with a fixed ratio, such as NxStage, the dialysate volume is limited. The average dialysate volume used with NxStage therapy is approximately 20 to 30 liters for an adult doing five or six treatments per week. Though initial dialysis prescription is estimated by above calculations, standardized weekly",
"    <span class=\"nowrap\">",
"     Kt/V",
"    </span>",
"    is calculated from measured single pool",
"    <span class=\"nowrap\">",
"     Kt/V.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208654\">",
"    <span class=\"h1\">",
"     DIALYSATE COMPOSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the machine used to deliver the frequent low volume dialysis treatments, the dialysate fluid is made differently. For the NxStage platform, the dialysate is either generated by a self-contained dialysate generating system (PureFlow&trade; SL) or is available as prepackaged &ldquo;travel fluids&rdquo; in 5 liter sterile bags (similar to PD fluids).",
"   </p>",
"   <p>",
"    There are limited options for altering the electrolyte content of the dialysate if using the NxStage. The dialysate buffer used is lactate, which generates bicarbonate when metabolized in the liver.",
"   </p>",
"   <p>",
"    The composition of dialysate is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lactate - 40 or 45",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Potassium - 1.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Sodium - 140",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Calcium - 3.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Magnesium - 1.0",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Chloride - 105",
"      <span class=\"nowrap\">",
"       mEq/L",
"      </span>",
"     </li>",
"     <li>",
"      Glucose - 100",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PureFlow&trade; SL generates dialysate in 40, 50, or 60 liter batches from prepacked concentrate that must be used within 72 hours of initiation of production. The 40",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    lactate only comes in a 60 liter batch and 2",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    potassium only comes in a 60 liter batch with a 45",
"    <span class=\"nowrap\">",
"     mEq/L",
"    </span>",
"    lactate.",
"   </p>",
"   <p>",
"    If using a standard conventional hemodialysis platform to perform frequent low volume hemodialysis, dialysate electrolyte options are similar to those typically available for in-center hemodialysis treatments.",
"   </p>",
"   <p>",
"    Marked changes in serum electrolytes do not occur during dialysis among patients using frequent low volume hemodialysis because of the relatively low volume of dialysate used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208661\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;If using standard center hemodialysis platforms for frequent low volume hemodialysis,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pumps can be used. NxStage System One&trade; does not have a heparin pump. Instead, a single bolus of heparin is used at the initiation of dialysis. A typical dose of heparin for a two to three hour treatment is 2000 to 3000 units.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7208668\">",
"    <span class=\"h1\">",
"     DIALYZER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard center HD platforms use typical blood lines and dialyzers. NxStage System One&trade; utilizes a pre-packaged cartridge system that includes dialysate, blood, and saline infusion lines. The cartridge is available with or without a pre-attached, gamma sterilized, polyethersulfone dialyzer (membrane area 1.6 m",
"    <sup>",
"     2",
"    </sup>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1155835\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The increase in home dialysis has led to the development of effective hemodialysis equipment that may be used outside of a dialysis center. Ideally a home hemodialysis machine should be portable, easy to use, have minimal storage space requirement, require no electrical or plumbing modification to the home, and be energy and water efficient. (See",
"      <a class=\"local\" href=\"#H7208619\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H6764688\">",
"       'Requirements of home hemodialysis machine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NxStage equipment provides effective dialysis with very low volumes of dialysate by maintaining a very low flow fraction (the dialysate flow rate divided by the blood flow rate). This allows for the efficient use of dialysate and minimizes the requirement for storage supply space and the use of water. (See",
"      <a class=\"local\" href=\"#H6764751\">",
"       'Frequent low volume dialysate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To be most efficient with dialysate saturation, the blood flow rate should be approximately three times greater than dialysate flow rate resulting in flow fractions of about 33 percent. (See",
"      <a class=\"local\" href=\"#H6764751\">",
"       'Frequent low volume dialysate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In systems that use a fixed ratio of dialysate effluent flow to blood flow, increases in the dialysate volume (such as ultrafiltration) mandates increased time on dialysis. A decrease in blood flow rate also requires an increase in treatment time. (See",
"      <a class=\"local\" href=\"#H7208633\">",
"       'Ultrafiltration'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Delivering the appropriate amount of dialysis to meet",
"      <span class=\"nowrap\">",
"       Kt/V",
"      </span>",
"      targets requires adjustment of the volume of dialysate. The average dialysate volume used with NxStage therapy is approximately 20 to 30 liters for an adult. (See",
"      <a class=\"local\" href=\"#H7208647\">",
"       'Volume of dialysate'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27940/abstract/1\">",
"      Kohn OF, Coe FL, Ing TS. Solute kinetics with short-daily home hemodialysis using slow dialysate flow rate. Hemodial Int 2010; 14:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27940/abstract/2\">",
"      Clark WR, Turk JE Jr. The NxStage System One. Semin Dial 2004; 17:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27940/abstract/3\">",
"      Leypoldt JK, Kamerath CD, Gilson JF, Friederichs G. Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates. ASAIO J 2006; 52:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27940/abstract/4\">",
"      Gotch FA. The current place of urea kinetic modelling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13 Suppl 6:10.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14021 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-71122602D8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27940=[""].join("\n");
var outline_f27_18_27940=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1155835\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7208619\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6764688\">",
"      REQUIREMENTS OF HOME HEMODIALYSIS MACHINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6764751\">",
"      FREQUENT LOW VOLUME DIALYSATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7208633\">",
"      Ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7208640\">",
"      Target Kt/V",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7208647\">",
"      Volume of dialysate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7208654\">",
"      DIALYSATE COMPOSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7208661\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7208668\">",
"      DIALYZER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1155835\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/14021\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/14021|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/53/35679\" title=\"figure 1\">",
"      Urea clearance NxStage vs conventional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/13/38110\" title=\"figure 2\">",
"      Flow fraction and solute saturation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/58/1962?source=related_link\">",
"      Adequacy of peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19144?source=related_link\">",
"      Home hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/14/6378?source=related_link\">",
"      Kt/V and the adequacy of hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/44/25286?source=related_link\">",
"      Organization and elements of a home hemodialysis program",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/24/3465?source=related_link\">",
"      Outcomes associated with nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18137?source=related_link\">",
"      Short daily hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27941="Ultrasound of renal duplex system and ectopic ureter";
var content_f27_18_27941=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F86775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F86775&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 533px\">",
"   <div class=\"ttl\">",
"    Ultrasound of renal duplex system and ectopic ureter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 513px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound images of renal duplex system with ectopic upper pole ureter. Asterisks denote the ectopic ureter with its insertion behind the bladder. White arrowheads outline nonhydronephrotic normal lower pole.",
"    <div class=\"footnotes\">",
"     UP: upper pole.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27941=[""].join("\n");
var outline_f27_18_27941=null;
var title_f27_18_27942="Shedding epithelial cell PI";
var content_f27_18_27942=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F73364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F73364&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Shedding of epithelial cells",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 440px; height: 428px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGsAbgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKM0Ug6mgBaKKKACiiigAooooAKKKKACiiigAooooAKKKKACijNZ+o6xYabGZLu5VQP4VBdz9FUEn8BSbS1Y0m9EaFFcDL8Rle/W1tPDfiRkYH/AEuXT2jhU44zn5v0xWF4h8W+LI7gPYWFy8BGRFbxRKx+rSn+lYTxVOPW/odEcLUl0t6nreaK+eNR8Z+NyoMTa/psrN1+xWl8uPTamGH1rM0/4s+Lre8aEa34e1V0JWS1voDp1ypHY7sLn8TULG03umjX6hV6NH01RXj9h8ctOt5BB4t0LV9CmwD5pi+0QMPVZE6j3AxXpfh7xBpPiOxF5oWo21/bHgvBIG2n0YdVPscGuiFSM/hZzVKNSn8SNWijNFWZBRRRQAUUhOK5O88d6Ss80GmudRlg/wBe8BAggHrJKfkH0BJ9qic4wV5OxUISm7RVzraM15HrXj7XbuOWLw1plxO20n7bOn2Wzi9CZJOXH+6OfWuGbw14s1+6Fx4n8c31xEo/49tGMiL+BAC5/Oud4yF9Fc644KT1k0j6VyPf8qMivm06H4U0xyL7xVrkcyfMRPr/AJTD2IDZFa2ka/oVrIp0/wAXaiuz+F9eW4Vj7iQml9djvYbwUujPfKK4XQPFUssW43CahFjhxtDfmvB/IV1FlrFrdEKGMcn9yQYP4Hoa3hXhPZnPOhOG6NKik3A0ua1MQooooAKKKKACiiigAoNFB6UAFFA6UUAFFFFABRRRQAUUUUAFFFFABSDqaWkHU0ALRRRQAUUUUAFFFFABRRRQAUUVBdXdvaIXuJkjUDPzGk3YEr7E9GQK848Q/FG3sGeHS9Gv7+YHCvM0dnCx/wB6Uhj+CmvM/GviPxdq651rxXpPhLT3H/HvYTSSXDr+ADEn2wOK554unHZ3Oung6k99P67H0FqOtadpx23l5FHISAI87nJPTCjJP5Vz2qeOrG2sp502wpGDuluZFjSP3PJx9Dg149oCounm38N6Xqk8Jj2tdXqG0hfP3nZz+8dm74H0xWfcaRbQ3nnalf2N7d5xbwSqXt7M/wDTGBMknpy+PWuOpjpW00OqGBgn7zudDffEWPXWeLTZ9W1bacMLGzkMY/4F8ox7k1myeKZdPQxpJZW6jot3qSLsPpth3sT9aoPoU96VbUrrxHrEa8rAYPs0Q+vPT6Cr1jo1vA2yz8FQ5PUzBm/XGBXBKs27/wCb/I7VCEVZI5r/AIkFyTstPDcs7c4e8vIwf+BsMA1ctrWW2j36bpGraeh5+0aJqhvIs+rRlufoa6p7G1j+W80Xw7bg9nlbP6Zqunh3RLqcPaXEdhccEGzmyM/Rtp/I1C5lorfkU533f6lDTr69u4ZLS8mh1YtjHmwLBdxntmGTCv8Ag2aXVrPSfEQaDV9CGozwAJ5loWivYR6NE2Nw+hOK6L+xtWtWRDdDVrVlyIbocsPbP9DUk1tZX8fkX1u1tcR/cZmw0Y9Fc849j+dWlP0f9epHMk9Dg7LTbvwxBFeeEfE6/wBkXMhjNhqaNHGsg6xsxyI3+uM0y5min1S7+z6XJpniHGHjtLn7HexNjh4mUql0ucEAnJOBXfoq2cjxamkFzBOPJeWZP9b/AHUmHrj7r1zus+HoI7A2l7HPfaSjMbe6VN9xp2OCjDqYx7dMVXNKOvYakm9T0r4L/ERPF+jGy1Rymv6eRBdK67DKRwJNuBtLYyVxwc16ZXyBqdpe2eu6ffx3Hl+JLRFls7qBjs1yJSPkLf8APUKCOevA619P+BPEtr4u8L2Ws2J/dzghlPBV1JVgfTkV6+FxHtVZ7nl4zDqm+eGzOgqC9uoLG0muryVIbeJS8kjnCqo6kmp68K+M3je3vlvNFhleDTrVgLy9Xn5+vlRD+KU8YHRc7j0rarVVONznoUXWnyrYq+J/iRJr0dxqctlc2/ge0Z44gW2SazN91V28FYgQxOTgjGR2rB0C91nUrdvEHiWIy6UpC6NoqKBHLMT8m1ABuC46kH1qxpGiWVg1nd6hpMep67qEQlj0+Vh9n0y3AyuSc7QF2gkjk5rpbiUXatcm4+zwsPKju2TYsaHhltV6nOMbjjivGqVXUlzN6nsRhGmuWK0MJbPUoLWS+8Qa1Hc6hI37t7py9vZv1ISMZEjj6bR60zTNJ1LUXk8nxR4lc9WuzH5MER9fncZ+gFdUyJI8UlravB5cQgt5bpMCNR/zzTqzGoZrazt5BNrV1cXzr92GchufaME/ris/Z6+X9f1sPnIZIrS10VbkRWvie+UtGt7dLAoU46NI3G0egzWA994quLTyrb/hHdPAP+tt54G2j2wDiti81KHzPPPh97l0GI5LwZVB7KBgfhSWnia9DYSysIkz91EIpNpu17eg1fsY9ppPiK4Hm3PijU5vVNODy8/73yoPzrSu7owRCK90LxNNFgAyNfPliP4sKeD+Nak1xFqgV7qO5iIGMwvuT8jTY7FU5stSeJvRt0f6jimqdvh/r7xc3coaLrUVvceZ4a8QapbSO26XTr6QTbznkKJmwCf9lvwrtNP+MPhc3UtnrE9xo97CdrxX0DR4P61zF7ZyzRY1XSbbUx2mIy3/AH0v9ayLuz0TULM2WqxCTAKwm+4lhH91JgDwOwccVrTr1aXX+v67GVSjTq7o9703UrLVLZbjTbu3u7dukkEgdfzFXM18d6h4Ut/Dd752neJtU8O3J+aOS4t3VH9CJoSVYe+K9F8J/Evxlp1nFDqGl2Pi21iHzX2j3yPcFfVourH8Fr0KWNjLSWhyVMDJK8Hc9/orz7w38YPBeuypbpqyWF6SVNrqKm3kU+h3fLn6Gu/RldQynKkZBHQ11qSlqjinCUHaSsOoooqiQoPSig9KAAdKKB0ooAKKKKACiiigAooooAKKKKACkHU0tc3458Xaf4L0qLUdViu5YZZxbqtrF5j7irN0yOMKeamUlFXew4xcnZbnSUV49L8crR4hJYeE/Etyh6MbdUU/jk1nt8avEF0CNM+HmoMezT3QQf8AoH9ay+tUv5joWDrP7P5HuNFfPtx8W/G7S+XHpHheBs4Mb6qjvn0xvHP4U3UvGvxRuIlf/imdBtiMefcTo2fpkn+VZvG0+hosBV62XzPoSobi7t7YZuJ4oh/tuF/nXzAPEXijUbr7J/wsC2vb0nb5OnaS867vTeqhfxrTMb2Yz4t8WsHPPkiKKGT/AL5UO/54rKWPSWiNP7Pa3l+DPeLnxRolsAZ9TtlBOB8+cn29axdX+IWlWOFRg8rcKsjBCx7YXlufpXhMvibRtLkk/sS0vb5nOfNuGwT/AMDcFh9FArMj1fxDKnlaXbrYQnJK28DO757tI2WY1yTzOWyt+ZvDL49T1nW9Y8aX5cm/0jRbdgRtEMs8wHsSVGfwrzzUNHsri8MuueKNW1HH3l/tCG1iPsVDO1ULL4e63qRWa8R1z0e7mwT+Bya6az8CaNpag6pftNKOfItVxn2yef5VzSq1amtn8zqjGFPRP7hLL+wEiS00wCGToBpv764b/tptB/HIrUsbK6sv+QP4ZVZM5+0T3EbSOe5Zh8x+ma1NPvZYLdYNI0lIrdRgHBZiPc06R9bnyGAiU8YAVcVSj1/Jf5kORhXnh/XdXuAddvYraHqUMwCj6IDzWtaaVYaRbmOwK724efzURvwbqPwFEfh24d9ztHzyWJLGri6BbQjMsksp9I1ApQpWd7a92wc7qxTRzEd0LWBfs8900hH6VG0Wp3kpK6lEzAZ2xTnAH0FaBsrJBzYXOP7zyqg/U1E9vpCyIPtMcLHukrbh+IyPzrTkfUm5Ug/tJGZBc2Vwcf6ueZWz9Aaq3sDySiO/0FozjdvtjjI9RwQa3PswuYjG17Hcx+k8COcf7ynIpumpDYSyW+n3sac/PbTElCf9ljyKXIFyPQVESFLd5JYD963m+/GfbsfwrUuQTDloUuYfR/vJ7A+lSNGJQGmgKzdtjAg+6t3/AB5p5ydrhtrA8MeBn0YetbJWViblCOGyuLWS3dm8lxsZX5aPPTB9M9KwgDL59o0rxX1pMsYk6fOBiN2x/Cw4b6Cti/ikt5hdWw2nJDKedpPY+xrM1hil/BrEUe62u0FpeqB/qx/f9setZTKicpcSW50S7aWHGnfaGaVCuZdOmU5bZ6FThgR1WvSfgrOlnf8AinRkZGiW9TUICn3THcxCT5R/dDBsGuUuofL1C5lnX/QtTQ2t+AM+XKuV3/iCDVD4XXN/ofjfw3a3+Qrpc6JM+ARI0GXhYdwCknXvxWmDfJUSCvH2lKS+f6/oetfE7xI+j6THp2llJNf1VxaWMRPQtwZDj+FRkk+1eAeH/CT654vWd/N/4RvSZ/IWSQZN00bcnHQvJIST7HFeieIZn1H4pav4k4Nh4btG02DP/LS6ZQzY+m8L9ara2t1omkWlpGUjht7fyoD/ABPdSKfMkPsiMx/3jV4upzS12RGGh7Kmkt3/AF/XzI7q7h1LV7uBQogEhn1G7Xo6p0jB/ur90ep6Vci+0/b2uJFjbU7j/UW7HItI+u5h/DgY4/GpdE0eHTNFihTBvischjcFsPyYww9B1PrjJ4FTfZILe4ks0m82Wch7gKd8056kHtGufWueMZbs0bWyGRhvIl8i4YIxxNfz5y3+zH3xT9Ph2Bl0yPZnhruZctn0UDvWgYLiW4R3RZpv4N/yQxj0UdW+tWpI/LB+1S+ZMy7QFUqAPQADP41ook3MlrO5WdWj1G6GPvs0m8t7BFJ/Wr0bNkF9MknZf+Wskaqx/DFNkkCR7R9oWMfwwQFB+JPNV1e0YnLXKH1JDU9hF/8AfN+9Z7m3CnAjKAj8hTXSzn5dlEnfaNmfwNRxBBgw3YH+9kVZ3SyLhhBOPZgDVAV/7OXGbeeSM+o5/UU2S2utpE0lncr6SwmRv8ae8caH54Z4j6qcigSTBdsEsE6+knysPz/xpWQGT5dpaPIHNtFDIP3luZCsDe/luuAfpWLfaJ4U1OXMdrokV5kFJYZUhckf3Sh3A/hXTz38lvlZ0urbPfYJU/Jv8axNSuNSuIpHtINJ1O3AJK/Zl8wexT7w/CspPlWn5Fxvc5/xOmkNZwabqx0W6vtwjkOuO8c2znlboxgk56ZB4pvhnwdr+gvHffD7xavlqMrpt1cfabYg9RujOCPfaKdF43mtYDZT6LYzWg4MLu5A/B91XIotPu4Te3ngq8soXG77TYyFSB/e2rtOKzp4mLfuPb1/yZpKDtZ7fI66w+IvjHTgB4p8CXEsS8Pc6LOtx+IiJ3Y/Gup0f4meFNUmWBdUWzuiOYNQie1cH0/eAAn6E15LLBYajBbQ6V4n1VXgcvApnj81WPqrhd303Grok8cFSi3WnazABg22rac9qzfRgCv61208bN+ZyVMHTfkz36N1kQMjBlIyCDkGlPSvCbXUtb0OKa6tPBuo2t3jKw2c6TwyN26MNo/4Ca6jwV4+1vVtYtdP1nwvqmneeSvnSQ7o1wpPLDG3pjkV2U8XGTSejZxVMJKF2tUj08dKKF6UV1HKFFFFABRRRQAUUUUAFFFFABXGfFISnQLdoHKSJdKQyxo7D5H6byFB9zXZ1wnxfayXw3anUfK8oXi4Eis2W2P0CkZPXqcVhif4UjbD/wASJ45rujnVpEl1efVZzGMKJLu1hUD6gnH5VnQ+EI7g/wCgeHtJucd5tTmlOffbgV0Vte6EkbSRWumwuDgG7T5j7hAGP6inTeIGddqa+1vGP4LCx2E/ixrwLxWrf4r/AIB7nvdCjZ+FtZssSsfCmiOudkqQkvH6lSx61Um8L6DLcG71rxJa61fHobh2EY+qoMt+Yqd7fTbyQPNHrGpydjNKB+HAJrTg0CFcND4e1FmPRJpcIPxABpc0n8K/P9EO9t2MhsFksRZWfiCFLEjb9j0yNIFPtmQljUFv4GhiYmLQ7i4z8xludQRA3/fIrWS2ns2z5WkaU3rt3yj+Zpst1CrFrjUL2/f/AJ5hjFGT9euPoKpxTXvf199yOZ9AtdK/sw/K+gaV6EFriQ/iTW5aXbomRd6nqbHpsgEafyFc/aPc3EhOnaRaEjqyw+Z+ZY1rQ2et3PFzeeSO6Kx4H0Xirhp8K/r8vwJk77k1zPeyljNLb2Ctwd0geQj8M/pio7SzgCboLaS4xyZZT5cefp/9erK2Ol2RId5bmfufLMnP0HH508Nvb59O1K6ToqyhY41/4CMVpy9ybjmJeLfdXG6IcbVOyIewPU/gKc15LboEtooIz/CZnCfknX86bcjUJyjwaJEzJ9xpZQwX6KDiqMtt4gaVn+yWkMjclxs3fmSTTbsA64j1e/8AkaaF1PO1ZBj+VRJoM3W4uIlPpGd5/mKDaeI3BEkx2n0uEA/SmW+nIsm251GAS/8APOEmZ8/hU77r7xlldFh7rcsfXMY/rTzo8GOY7n6Fox/Wp7fTImGWmukHrJDsH86tjSSADFCJh1DNPjP5CrUV2JM2PToreQOloqMOjy3QBH0xVx4re8Ci72CQDCyrOrEfyzUv9m3GeNNg+pkJ/rUo06VBl4LOIDqdpemkFxtraXFohWBkubc8lP8A63+FWseYTtj2yMPnifjd7ioYriG3yv2pCQfuxQipvtlvKwbzCrAYBaMVSEIoWQFAQGA2lH7j0rJlQafNLbzf8etzwGIyM9Cre2K15oDMA4f5+u9Rwfc/41nT3MFwTZ6kArsdmSOGPQc9j6GlIaKF3H9k1CaGYZs7pF3DrkAbTg+owDWNbxzwav4Lu7pQw07Wnsbhx1LPiKJsehBSuhntpJ7SW2nJN7p65DH/AJaxno36EH3WsDxFepB4S0rUFO2QarBOxI43RuBk/wDfApQ0mmUtdO5BoUV3rWriNZSNKvNRvdTlAX/WYuGCMT6bVAArSvYxrvjK4Ej/ALi3U5UnCpEp6k9tzZ/Ck+HEX2PwZa3szNvm53MfuRKNz49ASD+dQoWbRIbOBlj1jxIzM755t7Pks5+iA4/2mrKXvO/fUt7tI6bTrt9Rgjv4mQfaQz2wK42p0MzD/a4wD0BHvVDSGiaa5bSLUm0z+/1C4bJnYHPyDgHnPPSs55nuNWfQ9Fma3eIJFduoytpbBdqQrnrI2eff6V1MosrGK3soIWdYABHbp0XHQn+fP1q17z9DN6Akd1Dua1iV5X5bexVM+rMeWP0AFV5ftUO5tV1GUpjIisoGGR+RNWWe9fLXIECdQqNlz+WP51m3t00CCYziNd21Wu55Y1J9PlGD0q3orkiLeWiuZU1PUoUHaaBlH5lauJqNtIAP7SEgP8RCPn8AM1i3Ot6oqH7Rq+iQQNxgRSS5/MVXg177HLltY8PBOoaKElj/AMBUZH41j7VLf+vxHys6tYYZEV0CkHnc0JXP5kUxre2cYVDu7lGCj9Sa54+KdOnJ+2X8FyPSKzk/mWFSRa3oznEMsNuT/FPbHb+eTirVWD2a+8fKzoICseVE10hH8LJgH8cEVWvZrdSPt1tLk9GKZz+INVR4gtI4sTa1ap6LbxF+PrWRc+NtNtXI+1ajdqD0eKML+vNEq0EtWKzNgarZWyYjumt4++/zB/NSKz7nWNDNwsp1qwW5Q5R57Ynaf94YrPuPHnh64BFxcXduh4KPDHLHj6HmsDUNQ8BTSSPNeWOD08v7THn6qMgfhWcqnN8DTNIx7pnXJe6hdz+ZFp2gav382zvQrn3Ct3rEvVeDVG1K8HiTTb4nJuJIUnRfb5ccVgWs/ha1m+0aS2noQfllxqJcfioFbFv8RWuJFgi8R+DzETtYXCXSEL3zv6n2JqGufd/1+D/E05GtUjQs9WuJrkGC+0XU4mzugCC2mOe43jGfbNXjrcWnwuklldafu4b7XbO0LfjGSB+FQRnRZmDQ2uha1cHkJYCKM/huk/pU91rmoRW/k3Gi6vYQ4x+/0xbmID32P0qo8yV2/wBf6+8h2b0X9f15GetylzKraNc/Z5O8mmaiGK/WCYDcPYHNbPhC08VJ410yXUhpuo2YZle8SMwzRrsbGV4B5wOh61yrXdhfTEC28J3kucBf31jLn0+bjP411Xge4lj8WaZBJpkdkjs2Ma7538DdIsnd/k9q0w8rzV31/rpb8TKurQfoezL0FFC9BRXvHiC0UUUAFFFFABRRRQAUUUUAFcJ8YJZIfDVtJFPZ25W8XMt0u5UGx+QMH5vw9a7uvPfjVcPbeGLN4tTt9NY3yDzZ496t8kny4wee/wCFc+K/gyN8N/FieUprIc5PibTpAOpexJP4DbzVqLxBYq3/AB8yXZ7BLGGMH8Tk1if8JIkTBZvFkbkcHydJDD8yBViPxTar016/lz/z7adFEfzNfP8AO49f6/8AAj3OW/T+vuOms7+e8/49LPViOn7t4lH/AKCKtPbm3Xfem5hB7XWoEg/UIM1yx1mC4BJbxNdj0aQIv/joNFvegyhbPw8xkPRrkyTH9cCqVZdXf+vT9SXBnSJdaWr/AD/Y5f8AZigd2P8AwJjV5JZ3iB0/RFZD0aVFx+QrMtxrJjUyS2mmq/RI4wJP++VBar8OjXdy/wC+utSlYj5pciNB/wB9HP6VtFt7IzZZa51a2T96mnWSH+9x+gzVCfW9v+t1ed/9m0twg/NqmudI0SxIN/dyO3+1OBz9BzWdca/4csjttreNmXjItjIfzcgUSly7u3zBK+xattYubp/LsbS5uD/ekuCPzxgVdEevzA4ktLZPRQXI/nXPXXxAtkUKiXe3H3R5US/yNZp8U3F9+9sdFv7ps4DPPLKgP+6gA/Cs/bw/mv8A15F+zl2OyXTLiabyrjWrtpsZKR/LiqGoReHbCVkv9Tv3nX7yJIS36Csiey8QXFosmr6nYaHZyYxDJIImwemY1559zTZdC0vTLcyyXVtqcv8A03vVgi+u1Nzt+lDm3tH7wSXV/cSz+I9AtGxaaTcXBzgNc3LYP4c1tx6vqFpZpd3VhpOh2LciW4yzsv8AsqOSfyrL0O2u5Jo5dGPhKMIwLpbM/nsvoHfJX6gZqzqWjeM5JGmthpMUnbbZCRvpvkLE/WnDmtf8kDUb2ILn4jaeoKxQNeHON0wWJcewXJ/M01fiDbSKFbTrcAdB57D+lV/7I+JZ5WfS/o1tEv8A7JWbqQ+JWmxGS6tLWaIdfIt4Jf0C5/Spcqq1u/u/4JfJB6aff/wDpbbxdYSn95pybf8AYuG/rWlb69pcoyq3sB/6Zy7h/OvNrDxtrsU6yz6DbTuONz6UVbHplQK2pfiFYuoXV/CiRydsZi49sqD+tUq1vif4Euk+iO9gvtMuyI/NZ5G4AmUKT/wIVLcWUUbAZmiJ6KxHP0PQ15xB4r8LTyH7Rp+pWynk+VdBwPwOK6PQ7zTtSlNv4c8S3UEuMi2voQyH6Z4P4Vca0ZaKz/rzIdNrdG1N9ttAxtXd9v3kAwQPXB4I+lVFmtPEFm0koZLyNvKJhO0uSMrgdM9fyqtea9deHLxIPEttthfmK9sAQhGejKeAfbitK1TSNQ1i5hSXy7x4AJFT92Z425V17MR2ZeQarmUnZfcybWMyPUb77Ppmo2ixajaJKbe/nRijCHO0koepGeR2I461z3xTVofAN7ZxxGM2WpR20XOTIMqwbPuWqwmrHwt4wWw1vz47i7dV86JVNtqKk7Q7qceXIM/MR6ZrR+MkJ/4QkEMGKanagsO480Afpiqpptmi92SZsXWjzLolno8D+U/2eKzdh0jQgNM/1/hHuaq3f2Sw1W61KOLzLtLPbEhPyw2inbFGB/ekkHJ9K6m5Q392rDKW8Uj5Xo0jglV/4D1P1ArIjmW+1V5PICabbEuxC5LsgwufUZ6D2FDj2M1LuN0LQZtItUG6N9QnzLcTsMs8zZLO3suSFWrk1ysG5bGKK5uTwGnkEe4+uSDz+FS3kd1eeXFPdGzgmO3y48ea/HTPb1NcXqfivwRo11NZ3FpNdzxOY2Jty5yOp3McH6ihtQVloLd3NG81XxpDNGP+EfgMbc7o5fNOP++gKr3XiG5wE1GbU7Jwc7PsET8+xyahtPG3hK+YWul2dw08o2iP7OyBfxB4/CtGK61iPbDbLpcsZGPK+3tHN+DEnms/SV/68rD+RBA+oXhDaXr7TxEZK3VjyD6YC4q0+hapdwN9sXSL3jKiexaP/wAfXBH61k3lpq08rfa9L8SKvQ+TrmQPcDA5plr4PeWQXC3viiFz2lvoy357qSV9LN/f+ozTtfCk7MDPoehqnqk05P8A9arf/CK6YXYCylWXqV82QR/gcZqC10OazXMcU08vTzNU1Ivn6IpxVprZ3XbfjTlx0a3vnhYfkcVSpxS1j/X3CcmUp9A0uEAXVhGncCKWds/Xis0r4eEpitrS03DqJdOnmb8ywroF8PqSXi1rUIgedgvA+focipDaXMC7ZL7UGjH8c2ppH/LJpOl/dX3Cuc4IrESCO20rE3Yx6DGfy3vV660K+itnugdOhTAZnm0JPOX3wuQTUt1e6ailJtYfP9w6rJtP4hc1RsbyQStJoOoeG0J+9ulcSH3JkOTUvlT1/BlK5j3OoXEyvHYXniy5n6CSFYLdM+0ew8fWs6dEl2Q6vZ3FzfsfnjvPDdvMX/4HEyEn3rsZ/EkiSrDqmr6H5nVkilmAI9N6HANTXmi3N2rNp2u659ncb1W2vo5VAPYZYMRSV3s7lp2OCj0/QodQFpD4ba3vfQ6LM36G54ro459T0pkjima1Lj5Y4dFkJf6GWUgVZOh6lbosctx4vvI+mwXaRL+JDE1G+nXcSNGNKghRuoudWuFc++4tiklJdPz/ADHJt7s0LS414qZJLCa8B5G7TIIWH4+bg1s+ErjWJfFFgL7w8LW23N/pErxK4+U4wqk5rgZtDUt/pml+GTCDnc93IXB9d4euj8CRaInjLSxFNZG9Dv5aW7SsP9W3ckjpnrWtCb54p91u/wDNGFaPuN+TPcV6CihfuiivfPFFooooAKKKKACiiigAooooAK474nQTz6DbrazrDILpWDGyW7/hbjY3T6/412NcV8VTcjw/bfY4rWSQ3a5+03DQoo2PySpBP09/ascR/DkbYf8AiROAtrLVlIN3rltBH28zSIYc/wDfTVbn/tK1OfKupVH/AC0htoWB/Ja5zbqTtn+1vBiKesRiVx9CTkn8619Ntpg+THosygBlk0y6aB1br0JII9iK8VPtf7z2GtNS5bXOqXThUXU4AOryCOJT7fdNW7u7uraDEg892HCxRvOxPuBtFON1qRGXkitv9q4nEv6KAKjE964x/wAJCoz2gtSf6VpstySIQX80ZdtYTR2PRGt44iw9/mLVSfw2LstLf+JY7mDs63Hf8TgVprZXsx3JrTN67rHOfzFV7y38gD7ZdI59To6n9cVLhF7r8f8AgjTZzl/pnhHTJP8ATNes5mJ/1YO9h/3y4rJuta+H6bI102/vZBwZLdmiQ/m5rop9X0+2PyXMkhz0g0y3Tb/30KdD4rt3tfIFvqhOTmX+z4XPtwo2/pWDVO9lb7r/AKmq5v6Yvg+60O4izpng/UIQW/4+JLcTD6+YxPT2o8T6poVpfSx3niLayDBh/taZNvt5ce0D6ZrNubqS4uPtDXPjiZh08qARqB7ADH6VsX2naXq2jy22v3bXhVt0Vzcw/ZbmNeDtLlQD061rB6WX+QnFXuzhbrWfB+m3f2u7k8NXyyDcoi06W7nOehd5JuvtWvocFjqaSXPhy/8ABghWMzGOLSs3SL1OYy7cj2pP+EP8ExjLyWco9bnWAB+SCrlhH4W0mRJNJvPClhPEcpNFbPPKv0dj1qrprX8ynboVLDxTpFxcxQjXlI3bT9p0i3W3b64IYD8a17jTtDilM91daLDASTvt9anGR/soDgfTNXLFrHUflk1HT9URzkq2j5z68qBVqfwDoUx82LTEjBO4iKRox+RBxURpyautf6+Yna/9f8AxdMl0C7nkj0Ga+kvI1yvn3sqI/sCSf5Vdk1LUYwobUNS0OdTgpeWqzpJ/uOACaluvC+gW6ZmgtIyeB513Jg/ngZrmdY1YaUpt/Duo3UsS/wCtW2nIhjJ4A3E9fYUmpRXvfh/Sf4lQpOo7QVzpL3V9TS3/AH3iO7RT/wA8LRQ7fTdVGO+uyoEupeKoopCB9rmtYnjjPqQQcD1rh5PEupFPnv5VYcEvhmH0bkn86pNdtN5kr6jfznIJlMxAI7DBOPzFZe1u9H/X3nVHL5L4rHdXWn+IJWYw+IPCOsRA/u21K2j8zHpwOPpXH63FpYu2tfEek/2JcYympaMxuLVz/tRseB7giqoniJb7ddpDEv8AEuMt6ZC9etKGCMBBKhiPIkRCT9CKtyTWqNVhLdfwOt0rXNX8KSw6Z4i1c3egXaj+z9btv3kUbZwEkY8bcdVJJHY1rQafp+vT3emXaCx1CzkOLcNtEMh/5aWzddrcNs6dxiuO0XV59JgkZJIbZpSQ8KAbZFPAZoT8pH4Z9+a6iFdF8VQ20N3dw6LrNgoW3urTKoU6qjI38IPOAeOxFUnz2X4HLWw8oO/4r/I6VriTWZW0vUF2X1jtdQ6JIt5heQQw+XcRwRzzXKeN0vNe0HTmt4haz319bWlzCzHbFIJgyn2+8R+Fddpnn6mDHqsYtvEGnHAZTgTp2Zf7ynqP8ag8RQm4v9O8udUa4vreWSI4yGjOd4/AD8q1gm3f+v66HImkzq76X7JCzRBnd38uMZ/iY4H5CoJfJ0nTwGmWKGCPc7NjC+re7E8AU2/mt7aRb68uI7WC3UIhmYBFLYyxz6ZxXkXi/XtS12+mkiu7f+zkfEUEn3Qo4DnkZY9fxxVTny6lUKDrSstjotT8cWshxaXFxaKTjzIUj81h/vvn9BVXTfFcN0my4n1m6THyxXdtbNn6ErmuHnnt7SMvG8VzMTgKJGDEH+LuMduKI7rUFDNDbWxC9V8tgw+jZz+Nc/tG3qz0/qNO2h6Hd6wWgMVpoutyGQYMVtFFEHHuyLuH4Vgy6Rp9qv2jWdF0DRweQdW1aUSH6KME1zqZvZU3NdBPvMfOKBB3yQcmn2tvboJF0SPRbeUfP9rnsEndjnnaZM9OpoTUn7xjLBuOzNCf4g+FdElEVreI8veXS7MSqv8AwKaQ5+gFa2heM9G8STR26a3pk90+REusWIt3J/u743x9OKzLKXVZVx/wsBrZ9+wLb6CpQn22LW9DoviMQebceM7i9gHJRvDYkP4Ky1tywto/xOeVNx0en9ehMYbiKSQXUHgmyUNgPcX7y7hnqFJp8F34Yib/AEyTQbqQfe+w2jFT9CZKzX1Kw05yL/VCkueWfwxFCSfqVrQsfGFiCBBJqU4B6pZWyBh9AuawlKEXr/n+pDpsuxz+GZCRbaNdsp4GHI/IZNayeHPD9zbPLPp11aIBnddSNH+uajbxCt2N0A1e2yMYhslyR9cUWk8m51jvNetmxkPc23mIx9CMH+laKMX2fyRlYwbrS/CKvsRtHaX+E3FxNKgPvgqMVnPe+EuLB4vDqTZx9obSWMAPbLmXOPeur1jS9Cvbo3FxJHHJIo3iO5WBSfXawyKyZNE8KQndKdIJH/P1qLyH/vlMCo5JReiSX3FL5kN3FHo1jBeXV/oMFjJzG+maSkobPQKzcZ+pptjNo+twzQNqOkXZ+8I7+2WxlHussR/pW1pZtZt+n6NrGhwRsPMa2tbEFTjHJ3HB7c9a05PCtlexkalBpN0GGN8doYXz67lP9Kr2bk7x/r8f0K5klqcXc2XhPToib+8t1IOBFp2rzzufwyK6bw3ZWMlgraLeL9lmw7eY5mnj9sSBsD2ob4e+H7ctJ5bgHs8zKB+S5qiPCuhvKRpslgs8Z/1kd7IZUPuCRQozT1S/r5DlytbstjTtRlnlSHW/D9xGpIMb6ZGrj/exxXR+EUeLXrNPO0Y/M2UsYgh+6efvf0rjrmyW2bdrXjJjGvIjE+WI9MAnP41sfD/+y5vE1i+na7a3RVmIt1tUik+43U5yfXpWtFpVFprfv/wTCqvcl6dj2VegooX7oor3DxDN8T61b+HPDupazfJLJa2Fu9zKsIBcqoyQoJAzx3IrzvUPjTp8Ph7W7+DQ9TS803T4NTFpeNFGJoJmUIwkjaQLndnB59q77xpof/CS+EtY0T7R9m/tC1ktvO2b/L3qRu25GcZ6ZFeVL8CSdG1Gx/tyytBdaTHpWNN0r7NE22RX8+aPzW82U7cbsr1oA9VXxRoa6jbabcaxpsGrXCKyWL3aCdtwyMITuP5VheOfiPofhnRtant7/TdR1bTITK+lpfIs5wRkFRll65+7XN3/AMHRdardMNcKaVeapb6tcW5tMzmaJcAJNvwqH02EjsaefhRexeD/ABD4Us/EFsmharJNKvm6aXuYnkYMcyiYK4BHdAccZ4oA7ez8X6FNpb3tzq+mWwgiiku1kvIx9lLqGVZCSNvXjOM0zV/Gvh7TfD39sPrWktZyI5tpDexrHcuoJ2I+cMTjHGa89HwQEegS6RB4juEtY9Ui1iyJhcPDcKuH3yLKryKxOR8yuvZj1qSD4MNZvplzpur2dpe2bXgciynmhlW5QJIdstyziTjO7zMf7PXIB6D8P/Ef/CX+DNJ1/wCy/Y/t8Pm+R5nmbOSMbsDPT0FdBXP/AA/8Of8ACIeDNJ0D7V9s+wQ+V5/l+Xv5JztycdfU1xX/AA0H8MP+hm/8kLr/AON0Aeq1w3xdS0bw7afbzpywi8U5vo2dAdj9ApBz/wDXrD/4aD+GH/Qzf+SF1/8AG65vx18c/AmpaVDDo/iaLzhOGcS2NztKbWByDEQeSKxrpyptI1oNKomzOibw0vMtxokgH8MOlSA/gd1aNpc+HHOII7S3PaR7DcD+GeK4h/ih4SdcPqugt/v6Zc/0iFOg+KPgyFwxv9EJH8Uen3QP6x4rx1Qqp/D+D/zPZdWn/MvvR6PFdxwsPs8mmzoepgiELCrIuYbj719eW59A5cfpiuFi+MPgcj95r8qEf88raUD/ANFVKPjP4IHA12THq0VwD+kVbqlPs/uM/aQ/mX3nXXNrayH5tYlP++jmmRJBaDMesXzH+5aowH45yK5ZfjJ4Gb73iKVPdUuv/jVL/wALf8B5/wCRkkP+8l5/SKj2Eu35h7Sn/MvvOml1WdG2xQazc5/iwqn/ANF1Waa5upcXFv4ohjP8aXLLj8AorDPxd+He3EuvySewt7s/zUVA/wAYvh8gP2bWrqA55Mdi+T+LKaHQqPe/3FqpT/mX3m4fDcshLLr/AIqcdl2MD9MmovJvtJmH2e38QTjqPterqin2KEdK5W8+Mng+V+NRvpVAyC7zx5+gRQKxNQ+K2gXsXlRaze2kQ7B7hmP4lazlQa+GL+7/ADTNoShJ6zX3r/M9LF1Zvk6romk2DvwJzNbyN9cFearXl3plrgw+MbC2QnASDT4S2f8AgIrxW98ZaFNdNP8A2qklxn5JJIpmC+mcpmkm8Z6GhSWPVVa6ChneK3kQO393O0ELWfJV/kf4/pY6oww32qq+9f8ABO68Ra8XYxwaxrN9GDl3d/IiUe46fhWdBcR2w3S3csTYyPLuyzN6DAP61yz+OtIkO03WmoNu7/jzldd30K9ffFPi8d6KiK019ayylTsMVrJH5be+FGQfxxUOhUbvyv7mdMZYOK+KP/gS/wCGOnvtSNzHFImstfW+MsHDPszwRtOcVFJa2M6JE2pktswgP3UB+mBu/WsRPiHo0Vugs72GCRjmRWgkK59chMkVQl8b6KEd7O7Fvck7/MMcjYbPKr8pwp7ik6FT+V/czaOLw60U4r5o6WCxt/sn2a2m+3wpl3ZMb/bjr+NJBaysUVkjMABVSZPmUenpmufPjXRNnmtqEa3O4YW3glWML3yCvei78Z6GbdfJ1GISEhiqW0gwfqV5qXh6jd+R/cJ4yh/z8j96Ola5jt2WKC08yQjcx83IHsSBn8M06O+uPl820WCKTjz4CxJ9M5znpXP2XjTwoix+fdOZV53+XJgHPoFqxL458POONbLYOV822kbB/wC+OR9a0VCta9n9xi8Zh725l96Na2sEWaW5jkWA42tMwwG9vepWe4gKT2A2WpyRI77lf/eX064Arn5vGPhyVklm1a2kI4Ma204Ue6jZgGqr+LPDMDq+naltd2JkeaGRmA9htx+NJ0KvSLLWKw8t6i+9HqOjeINauLRYo3tpHspEuIF8gtJKmf3kcZJyCB8w+mAOa9GubW21XUtI1G1dJYN6ypKnKuD/AI18023jjR7WWJYdSX5W3CcJMGQ9iPlr134OeONJ1bfo1rqK3M8TtNEDG68Ny3LAd8nHvW9KM7e9Fo8vFujzc1OSd+zRR+Lmu3mo+JjotsitplgiTzLtJ86fkorH0AIbHqOa5D5EWPcpkncY+zKGKgnvn1rQvnmvdV1K8VrkG4uXZRFHuGAdq5HXGB6dKpBLhS4ZLqMDksRhWbuM9q46zcpXPVwsFTppdRFt7Sf5ri6Zdp5SVShbHT2PtinGeIkrDqF2IcbfKx8hH+7jAz7VVnttSuZV8hCULhgJGzt9gDxUt0wa4W0lhMfzfKYXJP4jPQ+1Qm10Oi3mTbJZoAt7eR7ARsVoNzHHOMD749c1GBY3jYFk08w+ZVkJAwBywUdF6YFAvLZGP9qXV2mz5dm4kY9Mj8uam3Q3UscdtKr2YbAkjJaY5H3ST0HsKpO+oWGXN1LOqxwvFGXAB+z7gcg/dyD6cnNQNaafKyyXOpS21/j92PPYN7YfOOfQ9Ku+bdWkrJKkNxMSFaN12MhPI2sMA8DPtVZ9QcXcKaja7zKxUeTnKHtlc4P4009bslx5lY6vw1qn2HTQsms+JJ5gdphEySR/huVsV0VtrmoXUf7rTPEZjP3ZI5QM/iIxXm12BJcGRhEqou1W52hfTjOCfbpUtreG0wNPM8UcgP7xrh9rEddoPXn8ar2jTtc454NS1ienxW8uoR/vLnxTpsoPQyPKGH5DFObQ5kAIv/E913+RvKA/OuE0rx3rW9klnj8hF6BAqr65cDP1raTxjaSmNkRpZXP3k1WQKT+fX2xWsXTkrnPPCVI9DbF9ewKYJNKnukzyNQ1OGQj8CCasW62N4wjWGw0256eWkEFxz/3zmufbx9cqLgDS/lhA3SC6cgemTwc/Sobjx7d3cZhh0yWRQPn2zyx5+jZBpqUV1v8AL/gE/Vaj6HXv4d1MgqfEZhB7RWccRA9scisO/wDBlq0hfVPF0vXnzJhn9XrhpryOachvCWmtIBlnubmaRsen38k+lRvMFfFr4G0ZDgFmmhkbPsBv/WobhLdfiy1han9WOxuNK0+wjT/hH76/165zhoYNaW3Kj1GOT9BV6TzbqW3hfWtc0y7kwBbalYidWPoHCDP1zXn0d7JdOFXwh4ZZwev2dwB+AfrWtB4j8WWtn5Flp2kWsB+URxQFgB9Cx4ppq3l8/wCvxB4Sfl953cOiacpZbl9LvJQfmWG03tn/AHQ/WtLwjFZDxZprWzRrh22qukGA/cb+MjivIYNW1gZY6RoTsvJAsljJPrlcEV13w21i7uviFosd3bval5H+VJnKN+6c8gsc1dKUeeNl1Xcyr4apGnJvs/yPo5egooX7oor3j5g5D4xXF3afCvxXcafOsFzHpszLIVJ2jYd2MEENjODng4ODjB8dsvHeq+AfCmkaTp1v4dsY4vD0GqRGWyeP+1ZnKjyYQso/e7SNzfMzNztAPH0lRQB8r65cy3niTX7qe2ktJp/Fvh+R7eT70TNCCUPuCcfhXU6R8TdVtr0WDzaXo9lPrOp28msas9xcW8QhYbI/3k4wzZ6b1Ufwr2r3+igD5w1DxpqHhLxd8S9b0mC21WaaTQonuo1/0eNHtWzcY8wDy+mAZAPmGWxzXrPwk8U6l4t8OXN7q6aYJ4byS3R9PuYpo5YwFKsfLllCNhuU3kj1wQa7aigArlf+FceB/wDoTfDf/grg/wDia6qigDlf+FceB/8AoTfDf/grg/8Aia4T4v8Agfwhp3hq3mtvDOi2rNdqjPb6dCrkbHOAQvsK9lrz742IX8K2uO16hPOONj1lWvyOx04RJ1op9z51bRNGEjLbaNYTMR/qZ7WJWX3yq/1pv9m+H4JBHJolhcdw0NrHwfQkjBrS1OLyLdpbr9zbKwyhX757gYyTx7VSjuoI4zHHbSyj74dI/kH+yV6j/wCvXhyqSTtc+tjQptX5RINM8MkjGlWOM/NHLYJv9sYHerDaf4ci5/4Rq0IHXfZwjH0GMmmmb5meSAWqEfdCndntgnqT6Uhubh4wtvthhUYMg+aRmz1J/hHtQqsu4PDw/lHf2d4fuMR2Wh6aZj8zB7GNWUeoBXB+lQv4b0a5EiHSrfC8HyrGFSD9FXNOYcqL1pZYT1idt7knuGJ47DFE0E9wN6RPBFCAgijfHHoWXvjnFHtZPcFQprZIqS+HfDpbaLOyjdRg+Zaqqsfb5eahk0LRY0QNpdlGynpJbJz6c7etaIt9QSfy3v3EGAyxmXe//AT16UGW4Qhbc3JBGdtyQ4H4nNS6kivYw7IzJtE04fMulaXbgjrJaxtk+g4wD7VUGl6aZwZ7LToyF2kCwjw57cbePrWyruAWdIy6HPOVfJ5xgD9asRZkV3Fs+1vvBLnbg46hWxu/A1PPJ7N/iUqcF9lfgYkej6QXbz9HsRFsyMQqpPHXp+lRxaHoTsQ1rp+3rk2+MfX5a25LizeEgw6gjKMqygfL7gg9qfDci5iIkF/KcYM/lhOffkcdzmnzy2uVyQ/lMWbw3pbDzJrbTkhxw0UMWM/guT9Knj0jRoI1ZNCtLkN92SW2RAx/KrHm28coaG8thMCRlLRmCj3HIz9KmQRNMZraaOSRx++RG2pN+B6fQCkqku/4idKHWK+4yJtB0WZh58Ngs+f9Xb2iAL7cJzUy6Lp5XyIdK0+YtyHayRWH0+UZrWlmkhXNvayWl0Oh3B1b1B9M0pWSYZk8+IEZIWJhg+vHIFHPLuL2cP5V+BkQeHNNwVmstPYrz5X2WNXI/wC+elJN4d0skhLLSdvXaYUDZ744rRbbwtxIsTJ0eUnawPp3z7VJE9rDA6qYj3M6ISqHoM5A/Slzvv8AiHsofyr7jNXQ9DVF2aZZyEcSbrZBg+o46UDw7pCgzDT7F4R1dLdGC+xGOK0IZy7hbe5tSo+8rjbu+m4U5ojG3nR5hYn/AFiD9MelUqkt0wdGHVL7jMk0LTXYRppWm7TyHW3jyR+VOXQ9FUDytM02ZDgAm3UEH8RV6PEaeWjoVJ6gD8c090LEmKZNn3WIO1T+dNzlvcSpQ2svuMw6FYhlB0fTo4zxl7SPB9TuxUM00fhPU7HW9LtLSCW3ZomFvEFDh1K5469a2ttuq7RvDgZcsxII9Rzgisrxdtbw8z+UyJHLG456jeM04SldXZM6UOV+6i6kUkgDSkhOsgtxtO7HUv17881MbJbcLm5SFRjMZuG/z+FP+3Fx9ptzcLD1jEs20jtgjkfiRmnQwEf6atpvHLH5lwG/ul/8RWSSZvqhvnqI1Om3qyRngg9SPoRSRS3kO+S73rbuQqKq5wfbPT8Kndr2Yrtso7Wfbw6kvtPbaQMDFQmC6tJjdSwyzTBThpMk5Ixuw3X1wKevQRBOkCDErqWz8m35iPcgdfxpIJ9yPtuI0T7vnW2I5F+vt9Bmp5bcxRqYla6BYN5yjIkPqaHaETb3gWI4GVxlxk9RnoPely63GpaDYBaJN9oMj3Ey4ZGVGxkerGrLagb6F41Ym46FI8puHfPfA9qiWS5wEjjjUEHDMfMP68CowzHPnl7naobZ5m3aR/tdh7CqWmiFe4heSFlij8ojuPmUE+h9/rUciyyws7Swxv3jMe9UGeuADjNWZLW/diUcwIy52IdrEcY+Y9T71HHHcCJWvLmeeQnGbZ8Y+uOM1LiNSGm5uJP3drbwoykbiF3A+4B5FRqq3Erw3JtFYY3bkIB+pA5pSsoDMBKOeXK5bj1xzipPPZc740cvz8rk/rjn1pW7sd+wm0maI2K28Lj5FZELMP8AgTevp2qWSaQhTeTnzwSJIvMIVRnjvzx9ala6kt41WaCbBGAYpVcH36gg+1U57uCNg1s19bk5JUwhw31Gap6ISbY1bW0VCZzGnZXlicD8WxQhgt3MbS3M0i9TFOwT/gRY9ParE8kRh8yRbm2cDIlnQNH/AN8FuT3yBVeG5hVWjGpFLY8GM2zKknqOnelsNXZJNcXLKBqDS+XjiCLCK3phhzj15qFLKJEM0OnPCXOUcyYA+vPPNSxiSJdumzQLGMlkdw5Uds56egA60qQXXmtI9uyI64kVW2Kx/vc8H6Ck9Q2EZfOdftVwZnU/6pnww9h2/Oum+FRtz8StAaGPYGkkwpBJB8p+57VzroXhxEsURX7rJIHIPoQO1dJ8K2/4uVoYaydH8yQmUvgE+U/atKK/eR9V+Zjif4FT/C/yPqFfuiihPuiivpD4YWiiigAooooAKKKKACiiigArz342xpJ4WsxIFKi9QkHHP7uSvQq85+OgjPhK087ft+3JwmOfkk657VjX/hs6sF/Hh6ngN2ggufMtpXgnxjKMCqjP8Q7+lRfarxwc3YkX+8qAMMemOuP61PcRzQo7JE5g6/6QMjP+9/SoArSOoYDLYk8tRs3Z6bfb9a+fktT7OOxLD5qMGlEDDrl3IHt171J9sBxG+mq7fwyJL3/Ko1gaJmEsLM64bJzu/wB0g1YF3NtMcFnDE+MK0T5bcemD2/WmroVrkM1wqQywiGa2ldebiRfNji6ZyFz+ZqsEifZI+tpJIi43RNtLd+R6VL9jlSTMyTzzKed56HryB61JLJeLEsl99h0+VSQgKZYDtheppNvqUl2KYgiAUQg3XJys0ACE9245zU+VBO2CGJvu/MSxYn1PY+lNmvZZV82C5msZV+R1gh/1vvtzgZ9zmnrqMfMUEaxkDIF1FkyN36H+dSpJdRtMURtGVzFJIinbtL7cN6gj/wDXSRIjzMfsTNMp2jLryevI698A96qpM/mkrfvb44WGWQPtH+xgdKtxwXEkReS68sgY37kVv++s/LVLXYTViWeUA7JQkTof9WNxJ9vTP1qBtl2+JZYpCnGyVig/757nnr3p8C2xCxvqqXDDgKZcyE+xIAzVeWW8WQRRKsVozHzdqkyv9SeD2/KnISRcjEVvEXeQXEK/KkcZ2/gQcEAU6NjcRvImmFbUffO4tj047fhmqroLeeKeeaRF2gBBKCWU/wARQjt15/Cmzvp8s0TjV5sqD5bR7gGY/wCwB/WkmFiRZwoxDezRRZ+bFuQG7Y45qSS3SPEk83msDt8xXySx6DAPBpDcJAT5Fo0sw6TTqQvTj5eufrUaRBbcCzkkIXmeSMDYrEcL9fej8QHSsI8vKoYDkiVGI/E4zTViWXbJJOh5DRtgnZ9FHA+tV7KVmtXF2TC27CyTvlSPqevNTWttcFWknuluUySs5fMcfquB0o31DYnuTbqoiuYprlyN3mLgjPsD/hQvl2yLJJHJavj5XdSu5f8AgPX9aiilt7fdC0VyFDbg0EZUEnswPIHp60kBi+dkuNRkySxjlU7c+gJ7fnRvqBYLIyhltJZRjLSLhkY/T/HFNZGPM0EYQ8Bd+APp71D5ojmEsNo8cnZWlBUf73AzQ7NBLLIYLq6+UHlgsat6gc0c3cEhFwgVJ4p3ccB4F+97n3qj4mgmm8O6gojZvKVX3dSoVgSDjjtVxblpAvlCbcTgqrYJ9QeOlUvEdqq6PdGNpIwAiMFcAYZgCCAeetEHqmgktNTUF1aQr5lvu+Zebnb8oHcoDyxHaoI4lkYTWd/cSoWOXDPEjfXOMtU0dwbOSRYbT7VHG3BkkErp/sqo4C+vpUs811htspKEja0IwmfQN69uaV1uUVDAzo8b3x2jrLJOcD6nOB7VJbwS2O2J9QkuraVTxnzArdmUkkA/SpHnhaL7PFaTEHPVVJX1C+oqNY/KURrAiFxnPl4fpnp0FNWWwm31HfvSVWJwoAKkhSqkD2HFTRyvbploYHbPC+Z81QpDJMrOP3n8RdW+UL6Eds+9TRt9nIkFnGSeSjthR+NUtCXroKblJwWOmNDj7/lyj8Dziori6WWWI/aDpkaZBjuEbMvuHwcj6VLO1zeRhfLMEa/O4hOF54Gf15qKGK8tXH2CzWRyQHecFgq+o/lSbYKKKrWtpja+otMjMW8uP94oPpz0609EUeYxtvOTqXkHlsfYkcYqxJdfY5T5otJ0b/WW8KBivvu6DHoagF0IpD9omvLu3xvSBY/lQn3Y81Ghdmx6p5nPlqqKN2IeoJ5A5PI9DSvvjRt8DuV+Zm35yD6qR+FRT3xuI1ZBjrhoMRyxt6ZOQfoKjt5Lhgnl6iZxnLfMCRn+8x70+ZdBcr6l21Ro4i0FiAqjLMZAwX8R1Hbmo2uQhaRJNv8AEWVWZV9j3pssDRPE0+pm2C8lVmVFP1UZJ/lUjrCYS8UovD/E0b5jPsw65qtbCt1IUt4WxL5tsGJ3CVmLvn364+v61YkuLeA+U9tJdzd38zC5PoQeOeOlVbY3dxLi53NOGIjWMbUC9l9ePeltpbaBfIuL50KniUsJQ5/uhsZB9+lStB2LV0GiRTe28ls38DKm847AZOecjniq0Ucc0jebeyyOfnKzqUXHoSTjrgYplqLJFYQ6hdXD/M0sXzSbj6ZwAO/NSPPDLsie3itLTcHd3G6QY6DPTND3DYc0EUchjVWEg+ZlSJWKj610PwuYf8LQ0FGR0JeRgpOVH7p+fY1y199riUEpdKSw2wkgMV98Yz9K6v4Y7G+J2geVMsWJJMxFhuYeU/b/AD0rWiv3kfVfmY4l/uJ/4X+R9RL90UUL90UV9EfDi0UUUAFFFFABRRRQAUUUUAFeefG+aSDwrZvCpdhfJlAAQw8uTIPoK9Drzz43yvD4VtHiZVcXyY3dPuPWOI/hs6sD/vEPU+fbom3mMwS+nTG8wlgkYPUHBzVR757mAqTnkh48CNlPYq45z+FWbi8vFV7cyhoZifMaQ9fdcdOfXiokkMU3lgl5XG5kYYJPt7/pXzcpa6H26joQWahlC217PIFOWUlwFz6kitJrdGRVmDSg56Hdj3wP50w3N3KBsIRiMmOFBmM543Z5p9rHOzSS6hIImzvzED5hHuOgFVG2wrPceI5IYhHBLdSjGNsbjC/XPIxnv7VD5FrBtM8ckMoPR2LtKexBIxtppurdHNxcR3McbjZ50ZLSEnI6Y+7355piNCFeaCC4Y/d3SEssoPqOq5pNlJEkuq30MquBExVSoQAMrH1Y/pmonlZ2N1MY0ZiXAxuAJ64yOR7dqtKIZ5EWOzlaYrnYrrtHuSTx9CKz7kRzMyNhU3BxGr71yOCSRz+HSpk33uCS7F5Z2KkwW1urR4IZwGJz02c849qoXf2i+u4g0fmKhOMptPqfcnOeP509HhvJlMjzSlPlVEwqofrmj+15YWjsYrjCn5R5qhpAc+o/rzT5r7is09CaVbTymhe2uxKMgM8Xyn8QfyyBTo7uCJhJZzI8jfJ50m4eV7kcnPb096ilM8IVN7zoxAcxupA9s1cM13PGYLNLnZjCt5aKxOPX09qtSJsIgv4ciW1tmjZ9zyXUuGV/Xj+VMkkt7XIMjXMrnZiOYE/XkfLn8agSJYGWDzTcqE+WJBuaDuS5xg9881LbxwXXmSNew7fvSIfkbgYztPPTnAP0ov0QrdWJDfTxEqNHWSBc7mWY71A+o6/zq2zS27veQm38krlldAu/2IU5BGew71GJb24Xyob6GWx2gGNlQ7V7Ywdw7dfxqqv2eK4RPskU6K2Yykpj8x+4BPH5kZ7VfNoK13/X6kitaWytKdNu0hfu0iOufQAc/wD6qZIifaUWBocMvGGyg9ye7Z7VNcwG1dpJrVoQ4x5Ef7wN6ZwffrkVCbeGW3/fGSOJc5CxEMuehC+/SpfYa7k4kkVSNRvorkQfdVICVA6Ese5pi3NzLO0Wn20G4cIWjLMR7K3Qe3vUVmVuUjiiVjGg8oMrKCV/2gTyfYGprm3s4rd7eaeOFH6mSYLnvzyTQm5aoLJaEv2u+jYRawLSNmGUkjXZ+DL3FU2nuEQ2nnRyW/OcknBzxg9h9acqSWlvH9meGeHnZKZfMGT1A/8Ar0+C/ukwL5LJo26PC21kHqQc5FOXvbsFpsRo7RNLBE+WZRu8wMxX1I96zdWhgGhzGETMiPGAXTBBMi9fatCa4mtcxrLE0LEliMnC/wCz/wDXqrr4l/siRhG8UZaPgHKtmRefY/jUQ+KwVPhubeoM0c00MUYtXyULrjcVz0z1H1qh9mjtY1M8twjMPljjUn8SelWNUFul7MBaSM0kjfPI+B17DuKrEZhNjchHtiNyoC3T3YfypbuzCF1FEoluHgNrKkzQHlJlGXXvgev1OKhS8eziVWhusk/NcTsHbAPXGKtS+etrFBFGsEXAVUbLEDvkZ4pt89xcSoLuT5VBUOw2Er3zzj8qbuthpp7lG7l86RGuZzHtP+vjZl+m5F71atInZwxnleNhkGQkbvXAPapIbqbjaY2B+UzOMiMf7XH+c02V9Rnj2oSxb7xdAsZXOe3bj60JrfcbXQlFvG0gcu8cq8+cCcH2DdPw9adNE0pCyw31xEhzzJjPb+HOcdwKJhHDAM75WlO3yoSRGB9SKqma2WIW8kFws6nd9njdljOfRscHiiVhpMnjljs5GawETPn5424CjspyASc9fwqudQu5omtJNjq53GQ/IQc5AU9x9amhaGJljNtK0ON22UhSuf8Aa6EU2VYfs7OtuxjY7d8sqrlv9nGcgVN33HZDI5BG7KQkrn5yoADA+w6/hUr3c0cZMUccKuodRHGTg9g57fjVFbhbdzcGUmRgEMjAEjHpjjApw8qONbhZLvdv3GQFV3E9Dg8Y+tKM+wnEW0gcvNcXEExDOX/dKNx9sdB9CakkaxFwJcT2qEYLPEwwfQ46frSRX1xqbFzdxqI22ttAQHsOvBNOtp3SVjOlyzx8IUCtnjsPT35qk0J36kglmuYntrVgIFHzQox3yDu5bG0D8TUjefIZFvo7G0PBcxTHe+O3faMc/hTZ47y7Mc1w8kEKndvfasasOhIHb25zVcugtwzbkRwUaZoyySk/eIwMqO+aq4rD5byP7ltbvP5PRjIAjc9cqMn61NBdy3AMNzpaWrSAqrhg6N7Nnp/vUeWlqFmW+hFwxzHKrKwzj8hj34ptwt3NEs2py28+wbovkVS3oPlODzVJtCdh05lEEdnex/ag/wB1YiEkQr0AOSpH6muh+Fzwf8LM0GL7JNbzCSQjziCf9U/cfyrmLRI7kTRwWCSTHmQi4wIj6YbBP1GR710fwsCr8S/D8eJHZZJMMyHCjynGM8fyP1q6L9+PqvzMsQv3NT/C/wAj6kXoKKE+6KK+iPhhaKKKACiiigAooooAKKKKACvPPjcxTwtZnYrr9uXcG6Y8uTmvQ684+OpkXwlaNGHOL5NwQckeXJkVjiP4cjrwH+8Q9Twa9ZFgdxBHHG+Runk+/n+6AMkD1rJWeOJftHmSHA2GQnccein+lX7yKxuZfKZ70yeWQrFSSq9SAO2AOtVoILe4tEt7MyyxoNwSVdrN+OMYr5uacnofcxskIn2WJRK8VzuDb1kaUK59MVLLPcBkBuboqrb0SFgvvltwGAPXFJMSF8q4u7QypjykRQpjHqS3enPPdKkUUi2tzNIOCSZZGQnBJwQMdsCqULDSJvt9te4nupUDj5HbzdxLD/ZAwfw60yS5tpx9mtpWEqEMkL25+YH+IEd/1onWeyVzdWts1uhGYorbyn/Fsnacc+9RRaqGbfB50Jf5Ip4YRKFH90huh7cVTXRgo9ULLJDPDIL67uI2dh5sax7d5A6npxjjrS29vZ211L5V6kks4AWN4yoAPQAkUl7M0N1EmpxRTTbceY52xjP99R1IPfgc0lwZbeKP+1Jo597FYjb482QdiWHGBnFRYLA9k8TSW8WxFJDPFK2Gc+ox2/wpu2yjQSfZHknVQ2UYPG3odw6evNMivG80wyywpfrwglQ7mH+8ehpmkTT2dpcTahAl2jZBhiZRsVeuckfgKSiugmmg0w2d1JJcW8k24blNts2NjHqOCPrilD6kkY+y3MsdtkHgBgDnoF64z6VNCkdwDJp0SR2n3pBENrDvhzuPP0H5VRu9StHu1gjdkucbVdF27aGrbCtdmrbywoPNkUXTA/vBaKMsD13rxtHXmmI5vJEfUQq2Ssf30hHA6DnAyBjAqiMxGIRXymb7puIXO9iegK4wRnvzWjPFfND5Nw4xNx5Sok0bMOpA/h9cfyqlroDikNu7O3hu4by2unmZRtUwgCNgf7x3fp3qbYiAj7RFbyyYy527do/u55H1xxVSC0nt4oGsYSbVWAYyqGG/1wfu47elV5reO8v1DXsc0ci7TCyNg98Bh3+mKdw5fMtRRzaXdyQW8lyiuN7Pu37h79j9ajjkU3LTRzTq2cNhWx+I649hUv2iNFFulvISBkok5K47ZJG78K2fCOl3Gt3bK2mxQWYHzXazF8+wU9Sf0604w55csTOc1TTlIg0601DVcQaXbJLCWJDrHlACMMxJPB9q1Lb4dz+UV1ExKCc4XJGfc8Y/CvQtJ0u00WzFvp0QjGd7EdWJ7mrLSOxzIMIeRg8fjXoQwkVrPVnj1Mwm5Wp6L8TyjUvDMugGXMUJ018Eu0jBQwHBPoayEtVG67V4JFcgGSKTfyBwCf6GvaLwxTxPby2/2iNhiRCAVAx0wa8kv9ITQtQmt7RFFow+bzJCFI6/ng1hiMOoarY6sJi3VupblFCLmJzIsLbeSu0oee/vVHWZlfTrSKR7kxzXEMZLkBEAcE4HXtUspLzSJAmZE6up3Eg9Ao9B696z9TlvJtY0m0uFjPzPKY2GQFA4LY/GuSN+a6O+cVazN25kdHbzdyyHdIJM7g6kkgcdBjjPWkt5ZpQHsVVrRhtZBJkAd8f40sTXD2Zke1m+zxDKbYF2svrycgY7e1a3hrRrrXW8iMx2+lrzLJEAOO6j3P6dauEJTkkupNWUacXKWyMJ4p9LieSCzgt45jgO8rFj9DkVFKzXsW5le4gY7wjjzGXH909jXsNn4S0O1VAljFKoGAZiZj9fmzTbnwlocyo8NobOQHcstu3lHPpjofoRXa8CraS/A8/+04X+E8n8jfaY8m7S3B/1bAKz/UDtikSSOORhZCSCdhu4kyox7DOPqcV1fibwpfaXGbuzvjLAnzF7o58kepHce9cqjbrlW0+4t3cjL/OI1l65zj5sdeK4p0nF2asz0KNSNWPNF3QRajJbTPJcT3EscwEUhkkURkdlHGSfp0zUn2iytxuZg0ijdtj/AH20ep4A4+tRxvcXjObWDT3SNSwlW3Lxg9+p44xzimz3kloypcwwfaXACukZiU+qYHXI/i/ClayubWuLLdJOGmguHuLeZdsrLbkN/unPfjikmtrO8Yp/aEplEYUMyHCqOcAflk4/GprK5upm2WTPbLF80kU8C+X9dwwTk8dqq20k87ONLMNrdK2W86QMZB3Xn+AelS4jJYbG3ubJIoGN5DCuCUGx8n1Bpgi3NG05t51PyJibaSB/CM8EgUy4mlillFth7iLibyQRCo/uge3rVTUJ5rm2ibTJLXyw+CQu3y2PXOf51LSYWZLfXWnWkO1LSdIm5VyoZge3BOCPfvU7xRR2kPkSSSjOY7gAjGTnAX1p0l1ZRRwWWpWaPMqYS5ODGcdSQDnApS32NFnucKuN0YC5QJ2wuTx6HP5U3HQkiWW/85hf3ihCAGSeMMuB0BYDA59atzXYt4dltDcifI8qbA8s56qh53Ajj3BrHtriG9O62vDbwK/KSfdY/TnrV2xNw8jRWtxuVTloDL8iqem1z3B6Uk3sNxRbt7W0Yv8AbJYLW9ckhSQS3fAGfy6VWsbRLYPaJJPJDnLeeACvsqgnB5PJ60XNs13Oj3jPOyMFZvIVWL9FG4ds8e9OK3cPnpfMtuWABlMY3k9uRy3Sq20sK3mS3MKXkTpHcKyRrlYEKhmx6kZLCui+E13PN8RdAWWWcx+dIFWT5v8Alk/Q9a47TLeJALiWaO7aH5Q43Qsgx0PGD+Ndj8LLkT/E3QGWGTBlkG+R8Y/cv0UcfnWlH+JDXqvzMMUrUKi/uv8AI+pl+6KKF+6KK+kPgxaKKKACiiigAooooAKKKKACvOfjm0q+FLNoZWiYX6EsBnjy5OtejV5X+0SSPBunYVXzqka7G6NmOQYNY4h2ps7cuXNioLzPAJbpZXeK3kjsJd3mLLktuIPrjhf9noaZcTbQ8rAXSowEkgzEBn+FQKeugXF6l0YhcXaRthvKi/d59Fx8zge1Rajpl9aeWlrds9uY8eV97ec4K9OCOODyBXhTozSvJaH3UKlKUuSMrsoXSf6XGsdohRzyobd5Y789+lWFkgimW2t2D2xbh4F2OCfR2AP4cCrEkupaXH9kmuImBTdGQq7kPoDj/wCv6VURbJkt5766leXJURHkMwP8ZzwOlRy20RtZ7suS2KywxRS3twkDOYlW6Yl3OeRgHGPerVrZXAsTHoIZthws8wCKD32gk5PuRWJc6jBFcss6LM7rsgkWMOsSjsFPU579KbMurlo3htmeSYhRLNHuwuOAvGAPpVJq5Lg7GlbrJp8JW4uMXMzNvldC4GOp9c+9R29vHaDy7a5gvYbkZ2SJlQP7wJIKtVlZJEZI9WuIYb1BgM7cyL23dhz681TW3k0oSCe4jMjsXQR9SndgR0Pp2NDVhWC7tWnnSC2v4bpocBlcMHUegOMH86v3MEcMXnbGmAOS237pBwd3qc+lZ/2hXil8u/2XS5ZVJCArg9McFjUelrPEipNdRJPJ8yK2dzgj8gT64zUtLsHIxunzTXd9PNdgu6kgLGB8o9xkcCtMWtiA10cGQEBi7gGMep4/lRHbWsbSXk62lsQcAwyBsn8en41HBpN54ll8u2eN3PyIUQbiB69gPc01Tbdoq7Im4wXNJ2SJVvbG5trg3BSztTkJKqE+bz1xjr7UW1rHaeX9lVVWVd8UrOxLjGSwx0PcA454q14h8I3emxW13rEbyLnZGLSUMDgZ2EYG04HXvisu0u2uYLiys7O4S3HzPGZwoTrnlh39MDmnKEo6SWpNOUKq5qbugutQ+z+eFmmW3kiJEUrmUOCfvKAQq89j0o066luNNN0IViQyBcuylXPGQqYBJ5z1qAQyNcxtYJEbXAZY85Zj6NnjdgHjpSNa2+qX7Wq3LRXC/MqtJvU/7O7tioSexo0kdN4e0xtQ1FLcBUXOfMyxK4PJwefp/hXrem2qWVqsFtyq/edlCs59TjjNY/g7Q/7H0zfefvL2UYdlycL2XJ5966CPgFkJ24xz1r1MNS9nG73Z81jsR7WdovRCSLvQlpGVl7qP1prPJFtUdxjeRx+XrStD5qb42ImHGCeAfQj0pg80MEfKcZyO/wDhXQcKJIk3MSSzEdTnbXlnxMa3s/EpjuJfIiuIUdSIi43DIOeeO3avV4/mUDMgYdc8Zryr4sW41DxDbW63KW062wZVc4Djce9c+KV6Z6OWa17PszlEngMYMr3DgExQnYMg/wB3jGevHpUCveN4hlkuEhV7a2SNWhXy/LD55PvU0MsXnxSLLciKPAL4xvx27555+lUdMeS5u9TmkuWlZrkwqZSXyiAbQc8nqeK81aJnvVF7yRslDKFe11KWaeX5I0+0MU8zcBjBHIBPQjBr27SNOi0u1SyhI3IuXIGAzHqR+P8AhXBeENDt4po73yIUVD5ioi/LuPRjnoa7yaUJJEEXMoOQxPA9q78LGycjwsfiFVlyQ2RalLfdY5J7dCaWPDRqCCwJ+XI4qJm8xmPRsZKg5BHqKeuF3Aknv7V2HmjmWKRWjkCuhGCrDOR714l4w0Cy0HW9nm21vayATwtKjMT8xDLge/6Yr25sBc7j74GTXCfFEwpZ6dcSWzXC+c0BIxhAy5yc9sr7VhiKcZwd+h3ZdWlTrKK2ZwH2aO43XllcStEJFQfY9yLv6AMrHOOetVnsbf7cHubsyzxMFWKENKQxzhck/wD6qd5nntLLh4NirGse/B5PUYxkDnn1NJKot7cwh5Z5Z1It0hhEcgTuSV529hnrzXlp+R9Ir7E2rWGozLEXzb2BIBDnMjnsXAJ/AZwPrVe6t7e+ZLJ72O38olUWRCCxA5JYccdqq6aNaguZTb20UMEIAMbJtEgP98nr61YvLUanbmPT57dpFbeYQclT6DPJHXnpVNX6FJWJII8rvkv1hFspT7SEw7jurYJ3Y7etM0613NPO9zE9vJgLJGpCtk/xAgHr6VDNOIQIY7lWKAAsFBUsOG6jBPoQOlVtQM1y0CafdmeNwSFY85/i3L29ah2Y+RlzVp5tOimjtY9kpHzO69vXr0p1ikZso1mWUbhkuMbSe5znp7Yp8P722bL2d3HjG2SQoFPfk9/Qk/SnyPDpsSw2ksaXAA/dJtYZPQeppcvUXL06g7WOmIVSKKTgCOItnzScHOAOPqfSnXMenX88MRud94R/x6gFQW64LY4/+t2q7o3gbWryZNRtHtIo2yqeYcKD3IwDkZzg1i32mwaFd3UF3Z3ctzC+2T978sZ6gggcjoQeM1o6U4q8loYU6tKpLlhK7RfZgLYkDCElVWGRkcuOcEtwMYyCOtZl1qzSfY42c3kjHywQpDcn+8xPOauXbyXYjur+3kUSDELSzKV3EcEqBkDj19Kp24mhic3TCRyPnWFsSx+hxjp69qzsbqJqTiVbgxuIywAbZu3spz0ZlAA/Kut+FMZi+JOhLlI5WeQsgIIK+U/IP+TXnlparFPHdaddCdmOx4+jKMc8dx7n8a7D4Q3UFz8U9BIZ/M82QLmNQuBC/TBrSj/Ej6o5sZD/AGep/hf5H1ov3RRQn3RRX0Z+fC0UUUAFFFFABRRRQAUUUUAFcJ8XtLbWNBsLTO23N8rTsPveWI5MhfQngZ7ZNd3XM+Pc/wBkwbSAftC9eh+VqmWxtQk4VFKO5wUSrZRLHbwQxwoAqBONqjjgVzvjqwhuNGkvUdluEKqxjbaxUnA59QT19CRXSPcBD+8McSg/efkk+wFU9TEd/Y3NtlxHLGykqu0c9Dn61ytJ6M9WlOVOSmuh4GgkRo0u7JfsAJIVWYEMO5J6/Q/hiq15fW63Ub2tk8sbDy9rrtVfqRyfWtTxFBIrrcIJWkc7JIpTna69ueOe3rTdFtL68uIzBapA9yyxpGULKWz2Gce5PbFeU6Uufksfbc8HT9onpa51/wAN/Dp1svLeSkWFqQoVBhyxGTGH6hQCCcc5OK7PXPCFi9lL/Zu6zmVQNxmby3/2W5Jz7jmtHQNMbRdJt7JpTMUBLhBt3sTlmJ7kmtMKJl+cjC9IyMAV6UKajHlPkMRjalSs6kZNLoeAJEsN28VlHbxQyAmV7pfMG7+4Cf4h3FNtNNlmi3zTC125EKk7Tx/T09K0/iHo1sPGGpJLO8SyGOaNU53715wP94GuUv7J4iEDs8cR2AHkD1IGen9a82pFRk0z6vDydalGouqRcuJJ7nCTWyNKmFlcJuYgdPp+FR2eni4NxNeXCW0CH5VcfMAc4GKinvLtIVjs2uAqDGAdrY9TjGfYdqbdQyR7Yr7zpJWQNGyyA7c9iD3rLfVm7j0RJo2kzazq1nDFINzPswmCyKMlmx6AA/pXvOiWtlbWMNnbRR2yqvyAjHmD1J7n1rnfhLoMMOjHU5xumnZo4ZGjAIhBx+rAnPsK7WOCCFfJIUpjITGSPp7V6dClyRV9z5TM8T7aq4LaP59ShfWa32lXlgysjFTt4yNwGVK/iBXhuoWsUsxvL2+CdxExXLe2B2r6CbdGinJZcfcGAfzrwrxUf7K8TXFslptmEzGKQsQygnKnPQ8HpUYuPuX7HRk9T35Q76lG/MQsoJLcfaHlYBkRiwQ9gw459K6X4bWNrN4nhxbrG0SM8sckeWyMYbJ6DP05rnpHmjZnlhZ5W+UySHbuHPXnrzweOmK9i+H2hto+ghpkkFzcEM5ZtxC4G0Z9Opx71zYWClO9tjuzKt7Ki1fV6I6dlDL+8KsfbIxSKhyynBBpclFxksfc0xX3NhQCT19RXqHy4bTufyuG6E+oqESmOVklKqwAJcngj/GpJImV98cmHHIbHT2+lOJ86PO1FTHzMVzg/SgCubhtwPlgQ9iefzry34mqZ/EsUMVzC0qRooiLAMmcnII59OK9fW2hii5UPkd68C8YrZXviXVboS/vFkEWC4AO0bcDPQjHWubFP3LHr5NDmrtroiMNHYxySxMk4iUvNy24YzkHtVHwYjvbXDzxKs0ly0j54IyAw4/Go9URBZWthbPK13eyLANj44ON2R3GK33U2usa7DAjeTFfyKCOcKqqOntjrXnJ2jqejVleryev6Hrfha2im0VJZMMHY9D1xxWshUOEjjQYH8XWsLwRdK/hm1XawU7sSY4+8ea2osiQK2wFT0PrXq0ElBWPmaq5ZyXmOG1jlRt56EYz60W+4biF+mOwqQtkA/MT6D+VRykkY5B789fpWpAOynaNnf1xmsfxbALnRWRkxsbcu0E84IrbKngjC8Z2kZ/WmPCjr83K4xgUNX0Lpz5JKS6Hzs8+oPrRUW7W8ka7R+6z5hbAUAHPUkcV674b8C2FnGLnWS15q0q4uJGcqq/7KAYwPfr9K2V0a0F5DcrGFeJsozDhT2P9a1CzKoBJY9d5Xp+ArKlRVK9up3YvHuslGGiPMfiDolrp+oWG6OY6dcMyxyyMWSCUDO1s8EMOhPIINcVqF7Lp7mVvIdhIV8uWNZBjHG1uCBXtPjyz/tPwbqcLMrsIDInHRlII4/CvFvOT7PAt1Ja3dsV2vEUw8OOnK8mubFxSaktD08rqyq03GTu4/kxuJ7OCG8tZBKkgzLCSOFPt24/Ks24V3SR4bYIzYERiUhVHrnv9felYlNRlmw+Tgr5KhRjp78URtqV/d7Y5pVQfMGLFVH4dBXFvoe0oWV2JdWqWVtbyLcRPdN8zIozsHUHNdR8O/DnmzG7ulMtusu0DGVmbGcBuwGefXpXKW9ubm5XyBKtxkAAgSK0mcAfQnHFfRFhodtp+lWtjHz9nUDOMEsOS31JJNdWFpczcjyM3xLowVNby/IR44mtvOtwjhRkIowy47Adq5b4l2SvpkGoQkrOXFtJIFAYxkHAJPBwR+prso4lucNAB5g4MiLkf/XrA8aW1xe+G9Qt9jNKkRfagAHy/Nn68V2yV013PAw0/Z1Yy7M8VWG10+YKs7Xzt99Y2A2D0B55PTGKZO1vBMbuaZ5JQcJbxscov+0TzkVGkdrEJd0TfN0uGYguCeqg9fWp4nihRfPCSNHhTuYZT0YY+8PbmvI6n2vJoTXU9rb2g2Nv89dwSBFjkX03NzjB7d+9dT8H72Kb4n+GFt7RAHlkMk23B3iF+BXEoxmSS6iI8yB93IG4r2yB1Hr9a7r4Ei6n+I+lXDwBQ8sm5I0CAARP82O2Mge+a3w6bqR9Tjx6UcNUu/sv8j63T7oooX7oor3z84FooooAKKKKACiiigAooooAK5rx2M6TBwTi4HHb7rda6WuY8fME0eIkkDzx0Gf4WqZbGlL40cK/BB5GTj7uc1FIWaQ5AbHPP+NK8m6NgmdoHoR/SnxMZHwrNsHJJ5yPauY9KxnX3h7StScS3FsYrnAxJE5VuOnsfxHFT6boNjp8pmTzZJ8FUeVwSgPXbwAM+vWr6JCMtIAmc8qccUxngIKwyzMegJfNBftJuPLd27dB11Osca4yWAyFB/wA/lSQXDyJ/q3455G38KfFCkag7gZjyzsdxH09KcEiZuT8hP3ScZNBOljx/43Ii63Z3IGWa0CtjnJVz3+hrgo5YXgSWSEwI/JjUnCgfxc9a9U+NCbf7ImSCMxxrKo3g46oa8zS4e6KvNAk0GCgXbhUHfb2rzcSl7R+dj7HKLywsfn+YsV2omBtoxJEw/uHdjr19fekstNmvL4R2771mkWOP5gW3OcDPfvz9KVfMEDtpkkgSPIYEhWCDpn2rtfg7o51HU5tZvIi/2MhY2b/nowOfrhcfTNKjT55pPY3xtdYei5vf9T1iwtre10+C2tGIigRYowCcAKMCrDjbwq9fvE9TT1kw4weB1z2qG6eJdyEt7cV6Z8PuyRpVyGGXYdCcAfn3rnvE3hyDW1Lea1rcNwZlwSR3HPat5IgV6KWxzzyKWRdmCG3sOrN/SlJKSsy6dSVKSlB2aOT0nwFplqYDeStemBt0YcKgBHqF+9+NdSN02QjBGHPBycUqbsY4VP4sjH/66Y8aoQ8bN8hyOefcfT2pQhGKtFFVa06zvN3CNmO5HxkdWXofwqeHOwBj+ZqMM0xypAQU9kxyGY54yRz+lUZDnZQp4BHTAGM+1QqykkgBB1I9KeIXkkyuQMcnoWqHUJLLT4jcXs6xR4wzSNjn+poCxT1LVotO0qWWQkQhgsbM3LZr54up5Hv5migV1kZtzSKH2jOcg/1rrPHfiJ9dvo10x5VsICfLCjazN/eNcq9xMtlLLdOURMoQi7ScdmH8vWvLxVfnlyx6H1eV4N4em5z0cvwSOi+HumHV/GKXKgvaaVGh3nrvbJA/z2qfxv8A8SvxjrEb26sLoR30TFjyCm1gAP8AaU13Xwz0CbQ/C6Lfw+TqV3I1zcrnJUn7qn0woAx2OapfFXTWFnYa/btsn0uTa5K5HkyMFYkeg6/jWUop+6eHHMPaY7n+y7pEvw+1I3OjRWj3Ci5VmkSMk7mUjOOewPFdtG4MSdS2cBcfpXjem6nNaX63L7ZJomGydAFDDuD7HnmvW9Iuo9QgW6tyrxsMLJ2B78eo6V24Oqpx5eqKzDDunPnWz/M0icZLr8vbFRFg2VRQcckg5zTjvZj5JBP8RPb8aUOVTagxj25P1rsPNHD7oIUD2z1/wpG3YKneT3ye1EY+X7xLH0pjli2GkXaO+efpQA+PG1sqevccfl2qG5mMUgChjk9hk1KojyQh+XuacwTaVY/L7ev1oBblO/k36Vd71OGhYYY/pj1r5x1QrbaxLCLYTq5O0HcNvoeOpr6biSMNnb5jg/XFfPPieaay8SXdvGqx3HmFTtX5wRx1/CubFJOCbPcyOX72cb7r8n/wTJEttFIVdmMmMIWGQceo/pTnY3FmY3UxLyY3UFVb2P8AnilYOPleDdOjE71++Oed2OtNmS7lkVLKV5YG/gDfdGehHavPS7H1DVtzrvhnonn6zZXNwwZbYmd9pBGRkJ09+fwr2ryldsFnZCOV/vVzfw70z+ztBWQRorXBDZUclQMA8e+4106SoQY3b5uoA6169OChFRPiMfiPb15SWy0Xov6uKxmVB5eAgGAgGCPriqchJSWCVQIiuDzw2eoPcVZWWN2ZQHVx1yMVHK68klSMccBv596qxxLQ+aruxWPVLmK9uRD9jd4gM5PynAAH0ANRRXUxkRS8ph6BUft7Gu3+KmgodSOqQxzG3uztlwmcSgAD8wD+VcPJHeW9usMYKxH5nB4Ax3avLrU3GdkfcYOsq1FVF8/Ul02Zf7Sgjt4n3/8ALQgkl8nG3H8vevfPhbpX9leJLHz40W9uHJdU4CKEbC/h+p5rivAnh28Vhql5ZRxTceVGRhiSOZCOx54HbnjNepeDIJI/Etk0rEFmbPOWb5G6+1d+Hp+zSPns4xntb04PRX+Z6wv3RRQv3RRXoHyQtFFFABRRRQAUUUUAFFFFABXMeP5Hi0iEx/eNwAOcfwtXT1y3xCXdo0A/6eFwfT5WqZ7GlL40eesLsjEkiNz91lJ/rVxJYZANjrnH3ehB+lQAHb1Bx0OOn40hgSUbmjjZh/ETk/ia5j07kjROxHmFTgZ4HJqdWXaCnyeoYYqGJViT/Wcemf5VKpJG4cjuzHAFAMkO3AZ9p5yCTn8qaZ0blEYkHhsVBIULYRI8E4Zug+nvTmm24/dO/wDdCrwPpQFjkfixCL7w1DIyiT7NOC+AThWGOR1HOK8bDM42hUSGNtqRPhfwH+NfRlzIZIjG9iZV6Y45BHI/WvDvFPhHVrS/K2VpcNZknym2ltqZyFOMkEDj361y4mk52cT6DJsbGlF0p6dV/kYL3TyzNugXco+9GNuwe+K9/wDA+mNpXhqzgkY/bGXzblWb5t7cnPuAQPwrg/BvhMz3dvfamEt7S3ZWEMqnMpHYA4OM85/CvVQqspKj5jz7D61VCk6au92ZZzjY1pKlB3S/P/gBsEkwaRmMY7EZyauyCN48vGTjouMH/wCtWcGcMQox6kcbvpTQrLJuk3KP9ldw/Oug8SxKJCpJcgdRgKV/n1pTmQH5ePYck09FWVcqVb8en4VKFAYY457GgCJWAUZDEj0Bpjs0jqEBOOuR0p81wwbbG5Dk4AB5NV57uGxQC6uoomJz+9kA3fh1oDYmeOXou1V6k4pJpIbW3e4uZPKhQfNJI+1R7VTGozahEY9HhkuP71w6mOFf+BEZb6KDWTf6JNNCzX13He3gzh2BVIh6Kvb69TVODWrNIUpTaTKOueNYwTHpMsbsv3pDyxX/AGU+8frj8K8w1zW59YdxczlplY4dyQpGeBipvFmiDTbt5uJZN4JZCVOayJri0hj8y9VkYnBTk7z2w3OTn868fEVqk3ybH1uDwVDDxVRfe/60DOpWcBmDlLc9UkwynP6fjXe/DLwfHqFwPEWrWmbIbX0yKXPzMDnztp6qOiZ68nHQ1d+Hfwzjlk/trxjYhbR1za6XNuV3OQRLMueAOyNnOckDpXp95KZXL447Dp+VVGn7Jc0t/wAjwM2zZVr0KO3V9/TyK8fzSYc9f1pL60t5reWC5RZIJUMciHkMpGCP1pVbaQew+9UU77myV+X27Vi5I+fPCxbvpj3GkXIZb7T5fLEwI5h6o4XvlSOa2fCOvx6FqEaTysNOkJ85VyxOehHoen4V0PxJ8N/2vZJqmnxF9UsAGwgy00IJLR47nnIHtjvXESwrciO9t8SByGhkUAL+Jzx3GOxrN80JKpA+swdeGMo8k9+p7tC6TRB4CpiZQ0cikFSD0I9aVgSMNtzjr0z615V4O8Ry6DI0d8JZNOYYZY5A/lNn74HUA56DrmvUra4iureO4tpRLbuMq8RyG9OnT6V69Cuq0fM8nE4WWHlZ7dGSHCoNw2qOufSkiUf6xgSh4Hy07pgyLx1/H3pk00p5Qbh6AVucxNwWOGGD+BppkRCdqhnPGEFQq/y/vQoz0UnJP4dqAWAZ9qhQOgIAA/3qB2JfOcFtilfYDd+YrxX4s20tr4pa6iCwxXqiTzGOMuo2uueo7HHvXqN3rlvCSqXaeYv8EA8zH1PT9agPhy58aWzJ58QswwJaVBMS3oF6L+dTOk6keU7cDWeFqqs1pseDKzOGW0llRVGWLPgD3z/Sux+H/hC51RotR1NW+wocruGDNg9B/s+rd+1dxH8LB4akMyWFjqcecgupQr36Hcpq/b+IommCXkV1E4O0J5akKf8AgJ5/KsqeE9m7vU9TF5pOvTaw6dur/wCGN/KrGoWLywBgIAAB7Cn27LAvG1STkknk/hUFtcR3iM9u0cq9CwPIPoR2PtS+UAT1K9+efpW586WJpVcfugu8dW43fhmq0kxOVH3+5x296AjQgsoV1+hBqRNj/MD06qVwRQNWKt7bxXlm9veWnnwSDay4yv8A+v3rBj8M6ZZXCXKWrvKhzG1y+8IfUD19zXUHChzk/nxWfJ+/b5JS0anJA70GkZyimk7JkkPmNllAAPTdjmtDwoZW8VWDSsOWbAHX7jdaogsJB1x75Jq74WLyeLrBiW2hmGMY/gamt0Yz+F+h6uv3RRQv3RRXUeULRRRQAUUUUAFFFFABRRRQAVyPxKUtolthA/8ApS8EkD7rdcdfpXXVyXxJAbRLcE4zdL3P91vSpn8LNaP8RHngl24z+8bHAAwD9BTwJn+eRQfTzPuJ7hR1/GnAqoIGAc8jGT+FPGxmUqOQc4ORk1ynp3GxrI2JJGJA7ADJ98VMyeaVJYhR270qscDkZPGe9Scj5iCFxyWbA/L1piuMG6Ifu0jKD1OGp4lDjOzDjna3Q/Q01rlExs2kHjJ4U/QdTQYxMyksQrD5gFwD7c0g9R8VwZspb5ZhlSQeF/H1phMsURQOzPjr/n+tTAlFRVAWMfwAcioTEGYncNzH5QODTELD5kgUyRsm3qCAfz/xqR0G0F1BwepFKGZAQyyAL3K5z+IprTqEI+YLjrgj+lADyFL7cc9gBkj3oZ41JQlnfHKryR78cCoDJPMAF/dwnoScE/h1NMn+z2sYa6m2RjtIcKT9B1oHbuPbfE+Yljd3GFUnH8u9V59U+zqGuLeRSW2oi8s7H+EAdT7Cql3rMKR7rWyu5GH3XWLyx+bEfyrY+H8kGpX099c3EcmoFcLa5z9lj6EDPOTxuNXGF3ZmrhOMedx0OdvdM8RajCzFX0+LOWEbZldf7rMOFHsuT71i2mhmzuPMSKNZgeGUfPn6nmvaNfmlS2MduCHJ4AQnd+NcFq00NuwdiFK8nJrSULJM7MBiLpxjE2tFvI7vSJGVir8qyt1BrC1eIwN5hVIkRCSVOS3FchpeqaxrGszHwnp7alZkBZpvNENvE46fvTwT6hQxrqbbwJdatNDP4x1GOS2ifeNM0/cIZcHgTSPzIP8AZCqKn2ySaM686WHnq7+X6HmskOp+KNTuLXw1ateSK5Wa4L7YIM/35OgPsMn2r0X4d+CLTweGvbySHUNek6TiPCWo7pDn68tgE+wrvYoba0sorSwt4LW1hGI4IUCIg9gOKqzgA9hXny5YvmW/c48ZmlbFrkekOy/XuU7q4zIXmYsT261UkkLfNjr0FOeMvIxzwTxT1jB4I6VxSk5M8/YgGQMd6acAen41YaJc9xTTCKzcRkKyLGpOfm7V5v4r8IXK3t1qeiOkqzMZJtMc7Y5GI5dD0Dk84PBNekvGPwqBrcOwAyAT2prsbUK86EueDszw4XtvJcmEwTR3UJHmwSpslGO23t+Ga6DQdU1PRblrizt/Mgkb94skhVXXsAB/FXoHizwZpXiS3/02JkuAAEuocCVD2wccj2ry3UvBniXT38qO1bUoI8iKa0lCsw/2lY5Qn1GafsnCXNA+joZnQxMOStp67HqPhjXk155FFldQypglZCCo/HNbd1FKskUQke3MrBAYxk5P14ryjwBrD+DdWuj4lsr3SobpVCS3QLRhgTxvGV712zeLdMudSsI31jT2VrhWMjXabVUHPJz7V7FCXNT5pbnNVwtN1H7LWNjpNa8MT6ZbiWPxBdrK3GDGj/iMirHhnQ7e50przWrmbUAJGVPtGAvH+yML+YrE8VeMNI1PWEttMvxfqq42WStOWJ7YQED8adoeq+LJtIhs7DRI9PiAI8/VJNmPmOCI1y5P12/WuhzhB6s5JQ5aKcmlK/Xe35ljxBZ6e7L9ntkijXKhWAH48dqk8M+K9B0SyurO81e2tpHk3oZHVQBgDjJ56VTj8Dpf6gL7xRqU2qS8n7IoMVoD7pklj7k1uwaDpVlHss9L0+FOwjtkH64rnliUpXiiK2Npun7LWX4Ga/i7Tb6eU2mr21xkY2wTAj64BNYklomoXsUVsqTTSPhgvO0Z6se1a+reH9FvM/a9G02Y+rWqA/mBmuXi8P3mj3Bk8PaxPAmdwtb0GeFccgKQVZR+dT9cjJ+/oaYbHUqatFW/E9Ku/B8d0iyrMba/C4S4hOCMdAR0YexzWFdXL6ZefZtXR4ZicJIgzC/0P8JPofwJqqfiC9uIx4itJNNlUBPtcbefaPz1LgApyf4wvXvVzX72PU9H8iXy5X2bRIOcjt1rqvTlG8Xczo0Zzeu3dCtdMeFUIOnRnf8ALpUMvmGQLbyOhPIDDAJ9DWT4c1hnWPTb4v8Aaoxtjkk5EoHv/f8A54z7VtyqZIyhLgZ4PQj3rFoU4SpScZKzK+byRHjMYR8cuD0HtT4fLVNsZDke2CKQzraOS7eZO3YKQAP1pHntrpCSjRN1O35T+dBLuxz7MryAV7ZxVzwm8Z8VWIj3Md7Zzxt+RqyngV02pLOPYvj9cVreEo0h8SacEwql2AHUk7G6mnHdETtyP0PV1+6KKF+6KK6jyhaKKKACiiigAooooAKKKKACuS+JLMuiW5RC5+1LnDYx8rV1tcl8SP8AkCQZ/wCflf8A0Fqmfws1o/Gjz4XBA+dVG3nsx/nSrPKwytuT/wADwfypqr0DeWq9cAEk08SpKcEMxHp/9auU9OwovLkbs2pXHsuf504QzTt5lzldwxsB3fme1SqhLgnJVOVHU5p+N/Lv8vcHt+NML22EWMRY2oF46rn/ACafHIrhonJLHkKOtRM8aj5HyPQZqS1ZbdTyAzHJJbr9BQIBIHcoUZXHcgc1LGNmTksW6nHQUSzhwBCwyO/f+VRebMTt5Jx949aAs2SPcNGQsYHsSaYxZELXMyrGuWYseAPck9KZcvHDEXnnjhQDku2CB3x71o+H/D8WqWkd7fswt92+C1B4GOjP6t0IHQe5zVRjzA7RVzCuNZZ0JtYXZMhRO67UX355IHt1rVtdJgt1N7lrm6cczvjJ9h/dHsKoa7sguXi/hyQAc/zrPbW5NIs2+3TQRWyLkSyNjjsPr6Y5NaJcm53woR5eaBNeGWSdhICV9dhXFcvq2p/8I5qUGr28sEM0Ibd5rYVlxyp+tX2vtf1j/jwsUsrZ+Rc3+VLD1WEfP/31tp+ieDrS21SDUtSmn1O/hbzImmCpFE/95Y17/wC8TXLiMRDaO5UcbSoJqT5n2/zZuweNvEGsWSnSfC98Y5Fz5l6VtEGR2LnLD3C1hTeC9U8Q3H/FVXtpbaeGy1nprO7zD+60rAbR2O0ZPqK76GUy8tnd3NWVUjnfx9KzliHNHkfXJxuqfu37f8EbAiRQRwW8CQW0Q2pHGgVVHsBwKm579KTcMfeA96jedV+6QaxlUS3OSw92AUknA96zrhzISF+761PLIZRgD61EIyOuAPrXLObk7IpIijQjkmnqnORzUqR7gM5x/OrkARVIxV04XEzPMeBzmoZExk1enAViM5+lVXGTluKmasCKbru5xxVi3gx83fFBUkjGSM1cC7V6HP0pQWo2U1dR8jnGPWoZAhPBBpZ1JkbOOtQmMfiaHNhYa43fKpUg9RnINMt9CsmlDtYWO7PX7MmfzxUwgHcVqWj7Rhj+NVGV3qHoTW8YhTaoCL3CjA/IVIJAo4HNRklyMZxT8Ac5xVubewrDJmZ+tVmd04B/CpZcAE96pzSHkLj8axk2tRoiuJwT8yfkazLhkY9CKnnkcE5UVSlfJ5BrBzZokU59vI+VlYEMpGQw7gjuK5jSrh/Dep2ekksdIuJNlrcN84hJ/wCWMh/9BPccdRXS3HU4Bz9Kw9b0yPU9PuLOdmRJlA3r1RgQVYe4IB/Ct8NiXTlc6sPVdGV1t1PTIPBlrJZSLJfebc3C7sxqF2jqNo9iBWbC0iSzQXLbbu3bZMq9D6OPZhz+Y7Vh+APF91PaR2t8yJqlmWt5cjglf6HIYH3rW1+8gk8VwXVsRvuovKfnnKjcOPYhvzr3nyyjzROipSquTc9VvfyFRFaZ3ZiXRuVJ4HpSSyqeWwNpz83elljEjF0AbcAr4/T8qr30EZjzLEZh7Egj8qxMtyWa5jiBIbzX/hQL+nHarvhDe/i7T3mKLICRsVsgfI361k2mLVC0NuluCMly+Rj6f41p+DWafxXpskh+UOxRWIDZ2NyRTjuiamkJeh7Av3RRQv3RRXWeQLRRRQAUUUUAFFFFABRRRQAVyvxEONGgJAIFypI/4C1dVXJfEncdDgCsFzcrk+21qmexpR+NHnrIl0pKu+091YipEiFsmIgkajnDfzqKIKUZ4uO2V4//AFfWkAl8tiHiQeqgsT9Sf8K5T1USeaiAGN5BJ/fVD/LvTvMM7YdndRySUCD/AD71XSO4NwJVbMeMEMeh9a0EjxtU4z9etArka7WGISFxwABwPrSrGxzlyp9RU6K2XULls8c9fxod1iO1gC47A9PqTTF6Eaq0QG1Y2B78jNE90IvLSCF5rmUfJEGAwO7Mey8jn8hUdzqEdraPdXZxbL3AwCTwAO5JPA6UnhzTmvZTfzt5N0+MBTxGgOQnv6n1P0FVGNy4xvqya80i3ijSfV3Se7JJQuvCf7i/wj36+pqHQPEL6TrMOnSkvZTPhST/AKo46fSjxfqUemwyy6pIwjhUH5F3F8nCgd8kkAD1rmYdDv7u5N5rF1Jp+77tnalTKq99838LHoQnT+9RWqRppanWpU4Umq2z2XmX/GXiC2vdantNAhn1K9hIRlTiOFv9t/up9Dk+1UbDw+ZLmC81u6fUbyNhJHEPltoHHQonUsOcM3PfArYsrG1sbcW9lbx28Oc7IxgE+pPVj7kk1eigxjNeZXxc6r8jz54qTh7OGkfz9RY1djls89cmrarwOlIkdTRpzXJzM5CWGRY1+XOfSp0uHGCMVHHGhYbhke1X4IYypIUY96uPPLRMllVmaQjC/lUkds8jBSCpPtVpzHEN2AAOelRDV44WJSMMcYyapRgn+8Yeg57HyY8yEjNVm2L1Jb69KZca2koIk4Ppis+S8DnKyDHpipqVaa+ApRfU0PMyeOAPSp1f5eUBrJScnpU63D/wnilCqJoszNlxgAVAx3ck8fzpC2/lic0BlH/16uTuIX0ODj1qwZCy8N+FRiePy8MCTVV5wrHb0qeZRC1wk4cg9/akVFznoaRT5rfU09kAztY5FJK+oD0Xnj9anVcNzUceBz7U7fzmiWgFhSB9KZJIT6cVFvyMnp6Ux3wuQauOwDZ5OOTzVCeQr93pUszk57VSlcmspspEUkxJ5U5qEvuP+NPYknkVDJIEPSsSxzIGXkDNZ9zGVJ4yPWrYnznAqCZztOfmxRoNXOYMTWHiazu4yBbX0yW0wCjckpBWOQH0OAhHuDXaa14e1exu7W/ECvFbyrKXicH5ejcHkcE1xvjEFPD19cwkpJbItyhHUNGwcf8AoNeyaRq6azZ+ROp2XNuSo7D5ea9zAP2lNxfQ9CniakaWmq2foznGaOKZ2jfeB/rFQZx+FMhuony8Dq+Rj61Dp6M2nW5Epw0a8KoHOO/c/WnWpt/OYxR+Wc4YejelbGWg2fTlmwxuJSpO4q2Nv5Vq+EhCPFOn87n3MAznLfcbpVSSPzEwHO88cVa8IrHH4qsFXOSzfeJJ+41Nbozm7wfoesr90UUJ90UV1HlC0UUUAFFFFABRRRQAUUUUAFcn8RkD6LbgsV/0lce/ytXWVy3xCUto0ChymbgcgZ/haplsaUvjRwAUDCg8Yx+FRkB9ybgDnqFp7xMuAZogp427Dn+fFIiSSMRh1jGM5Qgn6c9K5j00OjjKrvt03of7rY+vFPExDFVSbI7leKc0gjXcFxgdCMYHvTEluZ8HeUTHAPX8ulADSZpy6RgxqBlpCMY/DqamggXarACTPG516/4Cnx71TahBfGWJGM1V1ee4tbRTaEG7ndYYQx4DHnP4AE0JXY9XojmZ79tZ1d1UhbS3JSIdi/QuR6+npXQQag9qsSE7FQbUUd/UmuV1/Rrrw5JHKqSfZJiWSV8kqe6scY68g1iW73niDUv7KtrhoITGZbyfGWWHIXYvozZIB7YJpPEOmnFntvDUo0FWv7qX4/53Ox0yRfE14viC/QSQRMU0uNhwoUkNOR/fZgQvoo9zXQ2sPmtvY55796oxpHDFFFbxrFDEojjjUYCKBgAewFaVrKFXnivMqVXOV2fM1ZupJyLYtUPVQfemNCIzx0FTxSCQfLmrKQbutTyqWxkUF9qkA9q0JbcFBwBj0FQyRbBk0nSaC5D936Ur3rRA7QD2xVe4kG0iqEkvHHWuedRx0iUkWprl5M7mOKzriYknr+dRzzHGATzVGWYnjBArB3e5okSSXGG2nr/Onwzdc1mSyHOe/qaalwQcA9OtZ2sy7G/FIR396vQbmGeMetc/Dc8DP0rUtp2HQ9a6KbSMpI1FjY9CPzpjhlJB6jrSQ3KuQCMe/arcixyICzEEDqK6klJaGexnyNxVaWTr6U64OHZQ34joaoTSMOlc0nYuKL1tdojBWyO2TUzXiibG7j2rnXkOc7utMjkO8YPvRGq1oVyHVRzluR35qQOSefrj1rFhuD+Jq9DKdpJ6mrvdkNWNDeSKjkY4qGKQknmkmkO30rZbEkc5yD61TkPPWnyuSOtQsc9axky0hjvtqu0mewNPZskimYGeBWbLRGTz0xSsuV5pSB3BoY/L0oih3OZ8aqU8K60RyPsco/NcV0nhrVZbTQre4jOdkW057ELg1geKozd6ctimN95dW9ov/A5kB/TNen+JfCempaXUtu8trKI2kk2YMbHBPK9icdRXsZfFuLaPQwlanTXLV+0/y/4c53SXL6Dp8hBBMEZOOcjAqxc7pANjbVA6k9zVaxJ/sfT44jiNbeMb8f7IxV1gFVyQMHtjJNdTMZb3RErlYwhI3gYzjvVzweAvivTsbRlmJAyf4G7msyV3jJRCu9zwdvOK1PBbr/wk9gqeYV3NksOc7WojuiJ/A/Q9dX7oooX7oorrPJFooooAKKKKACiiigAooooAK5P4ju0ehwlOW+0qAB1Pyt0rrK5b4gjOjwcZP2gfh8rVM9jSl8aPOEgSTPnfM452Mf6VIpNoheGHdnhogMH6inMVI5GMDqecf409doXeSVUdWJ2ge9cp6dxqTR3HJRg4x8r8E1YXKgjcmw9iOlMDREF1UlfUqQM+2acjAjdu8tfUimDFaQrkCJuO/wDDWfp8jz+NIjMA6WVuGCsOkkuf5Ko/76q6xEjFUL7FPTu3+Fc3oF/t8R68JCFYXW3IOSAoAH6VpSaUk5G9GlKd1HdL/gfqewTQxahaz21yiTREKDuUEcj09q8X8MpCIb7UbeKONL65fylQYCwRkxxAfUKW9y5rr/GPitNC8C6jdwyAXHlsqEnkuw2qfzIrmrWBdP0uzs48bbeGOIf8BUD+dcuY1EkkjmlCdKnyy6v8jTjbKgkmp0boazEkIwCcirUcnYn/AOvXjORz2Nm1mZMY6elbljKsm0Ec1ykMuDnuK2LG9EZBJGa3o1LOzM5ROl2qqkk8Vm3u3BwSKhGp+dvXI49Kyr+9IRgrfN6ZretXhbQSiyrczfMcciqE1xwT3qKWZ+igDJ65qtcxMIGkDszjnHavMScjZIfLMdpYkYAyfQVXR/PXfGQ6ngFWDAn6iqvh/TrbxS9xeakVn0C1fy4Yz/qruUfedv7yqflC9CwYnOBi1aeBdEuvFaNDatYWawNJdLYSNbpMgwAjhcAg5+vvXpU8vlKClfc7IYW8XJu1tTE1HxBpNreG1n1K1inBwys2Ap9C33QfYnNSiRiQUYEEZBHOfetjxu+m2/h68Sx0uOfT7ZNkFhBCSspHAQKAep6nB9TXF+G5rSzs7DSHa5ivEgysV1bSQFwOW2bwNwXOOOwqcRg/ZbajqUFTimmdLbTMpIzk+9bNpISOenXFY9tExOeg/Kty0hJQEiuRUzjm0Xo24p5OfWmLH8vFGXHBPToD3oaaMwfkYxn8Ko3OdvFXWBxkCs26bazBuD71KQ0Uph3JzTUbac7QfamSEjrVSW8treaCK4uoIZZjiJJJVUyH0UE89ulP2etzVGzDJzkdavwyg4ORxWSjYP0qdJOevPrRsyGrmzBJljzipJX455xVWyUvbNLnLZ59hTmbHXpW/QztqNkNQOcnGac55ODURbB5FYtloiOAad2ps6gEEUkbcVAxxPGKhlbPFOlJVc96rO4VCzuFUDJYngDuatBYo6IBqXxY8PaV5Za3s1bV52HYoGSMH23MD+Fel+ONR8nSNWQMM7XOPovH9K4f4VXEa2V/r7r++1OZpU3jBWBfkiUexC7v+BU3xTqUmqahZacMH7XcIJcdTGvzMfphcfjX0WEtQppNanoU8HKTUnstX+ZtwRLFa29vjCGNUfJ6YUUxpCGVDCwGMK55/OrALS75C5bcD0HBPoKj2/KyTEDcAAQcVmYkM0ixDzCDIcgKFGTn2q/4Nuhc+LNP8vOwM5JP+41UM7HIYknB+Ymr/goKPFdi0ce1WZssP4vkanHdCn8D9D19fuiihfuiius8gWiiigAooooAKKKKACiiigArkviQ6pokBcZH2lf/AEFq62uV+IeRosOD/wAvAyPX5WqZ7M0o/Gjzb7aMlYQpkPACguc/jxUkMc0hD3Tssg/hXD4981MgdcuxzI33RnoPSlQPk4QLz8ykDmuU9W9thiQo7bjucd2LFiT6c1Y8vcCrr8o6be/1ojVj/CSeeATUhVlX5sIB3kpk3IyhA/dSGPH8IGR9SK5GytDH4o1gy/L5svmBugOQK6+S5C/LE43A/MzdB9AOSaqW0Fpc6vcreRlxiOUFxtySu0nH/AacVdnVhKrpTbturfr+h598URLJ4cmhh/eOrCXb1BCHcf0BrqDMJ0EyEFZAHUjuCMj+ddxeRaUITEtrBsI2OBGOhGCPyJry3w1IYtIFjKx+0adK9lIDz9w4Q/ihQ5964sfTatIMdUVaMZJWtobSnJ96tIueuPpWclwFIyRx2qX7ST3wteVdHnNGkJCv4UG6K5IrL+0Kf4s017jJIDcVEpAomi9y7Z2kqfUHrUTTrt+dvm9Kpedxk/pTHcMeuT71nqyrFiSY7hzUerNLdWS6fbMRdX7i1Qr1RTzI/ttQMc+uPaqF9exWsIkkWSRmcJHFEN0krk4VEHdif8egNWNL8PapbMdR8Qso1F0KRRwMfLtozztHqx43NznA7CvTwVByfNbQ6MPh/azV9Ejub23trTTra00+GOK0iG1VUYCKP8/rWQ1+EsLn7LKDcTzCDbHyxwPuj8TVVbm71IraIGULj7RIowEX6+pHQfjVyGys7GeS9sreCKWFFhVx1OefxIGOevJr3VJyaV7Ha3GnLkauy9aW6aTpoeYlL7aN4Y/6sHnH19a83nu317xjLceYZbfTN6Rt1HnuMN/3ygH4v7Ve8a6nezQx6dp0yDUr19qGQZVAOWdh6ADP5DvVnQdKh0+yjtoASiDJLcl2PLMT6kkmvPxlZL3IkYqp7Onyv4pfgi/aQHgGtmJegAGPrVa2iIGRgVbQkV5qZ40mSoT06UMByDzQeRwSDTc7uvWpZJFISvbI9cVn3jhlOcEVpOflPNZ93HtjLAfWpLRyF/JqN/rb6ToUscL28QnvbiSLzPJVv9WqKeCzcnnoBXSeDNB0OHTNZS9s/td9cKq3U98oeWZTwTnoFz0C4A47iqvgWID4geIQ4AF1Y2siZP3thZW/LcK19Q/4lrNJdEpGp8t5Dx8p7/ga93CU4qCmvmerQhF07Je8zmtN+02Ny1jeyeavzGzmbO6aJeCGPeReM+oIPrWoW7jp71r2kFpqvhu0sNTVgGbzIp4uHhYZ2yK3Zh+RBIOQSK5SWe70m5Sy8Qm3iuXJENzCcQXIzxgn7r+qnHX5c1xYrCcq547MwxNBxnLlWiNyzvGtnYA5R+CtStdKfunntmsoSbSQMg+hFPEoI5X8+1ee7pWOSyNES7xg9aDIegx+NUFmB7j61MJVI96jULE5BPTrUZbyjk03zsDHAqGSYdN3NNRBDpZg4JJ7Vxfia9k1bUE0CzXfbscX8oJG0cEQg+rD73oDjvWsp1PxDdNY+GACqyCO51FseVbf3tp/jkxngA4JGa7bQfhzp2lw7Y7iXAJYsWyxzySSRyT1J7k16GGwspWmzvwlOnGfPW2Wy7mTZQmG0Rc7YY1+gGBUPhmxNxfXGqzlt026CCPHSIEZb23EY+grW1WytorsWlpNNNcMAQrP8saZ5dv6e+K0rZUiiVI/kVBtAUDAx9a9GStodWKxfNFwj13IlY28rQKqi2UEgjrk9vpQp/fMXzzx0xgUtwZWIwy7lz16VUjkBnYBV5XjHUHP6VJ59rks3ykMGOAelX/B7ySeKdOLqqkSNnHpsbFYzxSi6HzyNAOfm5O729q2/Cm5fFembsHLNg/8AanHdCqfA/Q9bX7oooX7oorrPIFooooAKKKKACiiigAooooAK5P4jeZ/YtuIjtJulyfQbWrrK5H4kvs0S34JZrlQMDPO1qmfws1o/GjgN8oYhlNwp6FSAy/Wk/eyNgFY0H3sHn8/WomhhUbniU46kAj9RTkuVYiK2iZX7bUPHuSa5T1Euw+S3d1AS5kB9HG7NOgtZJJCJZ1eFeoVNmT6ZqVWKxnzHAU8fLyfwqdNjgJGQwX7y4wfyoFdoFQIuI1VQP4ep/PrWP4jZrWW2u1ZkXBgZj0BJ3Ln2yCK2GaFPkJwx7dSPamz29te20kF1H5tvKNjx84I+lVGXK7hCXK1Jma18bjbO3AMe1ye5HSuEe5jh8aDBHl6latvX/ptCQA34o2PwFXbey1a2eewME8zWp2b0AIkU/dbrnkfqDSy+A/Fl1fWOoWmmxpJbhwUupAgdWxkcZIPAxxWOKcqyaUT2J0aKw8rTWu2qLJyM5XH0p2fl6CqlzdPZ3qWOtW02mXrnEcVyRiT/rnIPlf6A59qtc547V4sqcoO0keG4taMQ4xTdwHHFDAEHpmmRoQc5yemRUONw0JUz0P41KBnqBn271Xvbu0sEV72eOEnhVc5Zz6Ko+Zj7AGmy2WsanEqCGbRrNyC00zBbmVO6pGOY8/3iQwHQCuijhpTeiKp0pVHaJ0nwrsrbV/FWoalNCGh0pjZW25ePO6zSD8CiA9vm9TXQeNLjyWaSVgUAJ2Lzgdh9a4/w/ff8IjdWnlqyaYD5TwR5wgJGGA7nP4nNdBrT3Ova3DJcWj2enQZOybaGlbnBIB4UdeeSccV7tFxp0+Wx2ug8PVUm7xt/SItLiuLfS/OuX2SsWllAHTPTP0UCsH+0pr+IxWoeSUkucDIBb/AYrsWhS5iW3TBWWQJye3Un6YBq3qkMWlWjy5QRh+qgDgDJpxg5LmFh60VUbkryex5VoFu83iDWri5BMkEwsY93UBFVn/N2/8AHQO1ddBHgCsHwc5utMa8PzG7urm5DHqwaZ9p/LFdKgArxazvNnBiZudWTfcemcd6kViaAQetL16VkzmHehNIxXORSAkHnmn/ACmoYDcg84qvdAGM46VOPlJA6Go5l+U0kxnPWFs0njCz8sfO1ncgsODw0bCtnU5n1WfTra7hMqC4BlXAIlCqTjHfkDg1D4akjg8eaI0pAicXMTE+8XGfxFamvaTJZ+I7MOCbWVpZlIOOiEcf99V7eD/g3PToVl7PkfZ2/Ewtbsr3ToJbnSULWUakvbbvmix3TPVQP4fy9K6HwZ4aiu7JtR8Swrcb1aOK2kG5VVhzuHQkjt2pyzRy/u4FDKBh88gj3PvWbNPqWkwyW8JlvbA/MI1O54fbnqPQ9a3g1e8jSOIqSp+xva/Xr6XMPxN4aOk3UcvhacLYZ/eWM7sU/wCAE5KH8x7VnXEktiFfUbeWzRx8srHzIWB9JFyo+jYNbkl8zqRcQ3NupGQ0sbKufdjwK6HSNSj/ALLjSFlcgAY46fyNZ1MNTqS7GlWhCUU931scNbyidd9s8c6esbhgfxFSST+QCZx5QHdyFH5mtzXdI0XUreV73S7SO5/57pGEc/Urj+dTeB9O8Gpb/vdC09p1Yo0k0CyEke75rmeXpStzGDwb5PaK7+X/AATg77xRZxNstne8m/55WieafxI+Uc+9RWVjd63c79auGt7JgAthbTYZvXzZF6g/3VP417le6f4Y1i2Rb/TrPZECIwGKMg9tuMfSuB8ReF9O0q8B0/XI9r/MtrINzr6AbTk/zrT6i6Tva5tgnhHpO6l5rT8P1L1pIljbQ2tokdtBEoVQi4RB6KBxTrnXJJ5PsWlI8tzj5mboD6seir9evasCHQNTu3Au75bKz3AlQH8517gBgNn1PP0rrbWC3s7VbeyiSKAHhIxnn1J6k+5rrVa0bJBXlCL913/Ir28EdrGsRf7Rcud8kn99+7ew9B2GKubVSRuxJ6k9fpVdFRGJSPaCckgkc08+cwJYqUzxgdPpWV7s4nqRb2ZnZVfHTcwpt2qo5kUhQpwc81LLIWXjhcjJI/pTZ1SSB1GFPQcUgKkhEYYvLG5DYyONo9K3fCe0+KbAB+jMSP8AgDVzqWixsz4HOA/H61u+E9i+K9Mw2cs4HHH3Cacd0Kr8L9Getr90UUL90UV1nkC0UUUAFFFFABRRRQAUUUUAFcn8RyRocOBlvtK4/wC+WrrK5P4jMw0W32IGP2kdTjHytzUz+FmlH40efFud2Mtj7o71LErRKdxDyMck5PA9KgZ3dVCEKDyGHB/CnrM7ZJMUiL/y0GAR9fWuU9S2hIWHmAugwoJz/hUbmRzultY5AOF/eYP6iiVsIHbYr9uP4e9AkDzFdytxng4IoDYkiYqjsY/LPTCgsVH0FSQuQC/zfZ+h3DBB9cHtTFdRIvLDcODjn8KczP5yukbnA6svWmBX1SK5jniv7BElu4QVMZcL5yHnAPqMZH1I711ei+KrPV7NJ4ZpYCVA2kY2sOqsD0Oe1YMMjnMSLmROQCCOKyL/AES++3S6ho88VvdSAeZDOSY5sd/l+6e2ec1rTqKO4csai5Ju3mdt4ii07xBo8ltfx28iyKyskighj7Zrxuz0LXLaU6dFqds0SSFYnubdpZtnUDdvAOOgyOlajeI5obn7LrdvLp9yP4JR8pHqrDgj3FOgvIINeRhLlWRXBKkYznBGR7damcIVn7y0PRjhVTpqL97t/wAAk/4Vxr8+C/iq8jBHKx20a4+h5qje+Cb6xSFNR8T6vcQPKsbmExxEAnHJ25x9K6TVPEohVVllVQmPmDckfSue1DxXbX4micmOELkux/ID3qZ0aMdElcuhg5zXNKGnoei6b4T0Tw9bNNpVhbRXW3BudoaVvXLnLH865DWneW5DyPHEqNuZwc9Pc1Paya3c6XaKTDGrRhj5rtvwRwGwOvqKrr4XGoXQOr3fmxwEP5ESlUc+jE9R7Vo52Vkc9OVOm7zlexn6Sw13VLeWNXTTrSTzfNkXAuHX7qr6gHkn2FddcMfKbnb8xzjnI706e1CSRuihI04CqAAo9vYelI4+eT93g9yeOvesjGvWdWXMJYOttNaqQFVY5CMe/HP51n/EbWki8I6hMDnyLWZzg9WK4A/MgVavLaWeeBYDvIicnHoMVwPxDkeDw1qEc6nBVGbPoJEJ/QGtOdqFuhvhqUZL2i3Rs+CLcweFdGicEOtnFuBHIJUE/wA66FFqjprrJbQvGQY3RWQ+xAI/Sr6k4rw9zxpu7Y8KKfxTM4o3HsOKlkknBFN6HinDJHvSAHnmosIa2MZHWmSH5cd6kbBBx1qGQ4U9qkaMNLcXXiXTUI+VBcStx0Aj/wATWrpN3Nc3pt7iZpBYo6xsxyQrFT/Qiqnh90l8WSr9429hLkY7yOij9Aa09Otvs93fs2DMJEXYP4cDofzr2cKrUVL1PUpytQ5X8vv/AMjTXKpz8xb5jz09BUIdgmYkUyMT1OB+NSGSQnmNQxOMg8NUDuiMyxuoQjIPv35rYwQw7gCPsqrn7xEmQB9KxZtGktZn/s5hHA7bkjCtiMnqFIGMd8ds1uROHAIGc8fKc0sD5TADMRxtVf5007bFxqSg7xObvND1i4Xyhe2keRlWYsc+xHY1Wi8JarDaiKDV4FlyXb905BJPbkYrqlWUhwEZSecYBqZGeaINkKOhEnBz0pOzOhY7ERVlL8F/kctbeHr918vUfEN7sXqtunlkeuSSxx7it/S9MsLFWW0tokzyZduXc+pfqasvBDw0swDDoew+npRbTxqWiIPXPTAGe49j+lF3sYzqyqayY8oACQ7rjsHOKqtG8qtskdcHIJ74q27lvlx07VWDbZMAfrgE+lBmmKIYQxlcEseuegphZjDtVimOenPWkLsNztEVPQuCGAqGe6iiRlJG/IxleuTSDULsSwoxl2vxwcdD+FMWVbiImMFDs3ELxz/Or85jd3XOARkjGM/jVNIxAdvBUHKnHQ+lA+g2SRGj3MFx1UjritLwhx4o00YPLsTz/sNWSglcMAVVkY4xyCK0fBsxHi3TUZGDM78dh8jd6qO6M6nwu3Y9iX7oooX7oorqPKFooooAKKKKACiiigAooooAK4/4mxrJodvvUttulYYOOQrV2Fcd8Tm2aJanLj/S1+7/ALj1E/hZrQ/iI4B3VoiHUISMH0/CmxwRoVkjjyyfd7Cm+ZIyAlQAeFX1oEnlyEgSA46AcH8a5j1C5O8UsGHXZ2weKgtomz85ZFHIGAWNDSSsn7wKoPRQMnFFm6FRsYsh75/Ue1O4iysgR0ZG4zkgj71LcJ5j4JIwN3TP61FM2F2sGb5shen6UiRGUnzZCGU5Codpz/8AWFIF3LADSwIUB81OHVjj/PtUiOj8EgP6ZwD71RKpM5F0585R8xBwGXsalVWkUbmlVSMLyMAdgR60waJjEA4Ctgrzwc4P+e1YWv6DbaxdJdy3E9vdxR+VuUb1kXORlevHPIrWKmAAq5Ug8KCCD+FSs/nKHPylThgeooLp1JU5KUXZnHP4Pa8Yb76UgcMojwT9CTj+dbWieE9K0m8iljt2e6Of3sshc9Ow6D8BWnM7om5MYUdCMH86ZbtIbmN5ZiwXORjnp60lpsa1cXWqR5ZTdixNCCCqMQM8jrj6VFZxeWLnYDhjzu5PSpfOBlJKEqRjO7tTkaIHKLtceh/nTOZscjb1B6jg5zjNMfHzBGyu305pIypXkYx0IOc/lRKwaZN2DIRgL1yP6UAWdFmRNXhY9XilQc98A4x+FZvxE8OpruiXIgfl4mRiPRlIB/z6VHqPnxzWktmQ0wuFIXoT8rdPXitCy1lZYmRl2oyEFSMEH0xW0OWUHFnRQU4tVIfM47wTKT4bsIZiPPtU+xygcYeI7D+gB/GukRh61yigaN4yuocN9h1qQzwntHcqvzKf99VBHupFdPGwIFeNWg4TaOHE0/Z1GuhYz6U4dOKiXIHGcU4OeymsGc5JSbuaTk9RinHgcVDAazELwOaq3EnyHA56AVPI+0Z7msPXtQNpaO0SmSc4SKNeS0jEKij6sRSSu7IqEW3ZDPAscba3qWrAlhdzLCozlRFDuUN+J3fpXTRzee80ygr50sjg+vJANVfD3g+90PQXbVZ44YbWA5RTueQj1PQZPb3qe1j8i1hhkyxUDjv05r3orlpxieriPZpqNN3sT26JbsNquykYJPOKju9rvmLBk9vShJn+7HuYn+8MAVHO+WXe2ecAqCMn0BoRzEqKFGXbJPG1RxUkbsxkG7IzuGB09vemI5ZMgksOhA6j+lQyuWdipGMfOxPGKAtceAElExDsrZ34TGBUkmY5TLEUKtyuec+veoNrxDzY2MjN/rFzwR6AdsVFGsalZLRj5jg4JPCjvkUhl/zI8blkWPv8xAP45qFo8oSmSQSVJ5/P2qMQtjKvICOodh+eajjb7O5ESlo+rKGzg+uaYJdiSa4mKBY0Af8AvdP8/WiC3ySxlKZxlMjg0vHmFh8x4IwOgNUbxWklCyEMo53Y5HtxSKVjTicG1bBzhyNuOtUJ4lWMsoGWIyxPPWn25WG02g7mLHDMcd6ek/yfOigj0Pb+tBOwTEh0csWJyoJ5Ht06UqbckgKdwwcck0x2XBKKoDEHBbANPG3cGUEN05GcUxdCKXakxILDgfKf8a0/CRH/AAlWm733He+AvTOxutZryAgbecdTnpWj4UA/4SzTcjJ3tj2+Rqa3RM/hfoz1xfuiihfuiiuo8oWiiigAooooAKKKKACiiigArjfiihk0C3VXK/6UucdxsfiuyrkPiWcaHb8gf6UvUZ/hapn8LNaPxo84BkOCrjIHRgSaRo36md32kErgD+VKA6RktgEEd+3TFPI+baGByOhGTXKencU+czAo6AHrlSzY9qVGhY7oOIycYJGMnuPakjjkMWMohOefvnp2qOJQ29Fky6jPzR4/lQMvDI+YhWmxyScAewoAAAOGJPJwu481SkuCFKMfMbnciLz7jPYfrQt0YPkZ/MGM7fKJ2Z7ZB/Si4crLc0UMmGlQEr0ycfyqQHcCyFYl6FmHBPtUMM/mFTJ5UsTZAZBjaR2Oeac0u4oMAg8KuP6UCJjEnIXLOBgu3WowN0boQzEDDL159aQEpkHLDg/Sn/7RLAjo2aA6ESMJgjlCwPOC2NppryBMsAmxTyRk498elLJJ5CNuIAB5/oKWLBgXegbPOR/F+FAPuMWaKVxHE5RpDhSU4P0oYy27nfukTH3wvPHbHepJlWVWRmwQNwxwV759KSKYzocvt2jkD7x+lAEC3MhKurRhOu1Rzj+tWkdg52RyO5GS/fHpU0awRw7o0BDDnI/nUUdwxbCttHIGB1xQDa6EN5L5USzGCRDA6ygsPQ88j2zU2pWkdwrXGnsqTqfmQnhxjg1KZ2ddrgDPVWGa5+7kl035Ucx2u4LFIDny/wDYb1GehrWm1tI6MPNp2X9eRyPxO1A23hm9mbzIL212zQurYaOQMNrKfxNbngfU7vUvCulXmpBftk0AaQrxu64b6kYP40zxJp9r4g0yaz1RAUmXBZTjPfIPY8ZrJ8MX/wBnD6NcFDdacqopjG0Sw9EcD17MOxHoa48VG6uXmFJyippbf19x3scnAIPHvUykEf4VhQX+Bglqtpfrz85x9K85+Z47izTJx2OKY0gAOPzrOe/QA5yffNUrjVeSBn8qzbBQZoXNyFDbckiuatbma78RxXCxKbHTJRI0sh+V7kD5Ux/sbt31wO1UdS15zctZ2Z3XbYBZhlIc929T3C/TOK6jR7ix8N6VG/kGbYSEDje80rHkknqSSa78DhnOXtHsj08NhnBKrUWj28zeutVvNSeK0ldjESJZweNwByq/icH6ClZ3Zn2kK2cA4zjuaqWMM6yzXV4R9tuiNwDZVMdFH07+9T71+0FVzhlJOBjkd69CbuyJtN+6tByhw53Ss7OMZxgfkKaflU/aWVozwoiXbz65PekYs2MFTg8/w0XIYLueRVCnkImf51BBKmd5UsOnJXuD6UoCkKqKoj69ep96rLhESRJFCkYLEcjnio2n8w7lk2bRu80JhV9cDv8AjRcLF7K9dpweeF/rUQSGJ2YR/M/XBJP5VXW+3cGSME9HkiKhvyNWIpcfeRVmDbSwXg8cHii4Wa3JAhOd8uwLzsH3h9TUcsewK0a4jHVQe3rmm5MjNluRwWHOT6U5XLLgbgcA545oC5HK4R42wxDjaZOnHbJpPljRyyBc8lifvU+QZUheO+CeFqrJNvmWIEEkglT6dhQNaiPOkbFJgAW6BVJ3fQ0IrXSF4LkgIcbNvIPv3Iq1xvJCYboTgMB/hVaXZDKtyhOWG0gHhhQFyLz3QKrptc8DcMqD9altzKRgybt393+VTEodnmv5gJ4A4H40okzbOduAG696AbKk8su37qrHuXjqTzW54SkJ8W6dhSFLNjK4/hasSSMzIpUrlSM57GtbwirjxbpZIAId84OQRsb8qcd0RU+F+jPYU+6KKF+6KK6zyRaKKKACiiigAooooAKKKKACuT+I+P7Egzji5Xrx/C1dZXI/EtwmhQklR/pK/eP+y1TPZmlH40edq4UuCAAeuDnJqQCNMbSueM88CqMU6tMcq24evIP0qxJOCpxtyBnHeufQ9PUdgRxuvAHZeozUUbxqfOgKFYsh1Udc+lRzXKBQWBYj+Eckk9BSNcRhEkiVmAyNgUAofQ/WpKSJ/Mjm3CB2BbliVxt/Kp4S0ahbfBdhli2efxqktyrqPkeNT1UryPf6U7zUIXl9n94H+dAW6EkxdH3qqkNjcuPunsTjvU6SRA/MSXPJYf8A1+lMbbGoeMD/AICKrylxlyFZM9O/1H+FAbllpU81WO5jjbuA7e5p8kgijZ9plwOOelU3vEVBsy8nYZxj6ilVzJywKkcN6/Q0CsSxyNmSMqfMUZ4IwwPc5q0wcBvmVuORjOPy61nMbiFd0ciiBeBkbmx6Edx+tWIpY5F+Rf3gH3V5yPVT6UIcu6JvMUA45P8AdJ7/AENQiXMj+ZhWXkgYH5VKIfNdVdsHHA7nHvRKsEeCkQLKOvNMWhUtLltsoVI0hJ+5k5H4+tWo22MG3kqw4YAc/hTWlzEu4KQeNqDpSZXcBGwGWyD6etKw3Ys7uR0z7mmyoroykBhjBUnIxQzEBuA/HK+1RReZcDEaKka8guuMUyUV9Ke303U4btLaOaONiJrYAHcCD8yA8bhx6d62detfDXiawiuTaxu4OVYfuZYj7kYZTWPfR+WVdyjuw27ox835Ui2EVyitJAsbqMCSRismPYjkiqjK2jRopWaldnJ3enXdpO0Vlf8AmRg8JfR7mH/A0IJ/EGmpBq25VaCzO7hSty2PyKcV0k2jwlsx3sxf/cVwv580sWluGBku94HYwhQfyNZzoUZPY6nLCyj70dfu/wCAcwIdUckS/Yrcf3md5CPwAX+ddZoPhnQHgE2uXt9d55KM/wBnix7qhz+bVnXmkXbhVTUlQscKBaqx+uS1Rv4etooxNfTz3vlkF1mIVCPZRxiiNGjDVRuwqLDNe5p6Xv8AiQa/pVlc62174TtIINOijCfMu2JXHUoOrZ9u/etnTNMhjaO5leW5vAufOmGApx/CucD+dJqcwhhVLZG8vK7WUcBfQDpVyGR5YvvtIehBxTvq7GdTE1KkIwk9Foi0m+L5lEe5uoJ6/jSsyySESYBXlv8AZqsI4ZGyQGZjx7CnxzCFhHJGEjIwrY4XHZjQc45ypQquCFx1PP1ptzNEoV5iNoGTuBz7Ypk8oAIQBgf+ebZFRxBVmDbCzdQR2Y+1AIeZI7eMJO4MUmWVkGQPahCspV2c+Wex6tVeR1s2yEJhc5IC8q3qB6GnqHkw5LLIRkIBgYpD8y47NIgGxPK6DcOn1BqCANyrn92ONwyCwHTpSpbEjdICeOjnOKJCdzpEpz144BpiJgyAfuyyD8OagjKYZULIQTgY459Kq+bJFNtmADEZVugI/wAabJdNuzHGWjHV8kj3/CgEmWp5HyY0T7o3EsQd1OgdpdjLlAylgzMCR6getV3j3KHDFZB80eD9002OWeKbZcmOQ5yEVQP++D/Q0D0a0LkhI/1nKgdQp/mOlMeRgp8sBuOWODxT1AIUxKSh5DdAfw/pSLHAi+Y7A5PJPApkkLkGMHAJPQZ6e9NnYmIq20+2SN1TT4RcxBVHUCs8rI7s3msB3GBz7UmNK5DJcRwFY8vkn0yF7cn0+tdD4Iy3i7Tc53B2Jz/uNXPG5gjV4WZSx6FgAcdMV0XgiCNPFem+SzFFdjt7fcaiG6FV+B+h7Mn3Riihfuiiuw8cWiiigAooooAKKKKACiiigAqjq+k2Wr26QajB50Sv5iruK4bBGeCOxNXqKNxptao5seCPD46WBH0nkH/s1PbwboLcmxOenE0n/wAVXQ0VPKuxXtZ92c5H4J8PxvuSwIb1M8hP/oVKvgzQVdmFk25vvEzyHP8A49XRUUcsew/az/mf3nPf8IboQYt9ibccc+fJ/wDFUHwZoJYn7EwJ4OLiQf8As1dDRRyrsL2s+7OdHgvQApUWB2+hmkx/6FSnwboLKFawyB0Bmk/+KroaKOWPYPaz7s5seCPDynI08g9f9fJ/8VTz4N0EnJscn/rtJ/8AFV0NFHLHsP2s/wCZnPf8IZoO7P2Dnr/rpP8A4qhfBugr92xIGc486TGf++q6GijlXYXtZ92c/wD8IdoWQfsTZByP38n/AMVTm8I6IzBjZEkdP30n/wAVW9RT5V2D2k+7ML/hEtExj7Fj6TOP/Zqb/wAIhomf+PM/jPJ/8VW/RRyrsHtJ92YLeEdEIwbI49ppB/7NTv8AhE9FChRZkKOwmkH/ALNW5RRyrsHtJ92YJ8I6Jx/oXI5z50mf/QqB4R0QKF+xnA6ZmkP/ALNW9RRyrsHtJ92YR8J6L/z6N+E8g/8AZqD4S0U9bMn6zSf/ABVbtFHKuwe0n3Zg/wDCIaHkk2WSf+m0n/xVIPCGhb9xsATjHzSuR+W6t+ilyrsHtJ92c5N4K0CZlaSydiuMf6RKAPw3U/8A4Q7Qt+4WRDe08n/xVdBRRyx7D9rP+ZnPt4P0JkKNYnaf+m0n/wAVSjwhoYTZ9jYr6NPI382rfoo5V2F7WfdmCvhHQ1ztscZ/6av/APFUf8IhoeMGxz/21f8A+Kreoo5V2D2k+7ML/hEtEHSzP/f6T/4qmt4Q0NxhrJiOv+vk/wDiq36KOVdg9pPuzn18G6EvSxOMY/10n/xVIfBuglgxsTu6586T/wCKroaKOVdg9rPuzBfwjobk77EHPrK/+NRL4K8PqcrYH6efJj/0Kujoo5V2D2s+7OeTwZoCDC2GARj/AF0n/wAVSHwZoBUg6eMH/prJ/wDFV0VFHKuwe1n3ZgDwhoYz/oR56/vpP/iqF8H6Eu7Fj97r++k/+Krfop8q7B7SfdnOjwXoAjKCxIU9R58n/wAVTZPBHh502tp+V9PPk/8Aiq6SilyR7B7Wf8z+85U/D/w0fvacx+tzKf8A2atGy8NaTZXcdza2myaMkq3mucZGOhOK2aKFGK2QOrN6NsAMDAoooqiD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    How acne develops. Increased shedding of epithelial cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27942=[""].join("\n");
var outline_f27_18_27942=null;
var title_f27_18_27943="Bilirubin metabolism";
var content_f27_18_27943=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bilirubin metabolism",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Namita Roy-Chowdhury, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Jayanta Roy-Chowdhury, MD, MRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Elizabeth B Rand, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27943/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/18/27943/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin is the potentially toxic catabolic product of heme metabolism. Fortunately, there are elaborate physiologic mechanisms for its detoxification and disposition. Understanding these mechanisms is necessary for interpretation of the clinical significance of high serum bilirubin concentrations. Furthermore, because bilirubin shares its metabolic pathway with various other sparingly water soluble substances that are excreted in bile, understanding bilirubin metabolism also provides insight into the mechanisms of transport, detoxification, and elimination of many other organic anions.",
"   </p>",
"   <p>",
"    An overview of the major aspects of bilirubin formation and disposition will be reviewed here. The settings in which bilirubin disposition is impaired will also be discussed briefly. Clinical aspects of serum bilirubin determination, the evaluation of patients with hyperbilirubinemia, and the classification of causes of jaundice are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=see_link\">",
"     \"Clinical aspects of serum bilirubin determination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=see_link\">",
"     \"Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FORMATION OF BILIRUBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin is formed by breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, peroxidase and tryptophan pyrrolase. Eighty percent of the daily bilirubin production (250 to 400 mg in adults) is derived from hemoglobin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/1\">",
"     1",
"    </a>",
"    ]; the remaining 20 percent being contributed by other hemoproteins and a rapidly turning-over small pool of free heme. Enhanced bilirubin formation is found in all conditions associated with increased red cell turnover such as intramedullary or intravascular hemolysis (eg, hemolytic, dyserythropoietic, and megaloblastic anemias).",
"   </p>",
"   <p>",
"    Heme consists of a ring of four pyrroles joined by carbon bridges and a central iron atom (ferroprotoporphyrin IX). Bilirubin is generated by sequential catalytic degradation of heme mediated by two groups of enzymes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Heme oxygenase",
"     </li>",
"     <li>",
"      Biliverdin reductase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Heme oxygenase initiates the opening of the porphyrin ring of heme by catalyzing the oxidation of the alpha-carbon bridge (",
"    <a class=\"graphic graphic_figure graphicRef65197 \" href=\"UTD.htm?12/7/12415\">",
"     figure 1",
"    </a>",
"    ). This leads to formation of the green pigment, biliverdin, which is then reduced by the biliverdin reductase to the orange-yellow pigment bilirubin IX-alpha. Iron is released in this process, and the oxidized alpha-bridge carbon is eliminated as carbon monoxide (CO). Measurement of intrinsic CO production has been used to quantify bilirubin production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heme oxygenase is present in the high concentrations in reticuloendothelial cells of the spleen, the principal site of red cell breakdown, and in the Kupffer cells in the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/3\">",
"     3",
"    </a>",
"    ]. It is also induced by heme, eg, in hemolytic states.",
"   </p>",
"   <p>",
"    Heme oxygenase is thought to be rate-limiting in bilirubin production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/4\">",
"     4",
"    </a>",
"    ]. As an example, pharmacologic inhibition of heme oxygenase by tin-protoporphyrin or tin-mesoporphyrin reduces bilirubin production [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Conjugation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bilirubin is very poorly soluble in water at physiologic pH because of internal hydrogen bonding that engages all polar groups and gives the molecule a contorted \"ridge-tile\" structure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/6\">",
"     6",
"    </a>",
"    ]. The fully hydrogen-bonded structure of bilirubin is designated bilirubin IX-alpha-ZZ. Water-insoluble unconjugated bilirubin is associated with all known toxic effects of bilirubin. Thus, the internal hydrogen bonding is critical in producing bilirubin toxicity and also preventing its elimination.",
"   </p>",
"   <p>",
"    Conversion of bilirubin IX-alpha to a water-soluble form, by disruption of the hydrogen bonds, is essential for the elimination by the liver and kidney. This is achieved by glucuronic acid conjugation of the propionic acid side chains of bilirubin. Bilirubin glucuronides are water-soluble and are readily excreted in bile. Bilirubin is primarily excreted in normal human bile as the diglucuronide; unconjugated bilirubin accounts for only 1 to 4 percent of pigments in normal bile.",
"   </p>",
"   <p>",
"    During phototherapy, which is used to reduce serum bilirubin concentrations in babies with severe neonatal hyperbilirubinemia, configurational and structural photoisomers of bilirubin are produced [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/7\">",
"     7",
"    </a>",
"    ]. These isomers lack hydrogen bonding and are excreted into bile without further metabolism. In the bile, the configurational isomers may revert back to the hydrogen-bonded bilirubin-IXa-ZZ.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measurement of serum bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reaction of bilirubin with diazo reagents causes breakdown of the tetrapyrrole to two azodipyrroles (the van den Bergh reaction) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/8\">",
"     8",
"    </a>",
"    ] which can be readily measured spectrophotometrically. Diazo assays are most commonly used for quantification of bile pigments for clinical purposes via the following sequence.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Because the central carbon bridge of bilirubin is buried within the molecule by hydrogen bonds, unconjugated bilirubin reacts slowly with the diazo reagent. In comparison, conjugated bilirubin, which lacks hydrogen bonds, reacts rapidly even in the absence of accelerators (\"direct\" van den Bergh reaction).",
"     </li>",
"     <li>",
"      On disruption of hydrogen bonds by addition of \"accelerators\" such as methanol or caffeine, the reaction is completed rapidly (total bilirubin).",
"     </li>",
"     <li>",
"      Unconjugated bilirubin (\"indirect\" bilirubin) concentration is calculated by subtracting the direct-reacting fraction from total bilirubin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Direct reacting bilirubin slightly overestimates the conjugated bilirubin concentration because a fraction of unconjugated bilirubin (about 10 to 15 percent) also gives a direct van den Bergh reaction. There are several other potential sources of error. As an example, endogenous substances, such as plasma lipids, and drugs, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    , interfere with the diazo assay. This can produce unreliable results, but only when the bilirubin concentration is normal or slightly elevated. Albumin-bilirubin complexes (delta-bilirubin) also may give a direct reaction. More accurate and sensitive quantification of bilirubin requires chromatographic analysis, such as high performance liquid chromatography and reflectance fluorimetry [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/9-11\">",
"     9-11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     METABOLISM OF BILIRUBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of steps are involved in the metabolism of bilirubin (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Albumin binding of bilirubin in plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Binding to albumin and, to a much lesser degree, high density lipoprotein, keeps bilirubin in solution in plasma; only a small fraction of bilirubin circulates in the unbound state. Binding to high density lipoprotein may become significant in states of severe hypoalbuminemia.",
"   </p>",
"   <p>",
"    Albumin binding keeps bilirubin in the vascular space, thereby preventing its deposition into extrahepatic tissues, including sensitive tissues such as the brain, and minimizing glomerular filtration. It also transports bilirubin to the sinusoidal surface of the hepatocyte, where the pigment dissociates from albumin and enters the hepatocyte (see",
"    <a class=\"local\" href=\"#H7\">",
"     'Uptake and storage of bilirubin by hepatocytes'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Free bilirubin can cause cerebral toxicity when the molar concentration of bilirubin exceeds that of albumin (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Bilirubin toxicity'",
"    </a>",
"    below). On the other hand, the plasma bilirubin content increases after albumin infusion because of transfer of the pigment from tissue stores to the intravascular space.",
"   </p>",
"   <p>",
"    Several other ligands bind to albumin at the same site as bilirubin, including sulfonamides,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , antiinflammatory drugs, and cholecystographic contrast media. These agents can displace bilirubin from albumin, thereby precipitating bilirubin encephalopathy in newborns without an alteration in the total serum bilirubin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/12\">",
"     12",
"    </a>",
"    ]. Many other compounds such as fatty acids bind at a different albumin site but may, in some cases, reduce the binding constant of albumin for bilirubin [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Albumin binding of bilirubin is usually reversible. However, irreversible binding can occur in the presence of prolonged conjugated hyperbilirubinemia, eg, during biliary obstruction. The bilirubin fraction irreversibly bound to albumin (delta-bilirubin) is not cleared by the liver or the kidney and, because of the long half-life of albumin, lingers in the plasma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/14\">",
"     14",
"    </a>",
"    ]. This may result in prolonged hyperbilirubinemia after endoscopic or surgical relief of biliary obstruction. Because delta-bilirubin gives a \"direct\" diazo reaction, this may give a false impression of a persistent blockage of the bile ducts [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/15\">",
"     15",
"    </a>",
"    ]. The presence of delta-bilirubin can be inferred by the absence of bilirubin excretion in the urine despite the apparent presence of direct hyperbilirubinemia and can be identified by high performance liquid chromatography of serum (",
"    <a class=\"graphic graphic_figure graphicRef65615 \" href=\"UTD.htm?2/2/2094\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Uptake and storage of bilirubin by hepatocytes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the liver sinusoids, the albumin-bilirubin complex dissociates, and the bilirubin is taken up efficiently by the hepatocyte while the albumin remains in the circulation. Bilirubin is taken up by hepatocytes by a process of facilitated diffusion, which is not energy-consuming; as a result, transport cannot occur against a concentration gradient, and is bidirectional. Defects in the specific transporters that mediate each of the steps in bilirubin transport can lead to hyperbilirubinemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"     \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sinusoidal bilirubin uptake requires inorganic anions, such as chloride, and is thought to be mediated by carrier proteins which have not been fully characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Passage of bilirubin across the hepatocyte sinusoidal surface membrane is bidirectional. Normally, canalicular excretion, rather than sinusoidal uptake or glucuronidation in the endoplasmic reticulum, is rate-limiting for bilirubin throughput. Bilirubin entering the hepatic sinusoids is efficiently extracted by hepatocytes close to its point of entry (ie, periportal region). A fraction of the unconjugated and conjugated bilirubin within the hepatocytes is transported back into the sinusoidal blood. This fraction undergoes re-uptake by hepatocytes downstream to the sinusoidal blood flow. The re-uptake is mediated by two proteins, organic anion transporter protein 1B1 and 1B3 (OATP1B1 and OATP1B3), encoded by the genes SLCO1B1 and SLCO1B3. This results in the recruitment of additional hepatocytes in this process, thereby increasing the net bilirubin excretory capacity of the liver [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/18\">",
"     18",
"    </a>",
"    ]. Within the hepatocyte, bilirubin and other organic anions bind to glutathione S-transferases (GSTs). GST-binding reduces the efflux of the internalized bilirubin, thereby increasing net uptake (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This process of bilirubin uptake is impaired in certain disease states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilirubin uptake is reduced in some, but not all, patients with Gilbert syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"       \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"      </a>",
"      ), and is inhibited by certain drugs, eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , flavaspidic acid, and cholecystographic dyes.",
"     </li>",
"     <li>",
"      The re-uptake of conjugated and unconjugated bilirubin is disrupted Rotor syndrome, which is caused by mutations or deletion of both SLCO1B1 and SLCO1B3, resulting in loss of function of both OATP1B1 and OATP1B3. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=see_link\">",
"       \"Inherited disorders associated with conjugated hyperbilirubinemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with cirrhosis, a portion of the bilirubin produced in the spleen may bypass the liver via portosystemic collaterals. Furthermore, the sinusoidal endothelium, which is normally fenestrated, may lose the fenestrae (capillarization), thereby creating a barrier between the plasma and the hepatocytes. As a result, serum unconjugated bilirubin concentrations often increase in this condition.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Conjugation of bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucuronidation of bilirubin, a large variety of endogenous compounds (eg, steroid hormones, thyroid hormones, catecholamines), and a wide array of exogenous substrates (eg, drugs, toxins, carcinogens and laboratory xenobiotics) is mediated by a family of enzymes, termed uridine-diphosphoglucuronate glucuronosyltransferase (UGT) (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/19\">",
"     19",
"    </a>",
"    ]. As noted above, glucuronides are more water soluble, and are readily excreted in bile and urine.",
"   </p>",
"   <p>",
"    Enzyme-catalyzed glucuronidation is one of the most important detoxification mechanisms of the body. Of the various isoforms of the UGT family of enzymes, only one isoform, UGT1A1 is physiologically important in bilirubin glucuronidation (",
"    <a class=\"graphic graphic_figure graphicRef65615 \" href=\"UTD.htm?2/2/2094\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/20\">",
"     20",
"    </a>",
"    ]. UGT1A1 is an intrinsic protein of the endoplasmic reticulum (ER) and its catalytic site is located within the ER lumen. Therefore, the sugar donor substrate uridinediphosphoglucuronate (UDPGA) must enter the ER lumenal space for conjugation. UDP-N-acetylglucosamine is the natural stimulator of the transport of the polar substrate, UDPGA into the ER lumen. It has been suggested that four nucleotide sugar transporter proteins mediate UDP-N-acetylglucosamine stimulation of [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilirubin diglucuronide is the predominant pigment in normal adult human bile, representing over 80 percent of the pigment. However, in subjects with reduced bilirubin-UGT activity, the proportion of bilirubin diglucuronide decreases, and bilirubin monoglucuronide may constitute more than 30 percent of the conjugates excreted in bile. Reduction of conjugating enzyme activity to approximately 30 percent of normal results in a mild but discernible increase in serum bilirubin concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Inhibitory factor(s) for hepatic UGT1A1 is secreted in the milk of some mothers (breast milk jaundice). In other cases, an inhibitory factor present in maternal plasma may be transplacentally transferred to the fetus (the Lucey Driscoll syndrome). UGT1A1 deficiency also may be seen in neonates, chronic hepatitis, and in certain inherited disorders (Gilbert's syndrome and Crigler-Najjar syndrome I and II).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Excretion of conjugated bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjugated bilirubin and other substances destined to be excreted in bile are secreted across the bile canalicular membrane of the hepatocyte against a concentration gradient that may reach 1:1000, indicating the presence of active transport [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/22\">",
"     22",
"    </a>",
"    ]. Among the four types of canalicular transporters, the multispecific organic anion transporter, also termed multidrug resistance protein 2 or ATP-binding cassette C2",
"    <span class=\"nowrap\">",
"     (cMOAT/MRP2/ABCC2),",
"    </span>",
"    appears to be the most important for the canalicular secretion of bilirubin and many other organic anions, with the exception of bile acids (",
"    <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enhanced bile flow (eg, by infusion of bile salts) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    treatment increases the maximal bilirubin excretory capacity. On the other hand, the excretion of conjugated bilirubin is impaired in a number of acquired conditions (eg, alcoholic or viral hepatitis, cholestasis of pregnancy) and inherited disorders (eg, Dubin-Johnson syndrome, Rotor syndrome, benign recurrent intrahepatic cholestasis). It can also be caused by a variety of drugs (eg, alkylated steroids,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=see_link\">",
"     \"Classification and causes of jaundice or asymptomatic hyperbilirubinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=see_link\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Degradation of bilirubin in the digestive tract",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bile pigment appearing in bile is mostly (more than 98 percent) conjugated. Conjugated bilirubin is water soluble and is not absorbed across the lipid membrane of the small intestinal epithelium; in comparison, the unconjugated bilirubin fraction is partially reabsorbed and undergoes enterohepatic circulation (",
"    <a class=\"graphic graphic_figure graphicRef78388 \" href=\"UTD.htm?3/52/3906\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/24\">",
"     24",
"    </a>",
"    ]. This fraction increases during phototherapy because of the excretion of photoisomers of bilirubin. Oral administration of charcoal, agar, or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    may interfere with the absorption of unconjugated bilirubin, thereby increasing the efficacy of phototherapy. In contrast, excessive amounts of bilirubin are available for reabsorption in neonates with obstruction of the upper intestinal tract, delayed passage of meconium, or fasting; this may increase the intensity and duration of neonatal jaundice.",
"   </p>",
"   <p>",
"    Bilirubin is reduced by bacterial enzymes in the colon to a series of molecules, termed urobilinogens [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/25\">",
"     25",
"    </a>",
"    ]. The two major urobilinoids found in stool, urobilinogen and stercobilinogen, are colorless and turn orange-yellow only after oxidation to urobilins. In complete biliary obstruction or severe intrahepatic cholestasis (eg, in the early phase of acute viral hepatitis), feces may take the appearance of china clay. Thus, the absence of urobilinogen in stool and urine in a jaundiced patient indicates complete biliary obstruction. Urobilinogens and their derivatives are partly absorbed from the bowel, undergo enterohepatic recycling, and are eventually excreted in urine and feces (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Urobilinogen'",
"    </a>",
"    below)&nbsp;(",
"    <a class=\"graphic graphic_figure graphicRef78388 \" href=\"UTD.htm?3/52/3906\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The intestinal microflora influence serum levels of bilirubin. In a study in Gunn rats (which have a congenital deficiency of bilirubin UDP-glucuronosyltransferase), treatment with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/57/14229?source=see_link\">",
"     neomycin",
"    </a>",
"    resulted in the disappearance of fecal urobilinoids while serum bilirubin increased dramatically (from 10.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    {186",
"    <span class=\"nowrap\">",
"     micromol/L}",
"    </span>",
"    to 17",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    {289",
"    <span class=\"nowrap\">",
"     micromol/L})",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/26\">",
"     26",
"    </a>",
"    ]. Intestinal colonization with C. perfringens led to reappearance of fecal urobilinoid production accompanied by a partial decrease in serum bilirubin levels. The authors speculated that prolonged use of certain antibiotics may lead to an increase in serum bilirubin levels in humans. Patients with abnormal bilirubin conjugation may be at particular risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Alternative pathways of bilirubin elimination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternative pathways of bilirubin elimination may be important in certain clinical settings. One such pathway is oxidation of bilirubin by mixed function oxidases in liver and other organs. In addition, induction of cytochrome P-450c by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    reduced the serum bilirubin concentration in one patient with Crigler-Najjar syndrome type I (enzyme catalyzed oxidation) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In conditions associated with elevated conjugated plasma bilirubin concentrations (eg, intrahepatic or extrahepatic cholestasis), the kidney is responsible for 50 to 90 percent of conjugated bilirubin excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. However, bile remains the main excretion route for unconjugated hyperbilirubinemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Urobilinogen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urobilinogen is produced by bacterial breakdown of bilirubin excreted in bile into the bowel. It is partly absorbed in the bowel and undergoes hepatobiliary recirculation. The fraction that is not cleared by the liver enters the general circulation and is partly excreted in urine. As a result, urinary urobilinogen excretion may be increased in the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excessive bilirubin production (eg, in cases of hemolysis or absorption of hematoma)",
"     </li>",
"     <li>",
"      Inefficient hepatic clearance of the reabsorbed urobilinogen (eg, in patients with cirrhosis or at some stages of hepatitis)",
"     </li>",
"     <li>",
"      Excessive exposure of bilirubin to intestinal bacteria (eg, constipation or bacterial overgrowth).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    By contrast, urinary urobilinogen excretion can be reduced or abolished in near-complete biliary obstruction (eg, carcinoma of the pancreas) or severe cholestasis (eg, in early stages of viral hepatitis).",
"   </p>",
"   <p>",
"    Standard clinical tests for urobilinogen do not distinguish between normal and low urinary urobilinogen levels. Furthermore, urobilinogen excretion can be reduced, normal, or elevated in patients with hepatitis as noted above. Tubular reabsorption and instability of the pigment in acid urine can also influence results. Because of these complexities, tests for urinary urobilinogen are usually not useful in the differential diagnosis of liver diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BILIRUBIN IN DISEASE STATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal plasma, about 4 percent of bilirubin is conjugated. This relationship may vary in disease states:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In inherited disorders of bilirubin conjugation, the proportion of conjugated bilirubin is reduced.",
"     </li>",
"     <li>",
"      In Rotor syndrome (defect in re-uptake of conjugated and unconjugated bilirubin) and in Dubin-Johnson syndrome (defect in canalicular excretion of bilirubin), both conjugated and unconjugated bilirubin accumulate in plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In biliary obstruction or hepatocellular diseases, both conjugated and unconjugated bilirubin accumulate in plasma [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In hemolytic jaundice, total plasma bilirubin increases, but the proportion of the unconjugated and conjugated fractions remains unchanged.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Bilirubin binds to the elastic tissue of skin and sclera, and is also found in all tissue fluids with a high albumin content. The usual tight but reversible binding to albumin precludes glomerular filtration of unconjugated bilirubin; similar principles apply to irreversible covalently bound bilirubin (delta-bilirubin). In contrast, conjugated bilirubin is less strongly bound to albumin and can be excreted in the urine. Thus, the finding of bilirubin in the urine, in the absence of albuminuria, indicates the presence of an increased amount of conjugated bilirubin in the plasma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Potential beneficial effects of bilirubin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although clinicians are generally concerned with serum bilirubin levels as a marker of liver disease and the direct toxicity of bilirubin (see",
"    <a class=\"local\" href=\"#H15\">",
"     'Bilirubin toxicity'",
"    </a>",
"    below), within a near-physiological range of serum bilirubin concentrations, the antioxidative action of bilirubin may provide beneficial effects. An inverse relationship between serum bilirubin levels and risk of ischemic coronary artery disease has been reported in middle-aged British men [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/30\">",
"     30",
"    </a>",
"    ]. A population study in Belgium showed an inverse relationship between serum bilirubin levels and cancer mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/31\">",
"     31",
"    </a>",
"    ]. More recently, the study of a very large number of subjects in the US revealed that the odds ratio for the history of colorectal cancer is reduced to 0.295 in men and 0.186 in women per 1",
"    <span class=\"nowrap\">",
"     mg/dl",
"    </span>",
"    increment in serum bilirubin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/32\">",
"     32",
"    </a>",
"    ]. However, such statistical associations do not conclusively prove a causative role of bilirubin. In addition to biliverdin (and bilirubin), the other products of hemeoxygenase-mediated heme breakdown (namely iron and CO) may also have physiological roles in the liver. As an example, one study found that induction or overexpression of heme oxygenase attenuated the replication of hepatitis C virus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bilirubin toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unconjugated bilirubin is toxic to many cells and organelles. Physiologic mechanisms that protect against bilirubin toxicity include, as described above, binding to plasma albumin, and rapid uptake, conjugation, and clearance by the liver. Because of these efficient protective mechanisms, the harmful effects of unconjugated bilirubin is limited to neonates with a high degree of unconjugated hyperbilirubinemia and subjects with inherited disorders of bilirubin conjugation.",
"   </p>",
"   <p>",
"    Markedly elevated serum unconjugated bilirubin concentrations (usually over 20",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    in the newborn may result in clinical evidence of brain damage, ranging from subtle neurologic abnormalities to severe encephalopathy or permanent neurologic damage (kernicterus) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27943/abstract/34\">",
"     34",
"    </a>",
"    ]. The serum concentration at which clinical signs of neurotoxicity occur is variable. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants\", section on 'Kernicterus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3744821\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bilirubin is formed by the breakdown of heme present in hemoglobin, myoglobin, cytochromes, catalase, peroxidase, and tryptophan pyrrolase. Eighty percent of the daily bilirubin production (250 to 400 mg in adults) is derived from hemoglobin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Formation of bilirubin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bilirubin is very poorly soluble in water at physiologic pH because of internal hydrogen bonding that engages all polar groups and gives the molecule a contorted \"ridge-tile\" structure. The conversion of bilirubin IX-alpha to a water-soluble form by disruption of the hydrogen bonds is essential for the elimination by the liver and kidney. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Conjugation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of steps are involved in the metabolism of bilirubin (",
"      <a class=\"graphic graphic_figure graphicRef52393 \" href=\"UTD.htm?30/51/31536\">",
"       figure 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Metabolism of bilirubin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In normal plasma, about 4 percent of bilirubin is conjugated. This relationship may vary in disease states. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Bilirubin in disease states'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/1\">",
"      Berk PD, Howe RB, Bloomer JR, Berlin NI. Studies of bilirubin kinetics in normal adults. J Clin Invest 1969; 48:2176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/2\">",
"      Berk PD, Rodkey FL, Blaschke TF, et al. Comparison of plasma bilirubin turnover and carbon monoxide production in man. J Lab Clin Med 1974; 83:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/3\">",
"      Bissell DM, Hammaker L, Schmid R. Liver sinusoidal cells. Identification of a subpopulation for erythrocyte catabolism. J Cell Biol 1972; 54:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/4\">",
"      Sassa S, Kappas A, Bernstein SE, Alvares AP. Heme biosynthesis and drug metabolism in mice with hereditary hemolytic anemia. Heme oxygenase induction as an adaptive response for maintaining cytochrome P-450 in chronic hemolysis. J Biol Chem 1979; 254:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/5\">",
"      Drummond GS, Valaes T, Kappas A. Control of bilirubin production by synthetic heme analogs: pharmacologic and toxicologic considerations. J Perinatol 1996; 16:S72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/6\">",
"      Bonnet RJ, Davis E, Hursthouse MB. Structure of bilirubin. Nature 1976; 262:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/7\">",
"      Itoh S, Onishi S. Kinetic study of the photochemical changes of (ZZ)-bilirubin IX alpha bound to human serum albumin. Demonstration of (EZ)-bilirubin IX alpha as an intermediate in photochemical changes from (ZZ)-bilirubin IX alpha to (EZ)-cyclobilirubin IX alpha. Biochem J 1985; 226:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/8\">",
"      Van den Bergh AA, Muller P. Ueber eine direkte und eine indirekte Diazoreaktion auf Bilirubin. Biochem Z 1916; 77:90.",
"     </a>",
"    </li>",
"    <li>",
"     Roy Chowdhury J, Arias IM. Disorders of bilirubin conjugation. In: Bile Pigments and Jaundice, Ostrow JD (Ed), Marcel Dekker, New York 1986. p.317.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/10\">",
"      Chowdhury JR, Chowdhury NR, Wu G, et al. Bilirubin mono- and diglucuronide formation by human liver in vitro: assay by high-pressure liquid chromatography. Hepatology 1981; 1:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/11\">",
"      Brown AK, Eisinger J, Blumberg WE, et al. A rapid fluorometric method for determining bilirubin levels and binding in the blood of neonates: comparisons with a diazo method and with 2-(4'-hydroxybenzene)azobenzoic acid dye binding. Pediatrics 1980; 65:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/12\">",
"      Robertson A, Karp W, Brodersen R. Bilirubin displacing effect of drugs used in neonatology. Acta Paediatr Scand 1991; 80:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/13\">",
"      Rudman D, Bixler TJ 2nd, Del Rio AE. Effect of free fatty acids on binding of drugs by bovine serum albumin, by human serum albumin and by rabbit serum. J Pharmacol Exp Ther 1971; 176:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/14\">",
"      Weiss JS, Gautam A, Lauff JJ, et al. The clinical importance of a protein-bound fraction of serum bilirubin in patients with hyperbilirubinemia. N Engl J Med 1983; 309:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/15\">",
"      Lauff JJ, Kasper ME, Ambrose RT. Quantitative liquid-chromatographic estimation of bilirubin species in pathological serum. Clin Chem 1983; 29:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/16\">",
"      Wolkoff AW. Hepatocellular sinusoidal membrane organic anion transport and transporters. Semin Liver Dis 1996; 16:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/17\">",
"      Kullak-Ublick GA, Hagenbuch B, Stieger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995; 109:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/18\">",
"      van de Steeg E, Str&aacute;neck&yacute; V, Hartmannov&aacute; H, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/19\">",
"      Dutton GJ, Burchell B. Newer aspects of glucuronidation. Prog Drug Metab 1977; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/20\">",
"      Bosma PJ, Seppen J, Goldhoorn B, et al. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994; 269:17960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/21\">",
"      Kobayashi T, Sleeman JE, Coughtrie MW, Burchell B. Molecular and functional characterization of microsomal UDP-glucuronic acid uptake by members of the nucleotide sugar transporter (NST) family. Biochem J 2006; 400:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/22\">",
"      Arias IM, Che M, Gatmaitan Z, et al. The biology of the bile canaliculus, 1993. Hepatology 1993; 17:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/23\">",
"      Jansen PL, Oude Elferink RP. Hereditary hyperbilirubinemias: a molecular and mechanistic approach. Semin Liver Dis 1988; 8:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/24\">",
"      LESTER R, SCHMID R. Intestinal absorption of bile pigments. II. Bilirubin absorption in man. N Engl J Med 1963; 269:178.",
"     </a>",
"    </li>",
"    <li>",
"     Stoll MS, Lim CD, Gray CH. Chemical variants of the uroblins. In: Bile Pigments, Chemistry and Physiology, Berk PD, Berlin NI (Eds), US Government Printing Office, Washington, DC 1977. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/26\">",
"      V&iacute;tek L, Zelenka J, Zadinov&aacute; M, Malina J. The impact of intestinal microflora on serum bilirubin levels. J Hepatol 2005; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/27\">",
"      Kapitulnik J, Bircher J, Hedorn HB. Chlorpromazine reduces plasma bilirubin levels in Crigler-Najjar syndrome type I (CNS-I). Hepatology 1989; 10:A708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/28\">",
"      Cameron JL, Pulaski EJ, Abei T, Iber FL. Metabolism and excretion of bilirubin-C14 in experimental obstructive jaundice. Ann Surg 1966; 163:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/29\">",
"      Cameron JL, Filler RM, Iber FL, et al. Metabolism and excretion of C14-labeled bilirubin in children with biliary atresia. N Engl J Med 1966; 274:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/30\">",
"      Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem 1995; 41:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/31\">",
"      Temme EH, Zhang J, Schouten EG, Kesteloot H. Serum bilirubin and 10-year mortality risk in a Belgian population. Cancer Causes Control 2001; 12:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/32\">",
"      Zucker SD, Horn PS, Sherman KE. Serum bilirubin levels in the U.S. population: gender effect and inverse correlation with colorectal cancer. Hepatology 2004; 40:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/33\">",
"      Zhu Z, Wilson AT, Mathahs MM, et al. Heme oxygenase-1 suppresses hepatitis C virus replication and increases resistance of hepatocytes to oxidant injury. Hepatology 2008; 48:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27943/abstract/34\">",
"      Shapiro SM, Bhutani VK, Johnson L. Hyperbilirubinemia and kernicterus. Clin Perinatol 2006; 33:387.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3622 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D40D2B0C78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27943=[""].join("\n");
var outline_f27_18_27943=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H3744821\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FORMATION OF BILIRUBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Conjugation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measurement of serum bilirubin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      METABOLISM OF BILIRUBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Albumin binding of bilirubin in plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Uptake and storage of bilirubin by hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Conjugation of bilirubin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Excretion of conjugated bilirubin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Degradation of bilirubin in the digestive tract",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Alternative pathways of bilirubin elimination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Urobilinogen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BILIRUBIN IN DISEASE STATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Potential beneficial effects of bilirubin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bilirubin toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3744821\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3622\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3622|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/7/12415\" title=\"figure 1\">",
"      Bilirubin synthesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/51/31536\" title=\"figure 2\">",
"      Bilirubin in hepatocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/2/2094\" title=\"figure 3\">",
"      Bilirubin and UGT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/52/3906\" title=\"figure 4\">",
"      Bilirubin circulation summary",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/57/7065?source=related_link\">",
"      Classification and causes of jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/28/36294?source=related_link\">",
"      Clinical aspects of serum bilirubin determination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/63/25593?source=related_link\">",
"      Clinical manifestations of unconjugated hyperbilirubinemia in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/50/42790?source=related_link\">",
"      Diagnostic approach to the patient with jaundice or asymptomatic hyperbilirubinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/7/8314?source=related_link\">",
"      Inherited disorders associated with conjugated hyperbilirubinemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27944="Cervical spondylotic myelopathy";
var content_f27_18_27944=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cervical spondylotic myelopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Kerry Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27944/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/18/27944/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylosis refers to a progressive degenerative process affecting the cervical vertebral bodies and intervertebral discs. This process can lead to narrowing (stenosis) of the central spinal canal, compressing the cervical spinal cord and producing a syndrome of spinal cord dysfunction known as cervical spondylotic myelopathy. Myelopathy occurs in 5 to 10 percent of patients with symptomatic cervical spondylosis. Other clinical syndromes associated with cervical spondylosis include neck pain and cervical radiculopathy.",
"   </p>",
"   <p>",
"    Cervical spondylotic myelopathy is the most common cause of myelopathy in adults over 55 years, causing progressive disability and impairing the quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to cervical spondylotic myelopathy will be reviewed here. Neck pain, cervical radiculopathy, spinal cord syndromes, and other spinal cord disorders are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=see_link\">",
"     \"Evaluation of the patient with neck pain and cervical spine disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link\">",
"     \"Anatomy and localization of spinal cord disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylosis is a general term for nonspecific, degenerative changes of the cervical spine that are common in older adults. These changes include degeneration of the intervertebral discs resulting in disc herniation; facet, uncovertebral, and vertebral body osteophyte formation; and ossification and hypertrophy of the posterior longitudinal ligament and ligamenta flava. The pathogenesis of cervical spondylosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical features and diagnosis of cervical radiculopathy\", section on 'Cervical spondylosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These processes can lead to narrowing of the central cervical canal. This in turn can produce dysfunction of the adjacent spinal cord, as the combined result of mechanical compression of neural elements and spinal cord ischemia due to compression of the arterial",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    venous blood supply to the cord [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/2\">",
"     2",
"    </a>",
"    ]. Flexion and extension of the neck may exacerbate compression; the canal diameter is reduced by 2 to 3 mm in flexion, while extension can cause inward buckling of the ligamentum flavum.",
"   </p>",
"   <p>",
"    The neurologic syndrome of cervical spondylotic myelopathy is sometimes referred to as a radiculomyelopathy because the spondylotic process can simultaneously damage spinal nerve roots as well as the cord itself. Injury to the anterior horn cells in the spinal cord gray matter can also cause lower motor neuron deficits at the level of spinal cord involvement (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Clinical presentation'",
"    </a>",
"    below). Because the C5-7 regions are most commonly affected, the lower motor neuron or segmental signs are generally observed in these myotomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spinal cord compression can give rise to weakness in the arms, legs, or both; sensory loss with a high thoracic or cervical sensory level; and urinary and rectal sphincter dysfunction.",
"   </p>",
"   <p>",
"    There is no well-defined pattern of neurologic deficits in cervical spondylotic myelopathy. Patients present with varying signs and symptoms that can include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pain in the neck, subscapular region, or shoulder, often radiating into the arms.",
"     </li>",
"     <li>",
"      Numbness or paresthesias in the arms. The sensory loss may follow a dermatomal pattern (",
"      <a class=\"graphic graphic_figure graphicRef53006 \" href=\"UTD.htm?21/8/21634\">",
"       figure 1",
"      </a>",
"      ), and often underlie complaints of loss of fine motor control in the hands.",
"     </li>",
"     <li>",
"      Gait disturbance, usually characterized by a spastic, scissoring quality.",
"     </li>",
"     <li>",
"      Sensory deficits, usually related to dorsal column function (reduced joint position and vibratory sense) and loss of pain sensation, can be elicited in the lower extremities and may contribute to the gait impairment.",
"     </li>",
"     <li>",
"      Weakness in the lower extremities with upper motor neuron characteristics: increased reflexes, increased tone, and present Babinski signs.",
"     </li>",
"     <li>",
"      Lower motor neuron findings (weakness, atrophy, and suppressed reflexes) in a myotomal distribution in the arms or hands. The C5-7 myotomes are most often affected (",
"      <a class=\"graphic graphic_table graphicRef74632 \" href=\"UTD.htm?0/56/908\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Bladder dysfunction, urgency, frequency,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      retention.",
"     </li>",
"     <li>",
"      Lhermitte's sign. An electric shock-like sensation in the neck, radiating down the spine or into the arms, produced by forward flexion of the neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Symptoms usually begin insidiously. Gait impairment is a common early symptom [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. This is often ill-described by the patient, who may complain of leg weakness or stiffness or of a vague unsteadiness. By the time a patient presents for surgical intervention, sensory deficits in the hands causing functional impairment are also a common complaint in 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. Clinical bladder dysfunction is less common, occurring in less than 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/2,8\">",
"     2,8",
"    </a>",
"    ]. The examination may also reveal crepitus of the neck with restriction of lateral flexion and rotation.",
"   </p>",
"   <p>",
"    Patients with cervical spondylotic myelopathy may present with progressive bilateral sensory loss and motor dysfunction in the hands, without other neurologic symptoms. These symptoms can be misdiagnosed as carpal tunnel syndrome, but electrodiagnostic studies (nerve conduction studies and electromyography) will fail to support that diagnosis.",
"   </p>",
"   <p>",
"    Some patients with cervical spondylotic myelopathy will present acutely, often after minor neck trauma (such as from a fall or a whiplash injury in a motor vehicle accident), with a central cord syndrome characterized by disproportionately greater motor impairment in the upper compared with the lower extremities, bladder dysfunction, and a variable degree of sensory loss below the level of injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=see_link&amp;anchor=H19#H19\">",
"     \"Anatomy and localization of spinal cord disorders\", section on 'Central cord syndromes'",
"    </a>",
"    .) It was previously thought that the injury in these cases was the result of a concussion of the cord with stasis of axoplasmic flow, causing edematous injury. However, autopsy studies have demonstrated that bleeding into the central cord is a more likely mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. This is a rare event in patients who are asymptomatic prior to the trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylotic myelopathy is often unrecognized in its early stages. In later stages, when impairments are clinically evident, several alternative diagnoses may be suggested.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Amyotrophic lateral sclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both amyotrophic lateral sclerosis (ALS) and cervical spondylotic myelopathy present in older adults. The neurologic examination in both disorders often demonstrates mixed upper and lower motor neuron deficits. With cervical spondylotic myelopathy, lower motor neuron deficits and fasciculations are isolated to the affected cervical myotomes, but in ALS they often appear in the legs and cranial muscles (eg, tongue) as well. Sensory deficits are not expected in ALS, but these are also often subtle or absent in patients with cervical spondylotic myelopathy.",
"   </p>",
"   <p>",
"    Further complicating this issue is that radiologic evidence of cervical spondylosis in asymptomatic adults with normal neurologic examinations is well documented [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/12\">",
"     12",
"    </a>",
"    ], and may be an incidental and misleading finding in a patient with ALS. Cases are reported in which continued neurologic deterioration after surgical decompression for putative cervical spondylotic myelopathy was later attributed to ALS [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/13\">",
"     13",
"    </a>",
"    ]. Electromyography is an important diagnostic aid in ALS. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=see_link\">",
"     \"Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other cervical cord disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other pathologies can affect the cervical spinal cord and produce a syndrome similar to cervical spondylotic myelopathy. Some of the more common of these disorders are summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef50336 \" href=\"UTD.htm?6/0/6157\">",
"     table 2",
"    </a>",
"    ) and are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4428935\">",
"    <span class=\"h2\">",
"     Guillain-Barr&eacute; syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guillain Barr&eacute; syndrome (GBS) and cervical spondylotic myelopathy can both present as a subacute progressive paraparesis or quadriparesis. Patients with GBS typically have reduced or absent reflexes and may have cranial nerve involvement, while patients with cervical spondylotic myelopathy usually have hyperreflexia and do not have cranial nerve involvement. However, these clinical signs may be absent early on in presentation and neuroimaging may be required to distinguish these diagnoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=see_link\">",
"     \"Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Normal pressure hydrocephalus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sharing clinical features of gait impairment and bladder dysfunction, normal pressure hydrocephalus (NPH) can superficially resemble cervical spondylotic myelopathy. However, in NPH, some degree of cognitive dysfunction is usually apparent, the gait disorder is usually apractic rather than spastic in quality, and urinary dysfunction is accompanied by an indifference representing its probable frontal lobe origin. These features are distinct from those of cervical spondylotic myelopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=see_link\">",
"     \"Normal pressure hydrocephalus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis requires a careful correlation between findings from the history, physical examination, and imaging studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both magnetic resonance imaging (MRI) and computed tomography (CT) with myelography can be used to diagnose cervical spondylotic myelopathy, providing a quantitative assessment of central canal narrowing [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/14\">",
"     14",
"    </a>",
"    ]. MRI is superior in providing intramedullary detail of spinal cord pathology, but CT provides better images of bone and other calcified tissues. Because it is noninvasive, MRI is generally considered the test of choice [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/5,14\">",
"     5,14",
"    </a>",
"    ]. MRI is also useful to exclude other potential causes of cervical myelopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=see_link\">",
"     \"Disorders affecting the spinal cord\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Various measures of canal narrowing are used clinically and in research studies. The simplest of these, and perhaps the most commonly used in routine clinical practice, is a measure of the anterior-posterior diameter. Cervical spondylotic myelopathy is considered unlikely if the diameter exceeds 16 mm, and probable if less than 10 mm. Others use measures of canal area as a more reliable measure of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spondylotic cord compression can be seen at one or more levels. One-third to one-half of patients have multilevel disease (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55057 \" href=\"UTD.htm?18/20/18753\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/8,16\">",
"     8,16",
"    </a>",
"    ]. Compression at more than one level usually correlates with more severe neurologic deficits and perhaps a worse prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potentially important marker of disease severity and prognosis is a finding of signal abnormality within the cord (intramedullary). However, investigators report mixed results when attempting to correlate neurologic impairment with this finding [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/3,17-20\">",
"     3,17-20",
"    </a>",
"    ]. Hypointensity on T1-weighted images, though less frequently seen than hyperintensity on T2-weighted images, may be a more reliable marker of disease severity (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55057 \" href=\"UTD.htm?18/20/18753\">",
"     image 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/3\">",
"     3",
"    </a>",
"    ]. Signal abnormality at multiple cord levels also appears to be a more significant finding than more restricted areas of signal change. One study found that diffusion tensor imaging provided a better correlation with clinical findings compared to more traditional MRI techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a high incidence of MRI abnormalities of the cervical spine in asymptomatic older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. One study showed disc bulge or herniation in 57 percent, spinal cord impingement in 26 percent, and frank cord compression in 4 percent of patients over 64 years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/22\">",
"     22",
"    </a>",
"    ]. These findings worsen over time in most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/23\">",
"     23",
"    </a>",
"    ]. Careful clinical correlation between imaging studies and clinical features is necessary to diagnose cervical spondylotic myelopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Electrophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electromyography and nerve conduction studies usually do not add to the diagnosis of cervical spondylotic myelopathy. However, these tests can provide information regarding the presence and degree of anterior horn cell or spinal nerve route damage and are useful to exclude other diagnoses, particularly amyotrophic lateral sclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=see_link\">",
"     \"Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Motor and somatosensory-evoked potentials do not have a defined role in the clinical diagnosis of cervical spondylotic myelopathy. Though often giving abnormal results, sensitivities are low, and the observed abnormalities are not specific to cervical spondylotic myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/6\">",
"     6",
"    </a>",
"    ]. However, investigators are studying a potential role for these tests in determining prognosis in patients with cervical spondylotic myelopathy both with and without surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/12,15,24,25\">",
"     12,15,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of cervical spondylotic myelopathy is not well characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/7\">",
"     7",
"    </a>",
"    ]. Some patients experience a slow and stepwise deterioration, with worsening gait, leg and arm weakness, sensory changes, and pain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/5\">",
"     5",
"    </a>",
"    ]. Some patients experience prolonged periods of stability. However, abrupt worsening can occur, often following minor neck injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Identification of clinical or radiographic risk factors for neurologic deterioration has been somewhat elusive. In one study of 45 patients treated conservatively, female gender and higher degrees of cervical mobility appeared to be risk factors for deterioration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/28\">",
"     28",
"    </a>",
"    ]. A larger canal area was predictive of a good outcome in one study, but not another [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Intramedullary signal abnormality on MRI was found not to be associated with deterioration in two studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/12,18\">",
"     12,18",
"    </a>",
"    ]. Others have found that abnormal motor and somatosensory-evoked potentials identify patients at risk for neurologic progression [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/6,12,15\">",
"     6,12,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for cervical spondylotic myelopathy, specifically when and if to operate, remain controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Conservative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonsurgical treatment often includes some form of cervical immobilization (soft collar or brace), restriction of high-risk activities and environments (eg, slippery surfaces, vigorous neck movement, heavy lifting, action sports), and pain management [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/18,24,29,30\">",
"     18,24,29,30",
"    </a>",
"    ]. Patients should also take precautions to avoid whiplash while in vehicle, by adjusting the headrest to a position at the level of the occiput. Although some regimens also include exercises and cervical traction, other clinicians suggest that these are contraindicated in cervical spondylotic myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. There are no published data supporting the efficacy of any of these measures.",
"   </p>",
"   <p>",
"    Pain control for neck pain in cervical spondylotic myelopathy may be achieved using various pharmacologic strategies including nonsteroidal anti-inflammatory agents and other analgesics, muscle relaxants, and antidepressant medications. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=see_link\">",
"     \"Treatment of neck pain\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgical decompression",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the indications and timing for surgical treatment of cervical spondylotic myelopathy.",
"   </p>",
"   <p>",
"    A number of different surgical procedures are used to treat cervical spondylotic myelopathy. Anterior surgeries include cervical discectomy and corpectomy (removal of the central portion of the vertebral body) alone or in combination at single or multiple levels, often combined with a strut reconstruction (bridging the space between the end plates of the vertebral bodies) using bone or synthetic materials and plate fixation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/16,34\">",
"     16,34",
"    </a>",
"    ]. Posterior surgeries include laminectomy and laminoplasty (decompression and reconstruction of the laminae) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It is not known which type of surgical procedure is best as randomized trials are lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Overall, 50 to 80 percent of patients are reported to be improved after surgery, while 5 to 30 percent are worse or subsequently deteriorate [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/8,16,35,41-44\">",
"     8,16,35,41-44",
"    </a>",
"    ]. In one retrospective case series, benefit was apparent in the first postoperative week and maximized at about six months, after which recovery was marginal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Investigators have attempted to identify factors that predict a good or poor response to surgery. However, for every clinical and radiologic feature reported to identify patients likely or not to benefit from surgery, there are studies both confirming and refuting an association [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/8,17,20,25,41-43,46-54\">",
"     8,17,20,25,41-43,46-54",
"    </a>",
"    ]. Factors reported in some studies to predict a poor response to surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older age",
"     </li>",
"     <li>",
"      Intramedullary signal abnormality on MRI, especially if multisegmental and with abnormalities on T1 as well as T2-weighted images",
"     </li>",
"     <li>",
"      More severe disability at the time of operation",
"     </li>",
"     <li>",
"      Longer duration of symptoms preoperatively",
"     </li>",
"     <li>",
"      Narrow canal size preoperatively",
"     </li>",
"     <li>",
"      Multisegmental compression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgical complications occur in up to 16 percent of patients and include death in approximately 1 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/8,16,34,35,42,43,49,55-58\">",
"     8,16,34,35,42,43,49,55-58",
"    </a>",
"    ]. Cardiopulmonary complications are more common in older patients. Common complications more specific to the surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nerve or nerve root injury, usually C5 or C6, recurrent laryngeal nerve, may be permanent or temporary",
"     </li>",
"     <li>",
"      Wound infections",
"     </li>",
"     <li>",
"      Epidural hematoma",
"     </li>",
"     <li>",
"      Dural tear",
"     </li>",
"     <li>",
"      Failure of instrumentation (eg, nonunion)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Studies comparing surgical and conservative treatments are limited to two small, randomized trials in patients with mild disease and one nonrandomized prospective cohort study in patients with a broader range of disease severity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective, but nonrandomized study in 43 patients with cervical spondylotic myelopathy found that the 20 patients who had surgery had improved functional status, pain, and neurologic symptoms at one year compared with those who were treated conservatively [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/32\">",
"       32",
"      </a>",
"      ]. Surgically treated patients had worse baseline deficits.",
"     </li>",
"     <li>",
"      In another study, 49 patients with a mild functional deficit associated with mild to moderate cervical spondylotic myelopathy were assigned by coin toss to surgical versus conservative treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/24\">",
"       24",
"      </a>",
"      ]. Patients assigned to conservative treatment had a significantly better gait at six months but not at two years after treatment. A nearly statistically significant better gait at baseline in the conservatively-treated group may have biased the results.",
"     </li>",
"     <li>",
"      Another randomized trial of 68 patients with mild to moderate signs of myelopathy identified no differences in neurologic outcomes at two or three years between those who received medical versus surgical treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/15,30,60\">",
"       15,30,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conservative measures are probably not obviated by surgical therapy. Reported cases suggest that postsurgical patients remain vulnerable to the effects of high degrees of cervical mobility and to the effects of minor neck injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/51,61\">",
"     51,61",
"    </a>",
"    ]. One study reported that recurrent spondylosis occurred at unoperated levels at a rate of 2 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although unsupported by clinical trial data, it is common clinical practice to consider surgical decompression in patients with progressive deterioration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a moderate or severe myelopathy causing disabling neurologic deficits [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/2\">",
"     2",
"    </a>",
"    ]. For patients with mild clinical features of myelopathy, surgical consultation is recommended for those at risk for deterioration; examples include those with severe spinal cord compression on MRI and those with active lifestyles. When surgery is deferred, there should be close neurologic follow-up to assess for progressive deficits. Surgery to prevent neurologic injury in patients with asymptomatic cervical spondylotic disease is generally not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Acute deterioration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of acute myelopathy may occur in patients with cervical spondylotic myelopathy, even with only mild or no baseline deficits. An acute myelopathy may also be the first presentation for a patient with cervical spondylotic myelopathy. Relatively minor neck trauma may be sufficient to produce significant spinal cord injury in this setting, although this appears to be relatively rare in patients who were previously asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/11,62\">",
"     11,62",
"    </a>",
"    ]. Among a cohort of 199 patients with asymptomatic cervical spondylosis, 14 traumatic episodes occurred over a 44 month median follow-up period with no association with the development of symptomatic myelopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This is a neurologic emergency, requiring immediate neuroimaging for anatomic confirmation and prompt neurosurgical or orthopedic consultation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. High-dose intravenous corticosteroid treatment reduces cord edema and has been shown to improve outcomes in patients with acute spinal cord injury when given within eight hours of the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27944/abstract/64\">",
"     64",
"    </a>",
"    ]. The typical regimen is 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    , followed by an infusion of 5.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour for the first 23 hours.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/18/43297?source=see_link\">",
"       \"Patient information: Central spinal cord syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical spondylotic myelopathy is the most common cause of myelopathy in older adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cervical spondylotic myelopathy results from a progressive degenerative process affecting the cervical vertebral bodies and intervertebral discs and causing compression of the neural and vascular elements in the adjacent cord. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific stereotyped presentation of cervical spondylotic myelopathy. Usually symptoms begin with an insidious onset of gait disturbance. Other common symptoms include sensory loss, and weakness and muscle atrophy in the hands along with and neck and arm pain. The examination usually reveals other myelopathic features. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cervical spondylotic myelopathy must be distinguished from amyotrophic lateral sclerosis and other cervical cord disorders. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of cervical spondylotic myelopathy is made by correlating the clinical features with findings of cervical spondylosis and cord compression seen on a neuroimaging study, usually magnetic resonance imaging. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical course and prognosis of cervical spondylotic myelopathy is not well characterized. Patients can deteriorate progressively or in a step-wise fashion with long periods of stability. Some patients may deteriorate abruptly in association with a minor neck injury. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no large randomized trials on which to base treatment recommendations. For patients with mild, nondebilitating myelopathy we suggest surgical consultation for those at risk of neurologic deterioration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Close neurologic follow-up should assess for deterioration when surgery is deferred. Conservative measures include intermittent neck immobilization, pain management, and restriction of high-risk or aggravating activities. For patients with more severe myelopathy or progressing deficits, we suggest surgical decompression (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute deterioration or an acute presentation with myelopathy in a patient with cervical spondylosis is a neurologic emergency. After confirmation of the diagnosis with magnetic resonance imaging, patients should receive a surgical consultation. We suggest administration of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      within eight hours of acute deterioration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The standard dose is 30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV bolus, followed by an infusion of 5.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour for the first 23 hours. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Acute deterioration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/1\">",
"      Montgomery DM, Brower RS. Cervical spondylotic myelopathy. Clinical syndrome and natural history. Orthop Clin North Am 1992; 23:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/2\">",
"      McCormick WE, Steinmetz MP, Benzel EC. Cervical spondylotic myelopathy: make the difficult diagnosis, then refer for surgery. Cleve Clin J Med 2003; 70:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/3\">",
"      King JT Jr, McGinnis KA, Roberts MS. Quality of life assessment with the medical outcomes study short form-36 among patients with cervical spondylotic myelopathy. Neurosurgery 2003; 52:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/4\">",
"      Moore AP, Blumhardt LD. A prospective survey of the causes of non-traumatic spastic paraparesis and tetraparesis in 585 patients. Spinal Cord 1997; 35:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/5\">",
"      Sadasivan KK, Reddy RP, Albright JA. The natural history of cervical spondylotic myelopathy. Yale J Biol Med 1993; 66:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/6\">",
"      Lyu RK, Tang LM, Chen CJ, et al. The use of evoked potentials for clinical correlation and surgical outcome in cervical spondylotic myelopathy with intramedullary high signal intensity on MRI. J Neurol Neurosurg Psychiatry 2004; 75:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/7\">",
"      Baron EM, Young WF. Cervical spondylotic myelopathy: a brief review of its pathophysiology, clinical course, and diagnosis. Neurosurgery 2007; 60:S35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/8\">",
"      Chiles BW 3rd, Leonard MA, Choudhri HF, Cooper PR. Cervical spondylotic myelopathy: patterns of neurological deficit and recovery after anterior cervical decompression. Neurosurgery 1999; 44:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/9\">",
"      Morse SD. Acute central cervical spinal cord syndrome. Ann Emerg Med 1982; 11:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/10\">",
"      Dickman CA, Hadley MN, Pappas CT, et al. Cruciate paralysis: a clinical and radiographic analysis of injuries to the cervicomedullary junction. J Neurosurg 1990; 73:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/11\">",
"      Bedna��&iacute;k J, Sl&aacute;dkov&aacute; D, Kada��ka Z, et al. Are subjects with spondylotic cervical cord encroachment at increased risk of cervical spinal cord injury after minor trauma? J Neurol Neurosurg Psychiatry 2011; 82:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/12\">",
"      Bednarik J, Kadanka Z, Dusek L, et al. Presymptomatic spondylotic cervical cord compression. Spine (Phila Pa 1976) 2004; 29:2260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/13\">",
"      Yamada M, Furukawa Y, Hirohata M. Amyotrophic lateral sclerosis: frequent complications by cervical spondylosis. J Orthop Sci 2003; 8:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/14\">",
"      Modic MT, Masaryk TJ, Mulopulos GP, et al. Cervical radiculopathy: prospective evaluation with surface coil MR imaging, CT with metrizamide, and metrizamide myelography. Radiology 1986; 161:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/15\">",
"      Kadanka Z, Mares M, Bednar&iacute;k J, et al. Predictive factors for mild forms of spondylotic cervical myelopathy treated conservatively or surgically. Eur J Neurol 2005; 12:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/16\">",
"      Chagas H, Domingues F, Aversa A, et al. Cervical spondylotic myelopathy: 10 years of prospective outcome analysis of anterior decompression and fusion. Surg Neurol 2005; 64 Suppl 1:S1:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/17\">",
"      Singh A, Crockard HA, Platts A, Stevens J. Clinical and radiological correlates of severity and surgery-related outcome in cervical spondylosis. J Neurosurg 2001; 94:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/18\">",
"      Matsumoto M, Toyama Y, Ishikawa M, et al. Increased signal intensity of the spinal cord on magnetic resonance images in cervical compressive myelopathy. Does it predict the outcome of conservative treatment? Spine (Phila Pa 1976) 2000; 25:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/19\">",
"      Harrop JS, Naroji S, Maltenfort M, et al. Cervical Myelopathy: A Clinical and Radiographic Evaluation and Correlation to Cervical Spondylotic Myelopathy. Spine (Phila Pa 1976) 2010.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/20\">",
"      Zhang YZ, Shen Y, Wang LF, et al. Magnetic resonance T2 image signal intensity ratio and clinical manifestation predict prognosis after surgical intervention for cervical spondylotic myelopathy. Spine (Phila Pa 1976) 2010; 35:E396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/21\">",
"      Kerkovsk&yacute; M, Bednar&iacute;k J, Du&scaron;ek L, et al. Magnetic resonance diffusion tensor imaging in patients with cervical spondylotic spinal cord compression: correlations between clinical and electrophysiological findings. Spine (Phila Pa 1976) 2012; 37:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/22\">",
"      Teresi LM, Lufkin RB, Reicher MA, et al. Asymptomatic degenerative disk disease and spondylosis of the cervical spine: MR imaging. Radiology 1987; 164:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/23\">",
"      Okada E, Matsumoto M, Ichihara D, et al. Aging of the cervical spine in healthy volunteers: a 10-year longitudinal magnetic resonance imaging study. Spine (Phila Pa 1976) 2009; 34:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/24\">",
"      Bednar&iacute;k J, Kadanka Z, Voh&aacute;nka S, et al. The value of somatosensory- and motor-evoked potentials in predicting and monitoring the effect of therapy in spondylotic cervical myelopathy. Prospective randomized study. Spine (Phila Pa 1976) 1999; 24:1593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/25\">",
"      Uchida K, Nakajima H, Sato R, et al. Multivariate analysis of the neurological outcome of surgery for cervical compressive myelopathy. J Orthop Sci 2005; 10:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/26\">",
"      Firooznia H, Ahn JH, Rafii M, Ragnarsson KT. Sudden quadriplegia after a minor trauma. The role of preexisting spinal stenosis. Surg Neurol 1985; 23:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/27\">",
"      Whiteson JH, Panaro N, Ahn JH, Firooznia H. Tetraparesis following dental extraction: case report and discussion of preventive measures for cervical spinal hyperextension injury. J Spinal Cord Med 1997; 20:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/28\">",
"      Barnes MP, Saunders M. The effect of cervical mobility on the natural history of cervical spondylotic myelopathy. J Neurol Neurosurg Psychiatry 1984; 47:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/29\">",
"      Yoshimatsu H, Nagata K, Goto H, et al. Conservative treatment for cervical spondylotic myelopathy. prediction of treatment effects by multivariate analysis. Spine J 2001; 1:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/30\">",
"      Kadanka Z, Bednar&iacute;k J, Voh&aacute;nka S, et al. Conservative treatment versus surgery in spondylotic cervical myelopathy: a prospective randomised study. Eur Spine J 2000; 9:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/31\">",
"      Mink JH, Gordon RE, Deutsch AL. The cervical spine: radiologist's perspective. Phys Med Rehabil Clin N Am 2003; 14:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/32\">",
"      Sampath P, Bendebba M, Davis JD, Ducker TB. Outcome of patients treated for cervical myelopathy. A prospective, multicenter study with independent clinical review. Spine (Phila Pa 1976) 2000; 25:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/33\">",
"      Mazanec D, Reddy A. Medical management of cervical spondylosis. Neurosurgery 2007; 60:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/34\">",
"      Carette S, Fehlings MG. Clinical practice. Cervical radiculopathy. N Engl J Med 2005; 353:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/35\">",
"      Wang MY, Shah S, Green BA. Clinical outcomes following cervical laminoplasty for 204 patients with cervical spondylotic myelopathy. Surg Neurol 2004; 62:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/36\">",
"      Edwards CC 2nd, Heller JG, Murakami H. Corpectomy versus laminoplasty for multilevel cervical myelopathy: an independent matched-cohort analysis. Spine (Phila Pa 1976) 2002; 27:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/37\">",
"      Oh MC, Zhang HY, Park JY, Kim KS. Two-level anterior cervical discectomy versus one-level corpectomy in cervical spondylotic myelopathy. Spine (Phila Pa 1976) 2009; 34:692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/38\">",
"      Cunningham MR, Hershman S, Bendo J. Systematic review of cohort studies comparing surgical treatments for cervical spondylotic myelopathy. Spine (Phila Pa 1976) 2010; 35:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/39\">",
"      Hirai T, Okawa A, Arai Y, et al. Middle-term results of a prospective comparative study of anterior decompression with fusion and posterior decompression with laminoplasty for the treatment of cervical spondylotic myelopathy. Spine (Phila Pa 1976) 2011; 36:1940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/40\">",
"      Sakai K, Okawa A, Takahashi M, et al. Five-year follow-up evaluation of surgical treatment for cervical myelopathy caused by ossification of the posterior longitudinal ligament: a prospective comparative study of anterior decompression and fusion with floating method versus laminoplasty. Spine (Phila Pa 1976) 2012; 37:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/41\">",
"      Lunsford LD, Bissonette DJ, Zorub DS. Anterior surgery for cervical disc disease. Part 2: Treatment of cervical spondylotic myelopathy in 32 cases. J Neurosurg 1980; 53:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/42\">",
"      Kumar VG, Rea GL, Mervis LJ, McGregor JM. Cervical spondylotic myelopathy: functional and radiographic long-term outcome after laminectomy and posterior fusion. Neurosurgery 1999; 44:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/43\">",
"      Ebersold MJ, Pare MC, Quast LM. Surgical treatment for cervical spondylitic myelopathy. J Neurosurg 1995; 82:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/44\">",
"      Cheung WY, Arvinte D, Wong YW, et al. Neurological recovery after surgical decompression in patients with cervical spondylotic myelopathy - a prospective study. Int Orthop 2008; 32:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/45\">",
"      Acharya S, Srivastava A, Virmani S, Tandon R. Resolution of physical signs and recovery in severe cervical spondylotic myelopathy after cervical laminoplasty. Spine (Phila Pa 1976) 2010; 35:E1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/46\">",
"      Shibuya, R, Yonenobu, K, Yamamoto, K, et al. The motor conduction of cervical spondylotic myelopathy with intramedullary high signal intensity on MRI. International Congress Series 2005; 1278:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/47\">",
"      Papadopoulos CA, Katonis P, Papagelopoulos PJ, et al. Surgical decompression for cervical spondylotic myelopathy: correlation between operative outcomes and MRI of the spinal cord. Orthopedics 2004; 27:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/48\">",
"      Chen CJ, Lyu RK, Lee ST, et al. Intramedullary high signal intensity on T2-weighted MR images in cervical spondylotic myelopathy: prediction of prognosis with type of intensity. Radiology 2001; 221:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/49\">",
"      Hasegawa K, Homma T, Chiba Y, et al. Effects of surgical treatment for cervical spondylotic myelopathy in patients &gt; or = 70 years of age: a retrospective comparative study. J Spinal Disord Tech 2002; 15:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/50\">",
"      Yamazaki T, Yanaka K, Sato H, et al. Cervical spondylotic myelopathy: surgical results and factors affecting outcome with special reference to age differences. Neurosurgery 2003; 52:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/51\">",
"      Ogawa Y, Chiba K, Matsumoto M, et al. Postoperative factors affecting neurological recovery after surgery for cervical spondylotic myelopathy. J Neurosurg Spine 2006; 5:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/52\">",
"      Fern&aacute;ndez de Rota JJ, Meschian S, Fern&aacute;ndez de Rota A, et al. Cervical spondylotic myelopathy due to chronic compression: the role of signal intensity changes in magnetic resonance images. J Neurosurg Spine 2007; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/53\">",
"      Morio Y, Teshima R, Nagashima H, et al. Correlation between operative outcomes of cervical compression myelopathy and mri of the spinal cord. Spine (Phila Pa 1976) 2001; 26:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/54\">",
"      Yagi M, Ninomiya K, Kihara M, Horiuchi Y. Long-term surgical outcome and risk factors in patients with cervical myelopathy and a change in signal intensity of intramedullary spinal cord on Magnetic Resonance imaging. J Neurosurg Spine 2010; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/55\">",
"      Greiner-Perth R, Elsaghir H, B&ouml;hm H, El-Meshtawy M. The incidence of C5-C6 radiculopathy as a complication of extensive cervical decompression: own results and review of literature. Neurosurg Rev 2005; 28:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/56\">",
"      Nassr A, Eck JC, Ponnappan RK, et al. The incidence of C5 palsy after multilevel cervical decompression procedures: a review of 750 consecutive cases. Spine (Phila Pa 1976) 2012; 37:174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/57\">",
"      Haller JM, Iwanik M, Shen FH. Clinically relevant anatomy of recurrent laryngeal nerve. Spine (Phila Pa 1976) 2012; 37:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/58\">",
"      Leonard R, Belafsky P. Dysphagia following cervical spine surgery with anterior instrumentation: evidence from fluoroscopic swallow studies. Spine (Phila Pa 1976) 2011; 36:2217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/59\">",
"      Fouyas IP, Statham PF, Sandercock PA. Cochrane review on the role of surgery in cervical spondylotic radiculomyelopathy. Spine (Phila Pa 1976) 2002; 27:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/60\">",
"      Kadanka Z, Mares M, Bednan&iacute;k J, et al. Approaches to spondylotic cervical myelopathy: conservative versus surgical results in a 3-year follow-up study. Spine (Phila Pa 1976) 2002; 27:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/61\">",
"      Dickerman RD, Lefkowitz M, Epstein JA. A traumatic central cord syndrome occurring after adequate decompression for cervical spondylosis: biomechanics of injury: case report. Spine (Phila Pa 1976) 2005; 30:E611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/62\">",
"      Chen TY, Dickman CA, Eleraky M, Sonntag VK. The role of decompression for acute incomplete cervical spinal cord injury in cervical spondylosis. Spine (Phila Pa 1976) 1998; 23:2398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/63\">",
"      Ishida Y, Tominaga T. Predictors of neurologic recovery in acute central cervical cord injury with only upper extremity impairment. Spine (Phila Pa 1976) 2002; 27:1652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27944/abstract/64\">",
"      Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med 1990; 322:1405.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4820 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-D34A3220F9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27944=[""].join("\n");
var outline_f27_18_27944=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Amyotrophic lateral sclerosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other cervical cord disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4428935\">",
"      Guillain-Barr&eacute; syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Electrophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Conservative measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgical decompression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Acute deterioration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4820\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4820|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/20/18753\" title=\"diagnostic image 1\">",
"      MRI cervical spondylosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4820|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/8/21634\" title=\"figure 1\">",
"      Cervical dermatomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4820|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/56/908\" title=\"table 1\">",
"      Symptoms of cervical root lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/0/6157\" title=\"table 2\">",
"      Spinal cord disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/44/5832?source=related_link\">",
"      Anatomy and localization of spinal cord disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/22/5481?source=related_link\">",
"      Clinical features and diagnosis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36152?source=related_link\">",
"      Clinical features and diagnosis of cervical radiculopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/21/40280?source=related_link\">",
"      Clinical features of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16938?source=related_link\">",
"      Diagnosis of amyotrophic lateral sclerosis and other forms of motor neuron disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/42/32426?source=related_link\">",
"      Disorders affecting the spinal cord",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/24/1418?source=related_link\">",
"      Evaluation of the patient with neck pain and cervical spine disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/26/14762?source=related_link\">",
"      Normal pressure hydrocephalus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/18/43297?source=related_link\">",
"      Patient information: Central spinal cord syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/36/23113?source=related_link\">",
"      Treatment of neck pain",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27945="Fertility and pregnancy after bariatric surgery";
var content_f27_18_27945=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fertility and pregnancy after bariatric surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27945/contributors\">",
"     David W Ouyang, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Daniel Jones, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27945/contributors\">",
"     David L Hepner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27945/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/18/27945/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgery has become an increasingly utilized and effective approach for achieving sustainable weight loss, as well as reducing morbidities associated with severe obesity. More than 80 percent of bariatric procedures are performed in women, and approximately half of these are performed in reproductive aged women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, it has become increasingly common for women who have undergone bariatric surgery to present for preconceptional counseling or prenatal care.",
"   </p>",
"   <p>",
"    The data presented in this topic review have been derived from retrospective studies, case reports, and personal experience. There are no available data from randomized trials or prospective cohort studies. Other issues related to bariatric surgery are discussed separately. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPE OF BARIATRIC PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bariatric surgical procedures can be divided into two varieties, malabsorptive and restrictive. This difference is based upon the anatomic configuration of the procedure, which in turn contributes to the mechanisms by which they induce weight loss (",
"    <a class=\"graphic graphic_table graphicRef59447 \" href=\"UTD.htm?4/55/4987\">",
"     table 1",
"    </a>",
"    ). Some procedures have both a restrictive and malabsorptive component (eg, Roux-en-Y gastric bypass). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=see_link&amp;anchor=H15#H15\">",
"     \"Surgical management of severe obesity\", section on 'Choosing a procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Clinical implications",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is important for the clinician to know which procedure a woman has undergone in order to counsel her about potential complications and reproductive issues, as well as possible interventions. Multiple anatomic and physiologic changes that occur after bariatric surgery can affect absorption of medications [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/2\">",
"     2",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient has undergone placement of a laparoscopic adjustable gastric band procedure, the volume of fluid within the band can be adjusted during pregnancy to help manage pregnancy-related nausea and vomiting and prevent excessive gestational weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. The band is tightened by adding more fluid to a reservoir attached to the band, which creates increased pressure and tightens the band. The band is loosened by removing fluid from the reservoir, which reduces pressure in the band and loosens it.",
"     </li>",
"     <li>",
"      Procedures that create malabsorption, such as biliopancreatic diversion, jejunoileal bypass, or Roux-en-Y bypass, may interfere with the absorption of oral contraceptives, thereby reducing their effectiveness (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Contraception'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Restrictive procedures result in a small gastric pouch that may increase the risk of gastric ulceration from drugs such as nonsteroidal antiinflammatory agents, which are commonly used for treatment of dysmenorrhea and postpartum pain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/5\">",
"       5",
"      </a>",
"      ]. Use of drugs associated with gastric irritation should be avoided or minimized.",
"     </li>",
"     <li>",
"      Reduction in functional intestinal length leads to faster transit time and less time for slow absorption [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/5\">",
"       5",
"      </a>",
"      ]. Therefore, combination restrictive-malabsorptive procedures reduce absorption of extended release formulations. These formulations should be avoided, if possible; an immediate release formulation is preferable.",
"     </li>",
"     <li>",
"      When using oral medications in which a therapeutic level is critical, drug levels should be monitored [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/2,6\">",
"       2,6",
"      </a>",
"      ]. Dosing of common medications (eg, antibiotics, anticoagulants) after bariatric surgery is described in detail separately. Discussions on medication management and management of medical disorders are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"       \"Medical management of patients after bariatric surgery\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=see_link\">",
"       \"Postoperative management of the critically ill obese patient\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     FERTILITY BEFORE AND AFTER SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity can be associated with",
"    <span class=\"nowrap\">",
"     oligoovulation/anovulation,",
"    </span>",
"    as well as a reduced response to fertility treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both nonsurgical [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/7\">",
"     7",
"    </a>",
"    ] and surgical weight loss can improve fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,8-13\">",
"     3,8-13",
"    </a>",
"    ]. This was illustrated in a series in which 15 of 32 women who were unsuccessful in their attempts to conceive prior to bariatric surgery became pregnant following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In different reports, women who conceived following bariatric surgery had infertility rates of 15 to 44 percent prior to surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,10,11\">",
"     3,10,11",
"    </a>",
"    ]. Return to fertility can be rapid, as all 24 oligomenorrheic women in one series resumed normal menstrual cycles after a mean of 3.4&plusmn;2.1 months postoperatively [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/12\">",
"     12",
"    </a>",
"    ]. Post-surgical weight loss improves the multiple hormonal changes related to polycystic ovary syndrome (PCOS), thereby reducing anovulation and enhancing the potential for conception [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/12\">",
"     12",
"    </a>",
"    ]. In one study, 70 of 98 anovulatory women regained normal menstrual cycles after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/13\">",
"     13",
"    </a>",
"    ]. The patients who resumed ovulation lost significantly more weight than those who remained anovulatory.",
"   </p>",
"   <p>",
"    In spite of these encouraging data, most experts agree that bariatric surgery is not indicated as a primary treatment of infertility in severely obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In women who remain infertile after surgery, in vitro fertilization could be considered. If indicated, it can be safe and successful, but experience is limited to case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TIMING OF CONCEPTION FOLLOWING SURGERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women are generally advised to delay pregnancy for 12 to 18 months following bariatric surgery. This is done in an effort to optimize weight loss and reduce the potentially adverse effect of post-bariatric surgical nutritional deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/9,17\">",
"     9,17",
"    </a>",
"    ]. Since evidence supporting this approach is limited and inconclusive, counseling should be individualized. As an example, women who undergo gastric banding procedures typically lose weight more gradually than gastric bypass patients. The band can be adjusted if weight loss is deemed too rapid or excessive [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3\">",
"     3",
"    </a>",
"    ]. These factors might reduce the concern about conception during the rapid weight loss phase.",
"   </p>",
"   <p>",
"    While it is reasonable to recommend delaying pregnancy for 12 months after a bariatric procedure, women who conceive proximate to their bariatric surgery should be reassured of a likely favorable pregnancy outcome, based upon the following data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Effect on pregnancy outcome &mdash; Observational studies have found that the time to conception after surgery does not affect the risk of obstetrical and neonatal complications [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/12,18-22\">",
"       12,18-22",
"      </a>",
"      ]. As an example, a study that stratified 52 post-gastric bypass patients into groups by surgery-to-conception intervals of &le;18 months versus &gt;18 months and &le;12 months versus &gt;12 months found no statistically significant differences between these groups in terms of adverse obstetric or neonatal outcomes. There was no difference in growth restriction, preterm delivery, preterm premature rupture of membranes, gestational diabetes, hypertension, cesarean delivery, Apgar scores, or birth defects [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Effect on gestational weight gain and short-term postpartum weight loss &mdash; Time to conception after surgery may affect gestational weight gain and postpartum weight loss, but studies have reported discordant results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,18,19\">",
"       3,18,19",
"      </a>",
"      ]. In one such study, women who conceived within 12 months of surgery had less weight gain during pregnancy and less weight loss postpartum than those who waited longer before conceiving (mean gestational weight gain (1.8 versus 15.5 kg [4 versus 34 pounds])); mean postpartum weight loss (6.4 versus 9.5 kg [14 versus 21 pounds]) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Long-term effect on total weight loss &mdash; Only limited data are available on the long-term effects of time to conception after surgery on total weight loss. The only study describing this outcome suggested that pregnancy during the phase of rapid weight loss did not negatively affect total weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/19\">",
"       19",
"      </a>",
"      ]. Total weight loss in women who conceived before and after 12 months averaged 45 and 51 kg (99 and 113 pounds), respectively. The final body mass index (BMI) was also similar for both groups (33 and 31",
"      <span class=\"nowrap\">",
"       kg/m2,",
"      </span>",
"      respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CONTRACEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraceptive counseling is an important consideration for all reproductive-aged women undergoing bariatric procedures. This is especially important for adolescents in whom pregnancy rates following surgery are two-fold higher than in the general adolescent population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/23\">",
"     23",
"    </a>",
"    ]. While this increase is probably due in large part to enhanced fertility associated with weight loss, Roux-en-Y gastric bypass also appears to reduce absorption of oral contraceptives. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=see_link&amp;anchor=H15#H15\">",
"     \"Contraception counseling for obese women\", section on 'Postbariatric surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The American College of Obstetricians and Gynecologists (ACOG) recommends using non-oral forms of hormonal contraception in women who have undergone malabsorptive bariatric surgery and desire hormonal contraception [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24\">",
"     24",
"    </a>",
"    ]. The Centers for Disease Control (CDC) recommendations for use of hormonal contraception are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef74890 \" href=\"UTD.htm?12/13/12506\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PREGNANCY OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obesity is associated with numerous adverse pregnancy outcomes, including miscarriage, preeclampsia, gestational diabetes, cesarean delivery, stillbirth, and possibly congenital birth defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The frequencies of many of these adverse outcomes are reduced below those in obese women who have not undergone bariatric surgery. Sometimes they are reduced to the frequency of adverse events in nonobese patients. The magnitude of the effect of surgery on pregnancy outcomes varies depending upon the control group (general obstetric population, obese women who have not undergone surgery, or pre- versus post-bariatric surgery pregnancy outcomes in the same group of patients).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Miscarriage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although nonsurgical weight loss may reduce the risk of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/7\">",
"     7",
"    </a>",
"    ], available data on the impact of bariatric procedures on miscarriage rate have not consistently shown a benefit. Data are limited by small sample size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    design deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/9,27\">",
"     9,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gestational diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies consistently report a lower prevalence of gestational diabetes mellitus (GDM) among women who have had bariatric surgery than among obese women who have not undergone this surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/28\">",
"     28",
"    </a>",
"    ]. It remains higher than that of the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,29-34\">",
"     3,29-34",
"    </a>",
"    ]. As an example, a retrospective study that compared pregnancy outcomes of 301 pregnancies pre-bariatric surgery to 507 pregnancies post-bariatric surgery observed a significantly lower prevalence of GDM in the post-bariatric surgery group (17.3 versus 11.0 percent, respectively). This was the case even though the post-surgery group was older, an established risk factor for developing GDM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a history of type 2 diabetes prior to bariatric surgery may become euglycemic following surgery. These women may remain euglycemic during pregnancy, despite pregnancy-related insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women with a history of bariatric surgery who develop GDM appear to have similar perinatal outcomes and glycemic control as other women with GDM [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/6\">",
"     6",
"    </a>",
"    ]. It is unclear whether the type of bariatric procedure impacts the course and outcome of GDM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most observational studies noted that women who have undergone bariatric surgery have a lower rate of preeclampsia than controls consisting of obese women who have not undergone a bariatric procedure or the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/33\">",
"     33",
"    </a>",
"    ]. Following surgery, the incidence of preeclampsia may fall to that of the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,29\">",
"     3,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Preterm delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Obese women are at higher risk for medically indicated preterm birth and at lower risk for spontaneous preterm birth than nonobese women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=see_link\">",
"     \"The impact of obesity on fertility and pregnancy\"",
"    </a>",
"    .) Data from most observational studies have found that bariatric surgery does not affect the risk of spontaneous preterm birth in subsequent pregnancies, and may lower the frequency of medically indicated preterm birth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,9,20,31,33\">",
"     3,9,20,31,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Birthweight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have generally reported a reduction in mean birthweight resulting in a larger proportion of appropriate for gestational age (AGA) infants among post-bariatric surgery pregnancies compared with obese women who have not undergone a bariatric procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/9,20,32,36\">",
"     9,20,32,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Macrosomia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal obesity is an established risk factor for delivering a large for gestational age (LGA) infant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/37\">",
"     37",
"    </a>",
"    ]. Most observational studies have found that post-bariatric surgery reduction in BMI reduces the risk of delivering LGA infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/9,30,31,33,38\">",
"     9,30,31,33,38",
"    </a>",
"    ]. As an example, a study that compared pregnancy outcomes from 301 pregnancies pre-bariatric surgery to 507 pregnancies post-bariatric surgery reported a significantly lower prevalence of macrosomia in post-bariatric surgery pregnancies (OR 0.45; 95% CI 0.21-0.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Growth restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have reported increased rates of intrauterine growth restriction (IUGR) and small-for-gestational-age (SGA) infants in post-bariatric surgery patients, but these data have been inconsistent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,9,34,36,38,39\">",
"     3,9,34,36,38,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Concerns regarding poor fetal growth in post-bariatric surgery patients initially arose in pregnancies of women who underwent the now obsolete jejunoileal bypass procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Pregnancies of women who have undergone either restrictive or malabsorptive procedures have not consistently shown an increased risk of poor fetal growth. One study reported a decreased risk of delivering an SGA infant (&lt;2500 g) in women who had undergone a laparoscopic gastric banding procedure compared to obese women without surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/30\">",
"     30",
"    </a>",
"    ]. The authors hypothesized that a reduction in risk of preeclampsia may have accounted for this finding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cesarean delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies of cesarean delivery rates in post-bariatric surgery pregnancies have reported higher cesarean rates than in the general obstetric population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/20,29\">",
"     20,29",
"    </a>",
"    ]. This is not unexpected since both age and obesity are risk factors for cesarean delivery. Women who undergo bariatric procedures are typically older and more likely to be obese than women in the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/6,42\">",
"     6,42",
"    </a>",
"    ]. Cesarean delivery rates tend to be either similar to or lower than rates in obese women who have not undergone bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/20,30\">",
"     20,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Perinatal morbidity and congenital anomalies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies consistently demonstrate no correlation between prior bariatric surgery and low Apgar scores, meconium-stained amniotic fluid, perinatal mortality rate, and congenital malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/14,29,33\">",
"     14,29,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific concerns regarding an association between bariatric surgery and neural tube defects have been raised due to a number of reported cases [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. There is and the biologic plausibility of folate deficiency and hyperhomocysteinemia following bariatric procedures [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,43,45\">",
"     3,43,45",
"    </a>",
"    ]. However, the largest study examining risk of congenital malformations in pregnancies after bariatric surgery found no significant difference between 298 post-bariatric surgery pregnancies and 158,912 deliveries in the general obstetrical population [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, any possible risk of congenital anomalies in post-bariatric surgery patients must be balanced with the increased risk of congenital anomalies seen in overweight and obese women [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/46\">",
"     46",
"    </a>",
"    ]. Adequate",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation (800 mcg daily) during pregnancy in gastric bypass patients may reduce the risk of neural tube defects and is strongly encouraged (see",
"    <a class=\"local\" href=\"#H18\">",
"     'Micronutrient supplementation'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRENATAL CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;General aspects of prenatal care are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=see_link\">",
"     \"Initial prenatal assessment and patient education\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion applies to issues specific to pregnant women who have undergone bariatric surgery. Ideally, women planning pregnancy post-bariatric surgery should be co-managed by a bariatric surgeon, dietitian, and obstetrician.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Micronutrient supplementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metabolic and nutritional derangements can occur after bariatric surgery, particularly after malabsorptive procedures. Reduced oral intake and alterations in digestive anatomy result in malabsorption of various micronutrients and minerals, particularly iron, folate, vitamin B12, calcium, and vitamin D. Absorption of iron and folate are reduced due to lower acid content in the gastric pouch and bypass of the duodenum, the main site of absorption. Calcium deficiency can also result from bypass of the duodenum, as well as reduced intake of both calcium and vitamin D. A reduction in the availability of both gastric acid and intrinsic factor may lead to B12 deficiency.",
"   </p>",
"   <p>",
"    While women with prior malabsorptive procedures are at greatest risk for micronutrient deficiencies, women who undergo restrictive procedures may also develop iron, folate, and fat soluble vitamin deficiencies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/47\">",
"     47",
"    </a>",
"    ]. Further review of these nutritional deficiencies and their management is detailed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link\">",
"     \"Medical management of patients after bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of adverse pregnancy outcomes have been attributed to inadequate supplementation and resultant micronutrient deficiencies. Iron and B12 deficiencies have resulted in maternal anemia. Case reports have described neural tube defects possibly related to folate deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/45\">",
"     45",
"    </a>",
"    ], fetomaternal electrolyte imbalances [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/48\">",
"     48",
"    </a>",
"    ], microphthalmia attributed to vitamin A deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/49\">",
"     49",
"    </a>",
"    ], and fetal cerebral hemorrhage attributed to vitamin K deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Wernicke's encephalopathy due to thiamine deficiency is a particular concern in women with hyperemesis gravidarum and gastric bypass.",
"   </p>",
"   <p>",
"    To reduce the risk of complications from micronutrient deficiency, specific supplementation regimens need to be tailored to the individual patient and the type of bariatric procedure performed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/52\">",
"     52",
"    </a>",
"    ]. Guidelines for optimum micronutrient supplementation during pregnancy have been extrapolated from data from the bariatric and obstetric literature. In general, during pregnancy, it is reasonable to continue the regimen recommended by the bariatric surgeon, but the multivitamin is replaced with a prenatal vitamin. Total vitamin A intake from all supplements should be limited to 5000 international units per day to avoid retinoid embryopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Micronutrient supplementation after Roux-en-Y gastric bypass (RYGB), one of the most common bariatric procedures, should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vitamin B1 (thiamine) 1.4 mg",
"     </li>",
"     <li>",
"      Vitamin D 400 IU",
"     </li>",
"     <li>",
"      Vitamin K 120 mcg",
"     </li>",
"     <li>",
"      Zinc 11 mg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?9/25/9618?source=see_link\">",
"       Biotin",
"      </a>",
"      30 mcg",
"     </li>",
"     <li>",
"      Iron 65 mg",
"     </li>",
"     <li>",
"      Folate 800 mcg",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/46/38628?source=see_link\">",
"       Calcium citrate",
"      </a>",
"      1200 mg",
"     </li>",
"     <li>",
"      Vitamin B12: oral or sublingual: 350 to 500",
"      <span class=\"nowrap\">",
"       mcg/day,",
"      </span>",
"      intramuscular: 1000",
"      <span class=\"nowrap\">",
"       mcg/week,",
"      </span>",
"      intranasal: 500",
"      <span class=\"nowrap\">",
"       mcg/week.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These daily requirements can typically be met with a prenatal vitamin in addition to calcium and vitamin B12 supplementation. Additional iron and folate may also be required with certain prenatal vitamins. Chewable and liquid prenatal vitamins are an option for women who cannot take a large prenatal vitamin.",
"   </p>",
"   <p>",
"    We suggest screening for micronutrient deficiencies to individualize therapy and adjust doses as needed. The importance of monitoring was illustrated by a study that observed various micronutrient deficiencies during pregnancy in spite of prophylactic supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/53\">",
"     53",
"    </a>",
"    ]. We obtain the following laboratory tests preconceptionally or at the first prenatal visit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/54\">",
"     54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete blood count",
"     </li>",
"     <li>",
"      Ferritin",
"     </li>",
"     <li>",
"      Iron",
"     </li>",
"     <li>",
"      Vitamin B12",
"     </li>",
"     <li>",
"      Thiamine",
"     </li>",
"     <li>",
"      Folate",
"     </li>",
"     <li>",
"      Calcium",
"     </li>",
"     <li>",
"      Vitamin D",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Identified deficiencies should be corrected and monitored with monthly assessments. Further surveillance of blood count, iron, ferritin, vitamin B12, calcium and vitamin D is performed every trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24,54\">",
"     24,54",
"    </a>",
"    ]. Persistent deficiencies should be corrected with increased oral dosages or parenteral forms of iron, vitamin B12 and vitamin D.",
"   </p>",
"   <p>",
"    Supplementation and screening should continue following delivery in women who breastfeed (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Postpartum'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Fetal growth assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the inconsistent data regarding the risk of IUGR and SGA in post-bariatric surgery pregnancies (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Growth restriction'",
"    </a>",
"    above), we suggest performing one or two ultrasound examinations to evaluate fetal growth in the third trimester, especially in women with poor weight gain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Gestational diabetes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening for gestational diabetes is optimally performed at 24 to 28 weeks of gestation. However, it should be done as early as the first prenatal visit if there is a high degree of suspicion that the pregnant woman has undiagnosed type 2 diabetes (eg, marked obesity, personal history of gestational diabetes, glycosuria, or strong family history of diabetes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The glucose challenge test used to screen for gestational diabetes is typically not well tolerated in women with prior Roux-en-Y gastric bypass (RYGB) due to dumping syndrome, which occurs in approximately 50 percent of these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/55\">",
"     55",
"    </a>",
"    ]. This phenomenon follows ingestion of food or drinks containing high amounts of refined sugars. As a result of the hyperosmolar environment, fluid shifts rapidly from the intravascular compartment to the small bowel lumen causing distension, cramping, nausea, vomiting, and diarrhea. Tachycardia, palpitations and diaphoresis are also common, and may be related to intravascular depletion or a hyperinsulinemic response and reactive hypoglycemia.",
"   </p>",
"   <p>",
"    To avoid the possible occurrence of dumping syndrome, we generally recommend that women with RYGB avoid the standard 50-g glucose challenge test used to screen for gestational diabetes. We, along with others, suggest following fasting and post-breakfast blood sugars for one week as an alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24,56\">",
"     24,56",
"    </a>",
"    ]. Patients who regularly drink and tolerate sugared soft drinks are an exception; these women probably can tolerate a standard glucose challenge test. A third option is to measure glycated hemoglobin (A1C) and assume overt diabetes is present if it is elevated (&ge;6.5 percent); women with a normal A1C should undergo screening as described. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Dumping syndrome typically does not occur in women who have undergone restrictive-type bariatric procedures such as gastric banding. These women can undergo standard testing for GDM.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although conventional treatment of GDM involves nutritional therapy and insulin, some clinicians use oral anti-hyperglycemic agents, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/6/29800?source=see_link\">",
"     glyburide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    . If these agents are used, it should be noted that oral agents may not be absorbed completely after RYGB due to bypass of the duodenum [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H16#H16\">",
"     \"Medical management of patients after bariatric surgery\", section on 'Medication management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Monitoring for complications of bariatric surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common late sequelae of bariatric surgery are mild nutritional deficiencies, which are readily treated with replacement therapy. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Micronutrient supplementation'",
"    </a>",
"    above.) Small bowel obstruction after RYGB is an uncommon but life-threatening complication that requires a high index of suspicion and early evaluation for the disorder when patients present with often nonspecific abdominal symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48712524\">",
"    <span class=\"h3\">",
"     Bowel obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous case reports have described bowel obstruction during pregnancy in women who had previously undergone bariatric surgery, some resulting in fetal and maternal death [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Most cases involved women who had RYGB and internal herniation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/57,59-64\">",
"     57,59-64",
"    </a>",
"    ]; however, intussusception with necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], volvulus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/58\">",
"     58",
"    </a>",
"    ] and band slippage [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/50\">",
"     50",
"    </a>",
"    ] have also been described. The majority of cases occurred within two years of bariatric surgery, although herniations as far as nine years from the time of RYGB have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    RYGB procedures create potential internal spaces through which herniation of the small bowel can occur. Internal herniation is seen more frequently in patients who have laparoscopic versus open procedures with rates as high as 5 percent described [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/67\">",
"     67",
"    </a>",
"    ]. While the rate of internal herniation during pregnancy in post-bariatric surgery patients is unknown, increased abdominal pressure and cephalad intestinal displacement associated with the enlarging gravid uterus may contribute to its formation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The non-specific symptoms seen with early bowel obstruction often overlap with common obstetric complaints such as hyperemesis, esophageal reflux, and contractions. We recommend a low threshold for obtaining abdominal computed tomography (CT) in women post-RYGB with abdominal pain. Radiologic studies, including abdominal CT, may not reveal obvious bowel obstruction in patients with internal herniation; therefore, maintaining a high index of suspicion and early consultation with a bariatric surgeon are warranted in patients with gastrointestinal complaints, and possibly fever",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    leukocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/68\">",
"     68",
"    </a>",
"    ]. Exploratory surgery may be necessary. Two reported maternal deaths were associated, in part, with a delay in diagnosis and surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48712531\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other surgical complications associated with bariatric surgery include gastric band erosion and slippage, anastomotic leaks and bleeding, stomal stenosis, and marginal ulceration. Some of these complications have been reported during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/69-71\">",
"     69-71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=see_link\">",
"     \"Complications of bariatric surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The prevalence of cholelithiasis is increased in pregnancy, as well as after RYGB, especially during the period of rapid weight loss [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Gestational weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Optimal weight gain during pregnancy in women who have undergone bariatric surgery has not been studied. At present, weight gain recommendations are based on Institute of Medicine (IOM) guidelines, which are based on prepregnancy BMI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=see_link\">",
"     \"Weight gain and loss in pregnancy\"",
"    </a>",
"    .) Caloric restriction during pregnancy is not recommended, even if patients continue to be overweight after bariatric surgery, due to concerns that caloric restriction might impair fetal growth [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While poor antepartum weight gain has been associated with fetal growth restriction and small for gestational age infants in some reports, causality has not been proven [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/73\">",
"     73",
"    </a>",
"    ]. We suggest that women who are not achieving the minimum weight gain standards suggested by the IOM (0.5 pound [0.23",
"    <span class=\"nowrap\">",
"     kg]/week",
"    </span>",
"    for obese women in the second and third trimester) undergo ultrasound evaluation of fetal growth and dietary consultation. If adequate caloric intake is confirmed, we do not recommend encouraging the woman to consume significantly more calories. In patients with adjustable gastric bands, the gastric band can be loosened so there is less gastric constriction and oral intake can be increased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/3,10,29,74\">",
"     3,10,29,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Mode of delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cesarean delivery is performed for standard obstetrical indications. Consultation with a bariatric surgeon is advisable if the patient had a complicated bariatric surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients who have undergone uncomplicated bariatric surgery generally do not require alteration in cesarean delivery technique. An exception is favoring blunt entry into the peritoneum to minimize risk of inadvertent injury to bowel that may be adherent to the underlying surface.",
"   </p>",
"   <p>",
"    Specific recommendations regarding surgical considerations in the obese patient are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=see_link\">",
"     \"Cesarean delivery of the obese woman\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15290794\">",
"    <span class=\"h2\">",
"     Anesthesia for cesarean",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who have undergone abdominoplasty, standard methods of assessment of the sensory level of subarachnoid block can be misleading because of dermatomal changes [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Testing the posterolateral abdomen is more reliable than the anterior abdomen for determining the anesthesia level in these patients, as there is a downward shift in sensory dermatomal level anteriorly. Patients may retain sensation in the anterior abdominal skin despite an adequate posterolateral dermatomal level. Supplemental local anesthesia by the surgeon or a lower surgical incision should then be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     POSTPARTUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lactation is usually not adversely affected by bariatric surgery and should be encouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=see_link\">",
"     \"Maternal and economic benefits of breastfeeding\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=see_link\">",
"     \"Infant benefits of breastfeeding\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As discussed above, micronutrient supplementation and screening should continue following delivery in women who breastfeed. Breastfed infants of women who have had gastric bypass procedures may develop nutritional deficiencies, especially those that are exclusively breastfed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27945/abstract/77,78\">",
"     77,78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      More than 80 percent of bariatric procedures are performed in women and approximately half of these are performed in reproductive aged women. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important for the clinician to know specifically which bariatric procedure a woman has undergone in order to counsel her about the prevention and management of potential complications and reproductive issues (",
"      <a class=\"graphic graphic_table graphicRef59447 \" href=\"UTD.htm?4/55/4987\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Type of bariatric procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnancy planning and contraception options should be discussed with women who undergo bariatric surgery. Fertility improves soon after bariatric surgery, particularly in women who had been anovulatory. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Fertility before and after surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Oral contraceptives may be less effective in women who have undergone malabsorptive bariatric surgery. For women who have undergone these procedures and who desire hormonal contraception, we suggest non-oral forms of hormonal contraception (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Contraception'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest delaying pregnancy for 12 months following bariatric surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This provides time to optimize weight loss and reduce potential adverse effects of nutritional deficiencies. However, women who conceive proximate to their bariatric surgery can be reassured of a likely favorable pregnancy outcome with optimization of nutrition and careful monitoring and follow-up. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Timing of conception following surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bariatric surgery likely reduces risk of preeclampsia, gestational diabetes, and macrosomia when compared to obese women who have not undergone a bariatric procedure. The risks of spontaneous preterm delivery, cesarean delivery, and congenital anomalies appear to be the same or lower than in obese women who have not undergone a bariatric procedure, but data are less consistent than for other outcomes. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pregnancy outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend micronutrient supplementation and monitoring for micronutrient deficiencies in pregnancies after any bariatric surgical procedure. This is facilitated by co-management by an obstetrician, bariatric surgeon, and dietitian. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=see_link&amp;anchor=H11#H11\">",
"       \"Medical management of patients after bariatric surgery\", section on 'Nutritional deficiencies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women with prior Roux-en-Y gastric bypass (RYGB) should not undergo the 50-g glucose challenge test used to screen for gestational diabetes (GDM), as it is likely to cause dumping syndrome. An exception can be made if the patient regularly drinks sugared soft drinks. We suggest following fasting and postprandial blood sugars for one week as an alternative screening test. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Gestational diabetes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with abdominal pain or other gastrointestinal symptoms, the possibility of a complication of bariatric surgery, such as bowel obstruction, volvulus, or intussusception, must be excluded. We recommend a low threshold for abdominal computed tomography (CT) for evaluation of these women and early consultation with a bariatric surgeon. Exploratory surgery may be necessary, even after a negative CT. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Monitoring for complications of bariatric surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cesarean delivery is performed for standard obstetrical indications. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Mode of delivery'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/1\">",
"      Santry HP, Gillen DL, Lauderdale DS. Trends in bariatric surgical procedures. JAMA 2005; 294:1909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/2\">",
"      Magee SR, Shih G, Hume A. Malabsorption of oral antibiotics in pregnancy after gastric bypass surgery. J Am Board Fam Med 2007; 20:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/3\">",
"      Dixon JB, Dixon ME, O'Brien PE. Pregnancy after Lap-Band surgery: management of the band to achieve healthy weight outcomes. Obes Surg 2001; 11:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/4\">",
"      Weiss HG, Nehoda H, Labeck B, et al. Pregnancies after adjustable gastric banding. Obes Surg 2001; 11:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/5\">",
"      Miller AD, Smith KM. Medication and nutrient administration considerations after bariatric surgery. Am J Health Syst Pharm 2006; 63:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/6\">",
"      Sheiner E, Menes TS, Silverberg D, et al. Pregnancy outcome of patients with gestational diabetes mellitus following bariatric surgery. Am J Obstet Gynecol 2006; 194:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/7\">",
"      Clark AM, Thornley B, Tomlinson L, et al. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 1998; 13:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/8\">",
"      Nelson SM, Fleming R. Obesity and reproduction: impact and interventions. Curr Opin Obstet Gynecol 2007; 19:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/9\">",
"      Marceau P, Kaufman D, Biron S, et al. Outcome of pregnancies after biliopancreatic diversion. Obes Surg 2004; 14:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/10\">",
"      Martin LF, Finigan KM, Nolan TE. Pregnancy after adjustable gastric banding. Obstet Gynecol 2000; 95:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/11\">",
"      Weiner R, Blanco-Engert R, Weiner S, et al. Outcome after laparoscopic adjustable gastric banding - 8 years experience. Obes Surg 2003; 13:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/12\">",
"      Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis 2005; 1:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/13\">",
"      Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006; 16:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/14\">",
"      Karmon A, Sheiner E. Pregnancy after bariatric surgery: a comprehensive review. Arch Gynecol Obstet 2008; 277:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/15\">",
"      Merhi ZO. Weight loss by bariatric surgery and subsequent fertility. Fertil Steril 2007; 87:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/16\">",
"      Doblado MA, Lewkowksi BM, Odem RR, Jungheim ES. In vitro fertilization after bariatric surgery. Fertil Steril 2010; 94:2812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/17\">",
"      Beard JH, Bell RL, Duffy AJ. Reproductive considerations and pregnancy after bariatric surgery: current evidence and recommendations. Obes Surg 2008; 18:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/18\">",
"      Wax JR, Cartin A, Wolff R, et al. Pregnancy following gastric bypass for morbid obesity: effect of surgery-to-conception interval on maternal and neonatal outcomes. Obes Surg 2008; 18:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/19\">",
"      Dao T, Kuhn J, Ehmer D, et al. Pregnancy outcomes after gastric-bypass surgery. Am J Surg 2006; 192:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/20\">",
"      Patel JA, Patel NA, Thomas RL, et al. Pregnancy outcomes after laparoscopic Roux-en-Y gastric bypass. Surg Obes Relat Dis 2008; 4:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/21\">",
"      Rand CS, Macgregor AM. Medical care and pregnancy outcome after gastric bypass surgery for obesity. South Med J 1989; 82:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/22\">",
"      Sheiner E, Edri A, Balaban E, et al. Pregnancy outcome of patients who conceive during or after the first year following bariatric surgery. Am J Obstet Gynecol 2011; 204:50.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/23\">",
"      Roehrig HR, Xanthakos SA, Sweeney J, et al. Pregnancy after gastric bypass surgery in adolescents. Obes Surg 2007; 17:873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/24\">",
"      American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 105: bariatric surgery and pregnancy. Obstet Gynecol 2009; 113:1405.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Morbidity and Mortality Weekly Report (MMWR). U.S. Medical Eligibility Criteria for Contraceptive Use, 2010. Adapted from the World Health Organization Medical Eligibility Criteria for Contraceptive Use, 4th edition. Early release - May 28, 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0528a1.htm (Accessed on May 28, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/26\">",
"      Paulen ME, Zapata LB, Cansino C, et al. Contraceptive use among women with a history of bariatric surgery: a systematic review. Contraception 2010; 82:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/27\">",
"      Bilenka B, Ben-Shlomo I, Cozacov C, et al. Fertility, miscarriage and pregnancy after vertical banded gastroplasty operation for morbid obesity. Acta Obstet Gynecol Scand 1995; 74:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/28\">",
"      Kjaer MM, Nilas L. Pregnancy after bariatric surgery--a review of benefits and risks. Acta Obstet Gynecol Scand 2013; 92:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/29\">",
"      Sheiner E, Levy A, Silverberg D, et al. Pregnancy after bariatric surgery is not associated with adverse perinatal outcome. Am J Obstet Gynecol 2004; 190:1335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/30\">",
"      Ducarme G, Revaux A, Rodrigues A, et al. Obstetric outcome following laparoscopic adjustable gastric banding. Int J Gynaecol Obstet 2007; 98:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/31\">",
"      Wittgrove AC, Jester L, Wittgrove P, Clark GW. Pregnancy following gastric bypass for morbid obesity. Obes Surg 1998; 8:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/32\">",
"      Weintraub AY, Levy A, Levi I, et al. Effect of bariatric surgery on pregnancy outcome. Int J Gynaecol Obstet 2008; 103:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/33\">",
"      Maggard MA, Yermilov I, Li Z, et al. Pregnancy and fertility following bariatric surgery: a systematic review. JAMA 2008; 300:2286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/34\">",
"      Lesko J, Peaceman A. Pregnancy outcomes in women after bariatric surgery compared with obese and morbidly obese controls. Obstet Gynecol 2012; 119:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/35\">",
"      Adami GF, Murelli F, Briatore L, Scopinaro N. Pregnancy in formerly type 2 diabetes obese women following biliopancreatic diversion for obesity. Obes Surg 2008; 18:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/36\">",
"      Richards DS, Miller DK, Goodman GN. Pregnancy after gastric bypass for morbid obesity. J Reprod Med 1987; 32:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/37\">",
"      Ehrenberg HM, Mercer BM, Catalano PM. The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004; 191:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/38\">",
"      Josefsson A, Blomberg M, Bladh M, et al. Bariatric surgery in a national cohort of women: sociodemographics and obstetric outcomes. Am J Obstet Gynecol 2011; 205:206.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/39\">",
"      Granstr&ouml;m L, Granstr&ouml;m L, Backman L. Fetal growth retardation after gastric banding. Acta Obstet Gynecol Scand 1990; 69:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/40\">",
"      Olow B, Akesson BA, Dencker H, et al. Pregnancy after jejuno-ileostomy because of obesity. Acta Chir Scand 1976; 142:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/41\">",
"      Taylor JL, O'Leary JP. Pregnancy following jejunoileal bypass. Obstet Gynecol 1970; 48:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/42\">",
"      Wax JR, Cartin A, Wolff R, et al. Pregnancy following gastric bypass surgery for morbid obesity: maternal and neonatal outcomes. Obes Surg 2008; 18:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/43\">",
"      Moliterno JA, DiLuna ML, Sood S, et al. Gastric bypass: a risk factor for neural tube defects? Case report. J Neurosurg Pediatr 2008; 1:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/44\">",
"      Pelizzo G, Nakib G, Alfei A, et al. Fetal neural tube defects in pregnant women previously submitted to bariatric surgery: more attention to a new emerging entity. Prenat Diagn 2013; 33:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/45\">",
"      Haddow JE, Hill LE, Kloza EM, Thanhauser D. Neural tube defects after gastric bypass. Lancet 1986; 1:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/46\">",
"      Stothard KJ, Tennant PW, Bell R, Rankin J. Maternal overweight and obesity and the risk of congenital anomalies: a systematic review and meta-analysis. JAMA 2009; 301:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/47\">",
"      Ledoux S, Msika S, Moussa F, et al. Comparison of nutritional consequences of conventional therapy of obesity, adjustable gastric banding, and gastric bypass. Obes Surg 2006; 16:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/48\">",
"      Weissman A, Hagay Z, Schachter M, Dreazen E. Severe maternal and fetal electrolyte imbalance in pregnancy after gastric surgery for morbid obesity. A case report. J Reprod Med 1995; 40:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/49\">",
"      Smets KJ, Barlow T, Vanhaesebrouck P. Maternal vitamin A deficiency and neonatal microphthalmia: complications of biliopancreatic diversion? Eur J Pediatr 2006; 165:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/50\">",
"      Van Mieghem T, Van Schoubroeck D, Depiere M, et al. Fetal cerebral hemorrhage caused by vitamin K deficiency after complicated bariatric surgery. Obstet Gynecol 2008; 112:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/51\">",
"      Eerdekens A, Debeer A, Van Hoey G, et al. Maternal bariatric surgery: adverse outcomes in neonates. Eur J Pediatr 2010; 169:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/52\">",
"      Guelinckx I, Devlieger R, Vansant G. Reproductive outcome after bariatric surgery: a critical review. Hum Reprod Update 2009; 15:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/53\">",
"      Faintuch J, Dias MC, de Souza Fazio E, et al. Pregnancy nutritional indices and birth weight after Roux-en-Y gastric bypass. Obes Surg 2009; 19:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/54\">",
"      Poitou Bernert C, Ciangura C, Coupaye M, et al. Nutritional deficiency after gastric bypass: diagnosis, prevention and treatment. Diabetes Metab 2007; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/55\">",
"      Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/56\">",
"      Wax JR, Pinette MG, Cartin A, Blackstone J. Female reproductive issues following bariatric surgery. Obstet Gynecol Surv 2007; 62:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/57\">",
"      Moore KA, Ouyang DW, Whang EE. Maternal and fetal deaths after gastric bypass surgery for morbid obesity. N Engl J Med 2004; 351:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/58\">",
"      Loar PV 3rd, Sanchez-Ramos L, Kaunitz AM, et al. Maternal death caused by midgut volvulus after bariatric surgery. Am J Obstet Gynecol 2005; 193:1748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/59\">",
"      Charles A, Domingo S, Goldfadden A, et al. Small bowel ischemia after Roux-en-Y gastric bypass complicated by pregnancy: a case report. Am Surg 2005; 71:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/60\">",
"      Baker MT, Kothari SN. Successful surgical treatment of a pregnancy-induced Petersen's hernia after laparoscopic gastric bypass. Surg Obes Relat Dis 2005; 1:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/61\">",
"      Kakarla N, Dailey C, Marino T, et al. Pregnancy after gastric bypass surgery and internal hernia formation. Obstet Gynecol 2005; 105:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/62\">",
"      Ahmed AR, O'Malley W. Internal hernia with Roux loop obstruction during pregnancy after gastric bypass surgery. Obes Surg 2006; 16:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/63\">",
"      Bellanger DE, Ruiz JF, Solar K. Small bowel obstruction complicating pregnancy after laparoscopic gastric bypass. Surg Obes Relat Dis 2006; 2:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/64\">",
"      Efthimiou E, Stein L, Court O, Christou N. Internal hernia after gastric bypass surgery during middle trimester pregnancy resulting in fetal loss: risk of internal hernia never ends. Surg Obes Relat Dis 2009; 5:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/65\">",
"      Wax JR, Wolff R, Cobean R, et al. Intussusception complicating pregnancy following laparoscopic Roux-en-Y gastric bypass. Obes Surg 2007; 17:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/66\">",
"      Tohamy AE, Eid GM. Laparoscopic reduction of small bowel intussusception in a 33-week pregnant gastric bypass patient: surgical technique and review of literature. Surg Obes Relat Dis 2009; 5:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/67\">",
"      Higa KD, Boone KB, Ho T. Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients--what have we learned? Obes Surg 2000; 10:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/68\">",
"      Wax JR, Pinette MG, Cartin A. Roux-en-Y gastric bypass-associated bowel obstruction complicating pregnancy-an obstetrician's map to the clinical minefield. Am J Obstet Gynecol 2013; 208:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/69\">",
"      Kummer N, Cackovic M, Paidas M, Funai E. Hypoxic hepatitis in a pregnant patient: a complication of gastric bypass surgery. Am J Perinatol 2008; 25:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/70\">",
"      Ramirez MM, Turrentine MA. Gastrointestinal hemorrhage during pregnancy in a patient with a history of vertical-banded gastroplasty. Am J Obstet Gynecol 1995; 173:1630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/71\">",
"      Erez O, Maymon E, Mazor M. Acute gastric ulcer perforation in a 35 weeks' nulliparous patient with gastric banding. Am J Obstet Gynecol 2004; 191:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/72\">",
"      Villegas L, Schneider B, Provost D, et al. Is routine cholecystectomy required during laparoscopic gastric bypass? Obes Surg 2004; 14:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/73\">",
"      Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/74\">",
"      Skull AJ, Slater GH, Duncombe JE, Fielding GA. Laparoscopic adjustable banding in pregnancy: safety, patient tolerance and effect on obesity-related pregnancy outcomes. Obes Surg 2004; 14:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/75\">",
"      Assas A, Bryson EO, Frost EA. Deceptive level after intrathecal block for cesarean section in a patient with prior abdominoplasty--a case report. Middle East J Anesthesiol 2011; 21:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/76\">",
"      Joshi P, Thomas DI. The influence of abdominoplasty surgery on assessment of level of subarachnoid block. Anaesthesia 2002; 57:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/77\">",
"      Celiker MY, Chawla A. Congenital B12 deficiency following maternal gastric bypass. J Perinatol 2009; 29:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27945/abstract/78\">",
"      Grange DK, Finlay JL. Nutritional vitamin B12 deficiency in a breastfed infant following maternal gastric bypass. Pediatr Hematol Oncol 1994; 11:311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 411 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-7727F3B860-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27945=[""].join("\n");
var outline_f27_18_27945=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPE OF BARIATRIC PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Clinical implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      FERTILITY BEFORE AND AFTER SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TIMING OF CONCEPTION FOLLOWING SURGERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CONTRACEPTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PREGNANCY OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Miscarriage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Birthweight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Macrosomia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Growth restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cesarean delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Perinatal morbidity and congenital anomalies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRENATAL CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Micronutrient supplementation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Fetal growth assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Screening",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Monitoring for complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48712524\">",
"      - Bowel obstruction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H48712531\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Gestational weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15290794\">",
"      Anesthesia for cesarean",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      POSTPARTUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/411\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/411|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/55/4987\" title=\"table 1\">",
"      Types of bariatric procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/13/12506\" title=\"table 2\">",
"      CDC Medical Eligibility Criteria for Contraceptive Use",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44009?source=related_link\">",
"      Cesarean delivery of the obese woman",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/58/41898?source=related_link\">",
"      Complications of bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/8/4233?source=related_link\">",
"      Contraception counseling for obese women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/47/32505?source=related_link\">",
"      Infant benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/1/42010?source=related_link\">",
"      Initial prenatal assessment and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/27/1461?source=related_link\">",
"      Maternal and economic benefits of breastfeeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26362?source=related_link\">",
"      Medical management of patients after bariatric surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/31/33274?source=related_link\">",
"      Surgical management of severe obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/11/29882?source=related_link\">",
"      The impact of obesity on fertility and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19304?source=related_link\">",
"      Weight gain and loss in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27946="Seasonal influenza vaccination in children";
var content_f27_18_27946=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Seasonal influenza vaccination in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Flor M Munoz, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27946/contributors\">",
"     George B Mallory, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Morven S Edwards, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?27/18/27946/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?27/18/27946/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is an acute respiratory illness caused by influenza A or B viruses, which occurs in outbreaks worldwide every year, mainly during the winter seasons (in temperate climates).",
"   </p>",
"   <p>",
"    Certain groups of children and adults are at increased risk of acquiring severe or complicated illness from influenza (",
"    <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. Among healthy children, influenza generally is an acute, self-limited, and uncomplicated disease. However, it can be associated with severe morbidity and mortality. The 2009 pandemic H1N1 influenza virus was associated with increased morbidity and mortality among children compared with the usual seasonal influenza virus strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1-6\">",
"     1-6",
"    </a>",
"    ]. Influenza causes an appreciable disease burden (eg, school and work absence, increased frequency of outpatient medical visits), and children are important vectors for the spread of disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Immunization is the most effective means of preventing influenza infection [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. Influenza vaccination in children will be discussed below. The use of antiviral drugs for the prevention of influenza in children, the design of influenza vaccines, and influenza vaccination in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFLUENZA ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The United States Centers for Disease Control and Prevention (CDC), in collaboration with the World Health Organization (WHO) and its reporting network, tracks influenza virus isolates throughout the world to monitor disease activity and to predict the appropriate components for the annual influenza vaccine. This information, which is updated weekly during influenza season, is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/\">",
"     CDC",
"    </a>",
"    . In addition,",
"    <a class=\"external\" href=\"file://www.who.int/influenza/gisrs_laboratory/flunet/en/\">",
"     FluNet",
"    </a>",
"    provides global influenza virus surveillance.",
"   </p>",
"   <p>",
"    Since July 2011, H3N2 influenza A variant viruses caused by reassortment of swine-origin H3N2 influenza A viruses and pandemic H1N1 influenza A viruses have been increasingly detected in patients in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. These viruses are susceptible to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/59/18360?source=see_link\">",
"     oseltamivir",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/47/16117?source=see_link\">",
"     zanamivir",
"    </a>",
"    , but resistant to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/62/17383?source=see_link\">",
"     amantadine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/39/34420?source=see_link\">",
"     rimantadine",
"    </a>",
"    . The seasonal influenza vaccine is not expected to provide protection against these strains among children younger than 10 years, but may provide some cross-protection for older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. Additional unexpected reassortment combinations may occur; updated information is available from the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/weekly/fluactivitysurv.htm\">",
"     CDC",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H104949276#H104949276\">",
"     \"Epidemiology of influenza\", section on 'H3N2 variant influenza'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual influenza vaccination is the most effective strategy for preventing influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,7\">",
"     1,7",
"    </a>",
"    ]. During the 2010-2011 influenza season, the estimated seasonal influenza vaccination coverage (at least one dose) among children (&ge;6 months to 18 years) was approximately 49 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/14\">",
"     14",
"    </a>",
"    ]. At eight sentinel immunization sites (2009-2010), the average percentage of children who were fully vaccinated was only 22.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/15\">",
"     15",
"    </a>",
"    ]. Opportunities to vaccinate individuals for influenza, particularly individuals at increased risk for severe or complicated influenza, often are missed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Types of vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two types of influenza vaccines are licensed for use in children in the United States (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"       Inactivated influenza vaccine",
"      </a>",
"      (IIV), administered intramuscularly",
"     </li>",
"     <li>",
"      Live-attenuated, cold-adapted influenza vaccine (LAIV), administered intranasally",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A comparison of IIV and LAIV is provided in the Table (",
"    <a class=\"graphic graphic_table graphicRef60449 \" href=\"UTD.htm?3/34/3630\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83326789\">",
"    <span class=\"h2\">",
"     Effectiveness for 2012-2013 season",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccine effectiveness is determined, in part, by how closely strains chosen for the vaccine match those circulating during the influenza season (see",
"    <a class=\"local\" href=\"#H16\">",
"     'Efficacy/effectiveness'",
"    </a>",
"    below). In a case-control study of 1155 children and adults with acute respiratory illness early in the 2012-2013 influenza season, the Centers for Disease Control and Prevention (CDC) estimated that the effectiveness of 2012-2013 seasonal influenza vaccine in preventing laboratory confirmed influenza was 62 percent (95% CI 51-71 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/16\">",
"     16",
"    </a>",
"    ]. Effectiveness against influenza A was 55 percent (95% CI 39-67 percent) and against influenza B was 70 percent (95% CI 56-80 percent). Similar studies in the United Kingdom and Canada have documented overall effectiveness of approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the moderate effectiveness of the vaccine, influenza infection will occur among some individuals who received the influenza vaccine. This highlights the importance of early antiviral therapy (regardless of vaccination status), particularly for those at risk for severe or complicated influenza infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strains included in the vaccine are updated each year to correlate with the strains anticipated to circulate during the coming influenza season. Before 2012, seasonal influenza vaccines were trivalent, containing two influenza A virus strains and one influenza B virus strain (IIV3). In 2012, the US Food and Drug Administration (FDA) approved quadrivalent formulations of IIV (IIV4) and LAIV; these vaccines contain two strains of influenza A virus and two strains of influenza B virus [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Both trivalent and quadrivalent formulations of influenza vaccines are expected to be available for the 2013 to 2014 influenza season [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO and Centers for Disease Control and Prevention recommend that trivalent influenza vaccines for use during the",
"    <strong>",
"     2012 to 2013",
"    </strong>",
"    influenza season in the northern hemisphere (November to April) and the 2013 influenza season in the southern hemisphere (May to October) contain the following [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]: :",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/California/7/2009",
"      </span>",
"      (H1N1)-like virus (against 2009 pandemic H1N1 influenza)",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/Victoria/361/2011",
"      </span>",
"      (H3N2)-like virus",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       B/Wisconsin/1/2010-like",
"      </span>",
"      virus (Yamagata lineage)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The WHO also recommends that when quadrivalent influenza vaccines are used during the",
"    <strong>",
"     2013",
"    </strong>",
"    influenza season in the southern hemisphere (May to October), they contain the three strains described above plus a",
"    <span class=\"nowrap\">",
"     B/Brisbane/60/2008-like",
"    </span>",
"    virus (Victoria lineage) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The WHO recommends that influenza vaccines for use during the",
"    <strong>",
"     2013 to 2014",
"    </strong>",
"    influenza season in the northern hemisphere (November to April) contain the following strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/California/7/2009",
"      </span>",
"      (H1N1)-like virus (against 2009 pandemic H1N1 influenza)",
"     </li>",
"     <li>",
"      An",
"      <span class=\"nowrap\">",
"       A/Texas/50/2012",
"      </span>",
"      (H3N2)-like virus that is antigenically similar to the cell-propagated prototype virus",
"      <span class=\"nowrap\">",
"       A/Victoria/361/2011",
"      </span>",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       B/Massachusetts/2/2012-like",
"      </span>",
"      virus (Yamagata lineage)",
"     </li>",
"     <li>",
"      A",
"      <span class=\"nowrap\">",
"       B/Brisbane/60/2008-like",
"      </span>",
"      virus (Victoria lineage included in the quadrivalent vaccines only)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The H1N1 influenza A strain is the same as the one used in the 2012-2013 vaccines, but the H3N2 influenza A and influenza B strains are different. The H3N2 influenza A strain was modified because of antigenic changes in earlier",
"    <span class=\"nowrap\">",
"     A/Victoria/361/2011-like",
"    </span>",
"    vaccine viruses resulting from adaptation to propagation in eggs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Supply",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information regarding the influenza vaccine supply in the United States is available through the",
"    <a class=\"external\" href=\"file://www.cdc.gov/flu/\">",
"     CDC",
"    </a>",
"    . In the event of a vaccine shortage or delay in distribution, vaccination efforts should focus on individuals at high risk for severe or complicated influenza (",
"    <a class=\"graphic graphic_table graphicRef79334 \" href=\"UTD.htm?28/14/28908\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CDC's Advisory Committee on Immunization Practices (ACIP) and the American Academy of Pediatrics (AAP) recommend annual influenza vaccination for",
"    <strong>",
"     all persons &ge;6 months",
"    </strong>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. The AAP recommends mandatory influenza immunization for all healthcare personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/28\">",
"     28",
"    </a>",
"    ]. Expansion of the target group to include everyone older than six months has the potential to reduce influenza disease, influenza-related complications and medical resource use, and influenza-related school or work absence. Increasing the numbers of immunized individuals also may reduce influenza among unimmunized contacts within the household and community (\"herd immunity\") [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Herd immunity'",
"    </a>",
"    below). This may be particularly helpful in preventing influenza infection among infants younger than six months and high-risk individuals who did not receive the vaccine.",
"   </p>",
"   <p>",
"    Families of infants and children susceptible to severe disease from influenza should be reminded that these patients may contract acute influenza infection despite immunization. Such patients may be candidates for antiviral therapy, the efficacy of which is enhanced by early treatment (within 24 to 48 hours of onset of symptoms). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Influenza immunization is now recommended for everyone &ge;6 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22,27\">",
"     22,27",
"    </a>",
"    ]. Special effort should be made to immunize the following groups when vaccine supply is limited (",
"    <a class=\"graphic graphic_table graphicRef79334 \" href=\"UTD.htm?28/14/28908\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,31\">",
"     1,31",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children and adolescents who are at high risk for severe or complicated influenza infection (ie, six months through four years of age; chronic pulmonary (including asthma), cardiovascular (excluding systemic hypertension), renal, hepatic, neurologic, hematologic, or metabolic disorder; 6 months to 18 years of age and receiving long-term",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      therapy; immunosuppression; residents of chronic care facilities; Native Americans, including Alaska natives; morbidly obese).",
"     </li>",
"     <li>",
"      Women who are or will be pregnant during the influenza season. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=see_link&amp;anchor=H18#H18\">",
"       \"Immunizations during pregnancy\", section on 'Influenza'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Household contacts and out-of-home caregivers of children and adolescents who are at high risk for severe or complicated influenza, including children &lt;59 months of age, and",
"      <strong>",
"       especially contacts of infants &lt;6 months of age",
"      </strong>",
"      .",
"     </li>",
"     <li>",
"      Children who may transmit influenza to a high-risk household member.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Choice of vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of vaccine for an individual child depends upon age and risk factors for severe or complicated influenza [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,27\">",
"     1,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IIV is indicated for individuals &ge;6 months, including those who cannot receive LAIV. The following groups should receive IIV rather than LAIV (",
"    <a class=\"graphic graphic_table graphicRef67562 \" href=\"UTD.htm?5/4/5197\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Children &ge;6 through 23 months of age",
"     </li>",
"     <li>",
"      Children (of any age) with asthma and children two through four years of age with a history of recurrent wheezing",
"     </li>",
"     <li>",
"      Children with medical conditions that increase the risk for severe or complicated influenza infection",
"     </li>",
"     <li>",
"      Children who are close contacts of severely immunocompromised individuals (eg, hematopoietic stem cell transplant recipients)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Contraindications and precautions for LAIV'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Children older than two years who are not in one of the categories listed above may receive either IIV or LAIV. Given the potential advantage of broader and more durable immunity with LAIV, we suggest LAIV for such patients if they are not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'LAIV compared with IIV'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Schedule",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annual immunization is necessary even if the previous season&rsquo;s vaccine contained one or more of the antigens to be administered in the current season because immunity declines in the year after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22,33-35\">",
"     22,33-35",
"    </a>",
"    ]. Influenza vaccine should be administered during the fall of each year (October through December in the northern hemisphere) before the onset of influenza season (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"UTD.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of influenza\", section on 'Seasonality'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children six months through eight years require two doses of influenza vaccine during the first season in which they are vaccinated to optimize immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22,36-39\">",
"     22,36-39",
"    </a>",
"    ]. The recommendations for previously vaccinated children six months through eight years of age vary from year to year depending upon changes to the viruses included in the vaccine.",
"   </p>",
"   <p>",
"    The schedule for the 2012-2013 seasonal influenza vaccine in the northern hemisphere varies depending upon the age of the child and the number of doses of seasonal influenza vaccine received after July 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Children &ge;9 years of age should receive one dose.",
"   </p>",
"   <p>",
"    Children six months through eight years should receive:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       One dose:",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If they received at least two doses of seasonal influenza vaccine after July 2010,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      If there is clear documentation that they received at least two doses of seasonal influenza vaccine in any previous season",
"      <strong>",
"       and",
"      </strong>",
"      at least one does of pandemic H1N1 influenza vaccine (eg, monovalent pandemic influenza vaccine in the 2009-2010 season or as part of the seasonal influenza vaccine in the 2010-2011 or 2011-2012 influenza seasons).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Two doses",
"      </strong>",
"      , separated by at least one month:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If they are receiving seasonal influenza vaccine for the first time,",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      Received fewer than two doses of seasonal influenza vaccine after July 2010 (no matter how many doses they received before July 2010),",
"      <strong>",
"       or",
"      </strong>",
"     </li>",
"     <li>",
"      If the number of doses of seasonal influenza vaccine received after July 2010 is uncertain (no matter how many doses they received before July 2010)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For children who require two doses of vaccine, the first dose should be administered as soon as the vaccine is available, to ensure that both doses are received before the onset of influenza activity [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ]. The vaccine should continue to be offered as long into the season as influenza activity occurs (",
"    <a class=\"graphic graphic_figure graphicRef60877 \" href=\"UTD.htm?12/3/12349\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Recommendations for the 2013-2014 season will be updated when they are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Schedule in special circumstances",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Immune suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;IIV typically elicits a poor response among children receiving immunosuppressive chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The optimal time of administration of influenza vaccine in such children is more than three weeks after immunosuppressive chemotherapy has been discontinued, when peripheral granulocyte and lymphocyte counts are",
"    <span class=\"nowrap\">",
"     &gt;1000/microL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    antibody response is not affected by brief courses of glucocorticoids or glucocorticoids that are administered every other day [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/41\">",
"     41",
"    </a>",
"    ]. In contrast, the antibody response may be impaired by prolonged administration of glucocorticoids at doses &ge;2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day or &ge;20",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"   </p>",
"   <p>",
"    Influenza",
"    vaccination may be deferred in patients receiving high-dose glucocorticoids, as long as deferral does not compromise the likelihood of completion of immunization before the beginning of influenza season. A reasonable approach for influenza prevention in children who are expected to require high-dose glucocorticoids throughout the influenza season would include immunization with IIV, chemoprophylaxis, and immunization of close contacts. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H14#H14\">",
"     \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Chemoprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Travelers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with high-risk conditions who plan to travel to tropical regions should be reminded that influenza occurs throughout the year in the tropics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=see_link&amp;anchor=H8#H8\">",
"     \"Epidemiology of influenza\", section on 'Seasonality'",
"    </a>",
"    .) In addition, summertime outbreaks of influenza have occurred on cruise ships in the northern and southern hemispheres. Repeat vaccination is not necessary in those who received routine vaccination at the appropriate time in the previous fall or winter [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. However, high-risk children who receive the previous season's vaccine before travel in the spring or summer should be revaccinated with the current vaccine the following fall. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations for travel\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H79749360\">",
"    <span class=\"h3\">",
"     Children with documented influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unvaccinated children who have recovered from a laboratory confirmed influenza illness or unconfirmed influenza-like-illness should be vaccinated. Multiple influenza virus strains circulate in any given season and infection with one type of virus does not provide immunity to the other types.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Herd immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Widespread immunization of school and daycare children has appeared to result in \"herd immunity\" with diminished influenza infection in unvaccinated children and adults of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/29,30,42\">",
"     29,30,42",
"    </a>",
"    ]. In one report, as an example, unvaccinated household contacts of vaccinated children had 42 percent fewer febrile respiratory illnesses than unvaccinated household contacts of unvaccinated children; the degree of protection was greater (80 percent reduction) among school-aged household contacts who also had a 70 percent reduction in school days missed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INACTIVATED INFLUENZA VACCINE (IIV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intramuscular influenza vaccines are inactivated preparations of either whole-virus or subvirion components (\"split product\"). Split-product vaccines cause fewer adverse reactions and are preferred for use in children &le;12 years of age. Only split-product vaccines are available in the United States (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Influenza vaccines have traditionally been produced in embryonated chicken eggs. However, in November 2012, the US Food and Drug Administration (FDA) approved a trivalent",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"     inactivated influenza vaccine",
"    </a>",
"    (IIV3) produced in cultured mammalian cells for individuals &ge;18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In January 2013, the FDA approved another egg-free IIV3, which is produced using recombinant DNA technology, for individuals 18 through 49 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/47\">",
"     47",
"    </a>",
"    ]. Cell-based technology allows for a faster production of influenza vaccines, independent from the need to grow the virus in eggs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Efficacy/effectiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because IIV takes typically approximately nine months to manufacture, it necessarily contains antigens from strains that circulated during the end of the previous season. The protective effect of the vaccine is determined largely by the relationship between the strains in the vaccine and viruses that circulate in the outbreak (closeness of &ldquo;fit&rdquo; or &ldquo;match&rdquo;) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Estimates of vaccine protection also depend upon the activity and severity of circulating influenza viruses, which vary from year to year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,52\">",
"     1,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the \"fit\" between circulating and vaccine strains is close, rates of protection of 50 to 80 percent against influenza-like illness are expected [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/48,49,53-55\">",
"     48,49,53-55",
"    </a>",
"    ]. If the fit is poor, as it was during the 2007-2008 influenza season when most of the circulating influenza A (H3N2) and influenza B viruses were suboptimally matched, effectiveness is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/54,56-58\">",
"     54,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Laboratory-confirmed influenza",
"      </strong>",
"      &ndash; In a meta-analysis of seven randomized trials (1628 patients) comparing IIV and placebo or no intervention, the efficacy of IIV against laboratory-confirmed influenza in healthy children was 59 percent (95% CI 41-71 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Few data exist regarding the efficacy of IIV in young children, and the",
"      <span class=\"nowrap\">",
"       efficacy/effectiveness",
"      </span>",
"      will vary depending on the activity and severity of circulating strains. In the only randomized trial, the efficacy of IIV against laboratory-confirmed influenza in children ages 6 to 24 months was 66 percent during the first season [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/60\">",
"       60",
"      </a>",
"      ]. Observational studies have demonstrated similar rates of effectiveness of IIV against laboratory confirmed influenza (66 percent in a prospective cohort of children ages nine months to three years and 58 percent in a case-control study of children ages 6 to 59 months) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/61-63\">",
"       61-63",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Families of infants and children susceptible to severe disease from influenza should be reminded that these patients may contract acute influenza infection despite immunization. Such patients may be candidates for antiviral therapy, the effectiveness of which is enhanced by early treatment (within 24 to 48 hours of onset of symptoms). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=see_link&amp;anchor=H20#H20\">",
"       \"Antiviral drugs for the prevention and treatment of seasonal influenza in children\", section on 'Antiviral therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Clinical influenza",
"      </strong>",
"      &ndash; In a meta-analysis of seven randomized trials (19,388 patients), the effectiveness of IIV in preventing clinical influenza-like illness in children older than two years was 36 percent (95% CI 24-46) [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/59\">",
"       59",
"      </a>",
"      ]. Studies addressing effectiveness of IIV among children younger than two years were lacking. In cohort studies, the effectiveness of IIV in preventing influenza-like illness among children younger than two years ranges from 25 to 69 to percent [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/36,64\">",
"       36,64",
"      </a>",
"      ]. The effectiveness during any given season depends upon the match between the circulating and vaccine strains and the activity and severity of circulating strains.",
"     </li>",
"     <li>",
"      <strong>",
"       Prevention of asthma exacerbation",
"      </strong>",
"      &ndash; The efficacy of IIV in preventing asthma exacerbations related to influenza infection is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/65,66\">",
"       65,66",
"      </a>",
"      ]. In a randomized trial, 696 children (aged 6 to 18 years) with asthma were assigned to receive IIV or placebo [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/67\">",
"       67",
"      </a>",
"      ]. Pharyngeal cultures were obtained during asthma exacerbations. Reduction in influenza-related asthma exacerbations among vaccine recipients was not demonstrated (risk difference 0.01, 95% CI -0.02 to 0.04). Nonrandomized studies have inconsistent results [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/68-71\">",
"       68-71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Otitis media",
"      </strong>",
"      &ndash; The efficacy of IIV in the prevention of acute otitis media is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=see_link&amp;anchor=H11#H11\">",
"       \"Acute otitis media in children: Prevention of recurrence\", section on 'Influenza vaccine'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immunogenicity of IIV among children varies with age, dose, number of previous doses, influenza strains, and vaccine manufacturer [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/72-75\">",
"     72-75",
"    </a>",
"    ]. Most infants &ge;6 months of age, including former extremely low-birth weight premature infants, develop protective levels of antibody after two doses of IIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/76\">",
"     76",
"    </a>",
"    ]. However, antibody response among previously unvaccinated infants between 6 and 23 months of age appears to increase with increasing age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/77\">",
"     77",
"    </a>",
"    ]. Antibody response among infants younger than six months appears to be affected by maternal antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/78,79\">",
"     78,79",
"    </a>",
"    ]. IIV is not licensed for use in infants younger than six months.",
"   </p>",
"   <p>",
"    Exposure to influenza infection in previous years may affect the response to vaccination, especially among children &lt;36 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/80\">",
"     80",
"    </a>",
"    ]. Children with preexisting hemagglutinin-inhibition antibody to influenza A and influenza B antigen from previous exposure to influenza virus (ie, not persistent maternal antibody) are more likely to develop a protective immune response after immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Contraindications and precautions for IIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;A history of severe allergic reaction to influenza vaccine, regardless of the component suspected to be responsible for the reaction is a contraindication to influenza vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with allergy to chicken or egg proteins are at risk for hypersensitivity reactions following IIV because most formulations of IIV are prepared in embryonated chicken eggs [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ]. The administration of influenza vaccine to children who are allergic to eggs is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with sensitivity to thimerosal should not be given a vaccine that contains thimerosal (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Immunization with IIV usually should be withheld from children with moderate to severe acute febrile illness until their symptoms have resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. However, minor illnesses with or without fever do not contraindicate use of IIV, particularly among children with upper respiratory tract infection or allergic rhinitis. It is not known whether influenza vaccine increases the risk of Guillain-Barr&eacute; syndrome (GBS) among children who developed GBS within six weeks after previous influenza vaccination. This theoretic risk should be balanced against the potential morbidity and mortality of influenza infection in such children when making decisions about influenza immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IIV is safe for mothers who are breastfeeding and their infants [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     IIV dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose of IIV varies depending upon the age of the child [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      6 to 35 months &ndash; 0.25 mL intramuscularly (IM)",
"     </li>",
"     <li>",
"      &ge;36 months &ndash; 0.5 mL IM",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Administration with other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;IIV may be administered at the same time, but at a different site, as other recommended immunizations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,41\">",
"     1,41",
"    </a>",
"    ]. The preferred site for IIV in infants and young children is the anterolateral thigh; the deltoid is the preferred site for older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=see_link&amp;anchor=H2#H2\">",
"     \"Standard immunizations for children and adolescents\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Increased rates of febrile seizures have been reported among children, particularly those 12 through 23 months of age, who received IIV and the 13-valent pneumococcal conjugate vaccine (PCV13) at the same visit compared with children who received IIV and PCV13 on separate occasions, but the risk is low (approximately 1 in 2000 to 3000) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/82-84\">",
"     82-84",
"    </a>",
"    ]. Because of the greater risks associated with delaying either of these vaccines, the Advisory Committee on Immunization Practices does not recommend administering them at separate visits or deviating from the recommended vaccine schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequent adverse effect of IIV is a local reaction with soreness at the injection site [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,27,85-88\">",
"     1,27,85-88",
"    </a>",
"    ]. Fever may occur. It is usually low grade and occurs predominately in children younger than two years; 10 to 35 percent of such children become febrile, usually within 6 to 24 hours after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/27\">",
"     27",
"    </a>",
"    ]. Serious adverse reactions are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/89\">",
"     89",
"    </a>",
"    ]. The safety of IIV in children has been confirmed in population-based studies in which no significant adverse effects or associations were detected during specified time periods (ranging from 0 to 42 days) after IIV administration [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/90-92\">",
"     90-92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the 166 adverse events reported to the United States Vaccine Adverse Event Reporting System (VAERS) between 1990 and 2003 for children younger than two years, fever was most common (35 percent), followed by rash (25 percent), seizure (17 percent; 68 percent of these were associated with fever), and injection site reaction (17 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/93\">",
"     93",
"    </a>",
"    ]. However, in a large retrospective case-control study, the hazard ratios for these events were not increased during the 42 days after the first dose of IIV among children 6 through 23 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/94\">",
"     94",
"    </a>",
"    ]. Increased rates of febrile seizures have been reported among children, particularly those 12 through 23 months of age, who received IIV and the 13-valent pneumococcal conjugate vaccine at the same visit [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Administration with other vaccines'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Ocular (red eyes)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    respiratory symptoms (cough, wheezing, chest tightness) occasionally have been reported, occurring within 2 to 24 hours after receiving IIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. These symptoms generally were mild and resolved spontaneously. This \"oculo-respiratory\" syndrome (ORS) was described primarily in 2000-2001 in association with one Canadian vaccine; after reformulation of the vaccine, the number and severity of cases of ORS declined. It is uncertain whether the symptoms were related to the vaccine or coincident respiratory",
"    <span class=\"nowrap\">",
"     illness/seasonal",
"    </span>",
"    allergies; they do not appear to be IgE mediated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Immunization of children with asthma has not been associated with asthma exacerbation [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,66\">",
"     1,66",
"    </a>",
"    ]. Immunization in some years has been associated with a slight increase in Guillain-Barr&eacute; syndrome in adults, but only rare cases have been reported in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis of Guillain-Barr&eacute; syndrome in adults\", section on 'Influenza vaccination'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effects of IIV immunization in HIV-infected individuals have been conflicting. Some studies demonstrate a transient increase in the replication of HIV, but these results are inconsistent. Progression of HIV disease or decreased CD4 cell count has not been demonstrated after influenza vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,96\">",
"     1,96",
"    </a>",
"    ]. Most experts recommend that the potential benefits of immunization outweigh the potential risks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunizations in HIV-infected patients\", section on 'Influenza vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thimerosal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thimerosal is a mercury-containing antibacterial compound that has been used as a preservative in some vaccines (",
"    <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"     table 2",
"    </a>",
"    ). Multidose containers of IIV used in the United States contain 25 mcg of mercury per each 0.5 mL dose [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. \"Preservative-free\" preparations of Fluvirin may contain trace amounts of mercury (&lt;1 mcg per dose), but single-dose preparations of Fluzone, Fluarix, Afluria, Agriflu, Flucevax, and Flublok are thimerosal free.",
"   </p>",
"   <p>",
"    A risk related to the small amount of thimerosal in IIV is theoretical and unproven. In comparison to the considerable risk imposed by influenza, the potential benefit of immunization is considered to far outweigh the theoretical risk from a vaccine with a small amount of thimerosal [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349802567\">",
"    <span class=\"h2\">",
"     Latex",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following IIV contain latex in the syringe cap tip:",
"    <strong>",
"    </strong>",
"    Fluarix, Fluvirin, Agriflu and Flucelvax.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LIVE-ATTENUATED INFLUENZA VACCINE (LAIV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The intranasal influenza vaccine (LAIV, FluMist) is licensed by the US Food and Drug Administration (FDA) for use in healthy individuals 2 through 49 years of age who are not pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAIV is a cold-adapted live-attenuated vaccine prepared through genetic reassortment [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,85,97\">",
"     1,85,97",
"    </a>",
"    ]. The vaccine virus appears to be stable; reversion of the vaccine virus to a virulent strain in vaccinees has not been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/98,99\">",
"     98,99",
"    </a>",
"    ]. LAIV does not contain thimerosal, but may contain trace amounts of residual egg protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=see_link\">",
"     \"Influenza vaccination in individuals with egg allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a meta-analysis of seven randomized trials (9175 patients) comparing LAIV with placebo or no intervention, the efficacy of LAIV against confirmed influenza among healthy children older than two years of age was 80 percent (95% CI 38-87 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/59\">",
"     59",
"    </a>",
"    ]. Individual studies of LAIV among healthy children have demonstrated efficacy ranging from 47 to 100 percent, depending primarily upon the closeness of fit between the vaccine strains and the circulating wild type strains [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/97\">",
"     97",
"    </a>",
"    ]. Efficacy is also affected by the number of doses received. In studies comparing a single dose of LAIV to placebo, the efficacy of a single dose ranged from 58 to 89 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/100-102\">",
"     100-102",
"    </a>",
"    ]. The efficacy of LAIV in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H9#H9\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Immunogenicity, efficacy, and safety'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some data suggest that LAIV provides protection against influenza types not contained in the vaccine. In a study in which LAIV was administered during consecutive influenza seasons, influenza",
"    <span class=\"nowrap\">",
"     A/H3N2/Sydney,",
"    </span>",
"    a strain that was not included in the vaccine, circulated during the second season [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/103\">",
"     103",
"    </a>",
"    ]. The efficacy against culture-positive influenza illness during the first and second seasons were 93 percent (95% CI 88-96 percent) and 87 percent (95% CI 78-93 percent), respectively. The efficacy of LAIV against influenza",
"    <span class=\"nowrap\">",
"     A/H3N2/Sydney",
"    </span>",
"    was 86 percent (95% CI 75-92 percent). The increased",
"    <span class=\"nowrap\">",
"     efficacy/effectiveness",
"    </span>",
"    of LAIV compared with IIV against mismatched influenza strains has been described in other trials (randomized and nonrandomized) and meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85,104-107\">",
"     85,104-107",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     LAIV compared with IIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to several studies in children, LAIV may be more efficacious than IIV, may provide greater immunity against mismatched strains (as described above), may provide immediate protection during an outbreak, may provide better T-cell responses, and may provide longer-standing protection than IIV as illustrated below [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85,104,107-111\">",
"     85,104,107-111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In studies comparing IIV and LAIV in children, children who received LAIV had 32 to 55 percent fewer cases of culture-confirmed influenza than children who received IIV [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85,97,108,109\">",
"       85,97,108,109",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      During an outbreak in which the circulating and vaccine strains of influenza A (H3N2) differed, LAIV was 37 percent effective against influenza-positive illness, whereas IIVdid not provide protection [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/107\">",
"       107",
"      </a>",
"      ]. Protection with LAIV was similar within 14 days of immunization and &gt;14 days after immunization, suggesting that LAIV provides protection through both innate and adaptive mechanisms.",
"     </li>",
"     <li>",
"      Analysis of data from three large studies comparing LAIV and IIV indicates that the relative efficacy of LAIV versus IIV increases over time (25 to 60 percent at zero to four months and 49 to 89 percent at between four and eight months), although both vaccines were highly efficacious [",
"      <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/110\">",
"       110",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although LAIV is more expensive than IIV, its relative increased efficacy may result in decreased healthcare and societal costs for children 24 to 59 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/104,112\">",
"     104,112",
"    </a>",
"    ]. The relative efficacy of LAIV and IIV in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link&amp;anchor=H13#H13\">",
"     \"Seasonal influenza vaccination in adults\", section on 'Comparisons of inactivated and live-attenuated vaccines'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Contraindications and precautions for LAIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to LAIV include [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,27\">",
"     1,27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age &lt;2 years",
"     </li>",
"     <li>",
"      History of anaphylactic reaction to egg or chicken protein,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?36/48/37632?source=see_link\">",
"       gentamicin",
"      </a>",
"      , gelatin, or arginine",
"     </li>",
"     <li>",
"      Long-term",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"       aspirin",
"      </a>",
"      or salicylate therapy",
"     </li>",
"     <li>",
"      History of Guillain-Barr&eacute; syndrome",
"     </li>",
"     <li>",
"      Asthma",
"     </li>",
"     <li>",
"      Recurrent wheezing in children younger than five years",
"     </li>",
"     <li>",
"      Chronic pulmonary, cardiovascular (excluding systemic hypertension), renal, hepatic, neurologic, hematologic, or metabolic (including diabetes mellitus) disorders",
"     </li>",
"     <li>",
"      Pregnancy",
"     </li>",
"     <li>",
"      Known or suspected immunodeficiency or immunosuppressive therapy",
"     </li>",
"     <li>",
"      Receipt of other live virus vaccine within the previous four weeks (other live virus vaccines can be administered on the same day)",
"     </li>",
"     <li>",
"      Residents of chronic care facilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IIV is preferred to LAIV for contacts of severely immunocompromised individuals (eg, hematopoietic stem cell transplant recipients) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. Contacts of individuals with lesser degrees of immunocompromise (eg, persons with diabetes, asthma or HIV infection, those who are receiving corticosteroids) may receive either IIV or LAIV vaccine [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. Healthcare workers who receive LAIV should refrain from contact with severely immunocompromised individuals for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1,113\">",
"     1,113",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LAIV can be administered to children with minor acute illnesses, with or without fever. Clinical judgment should be used before administering the vaccine to children with nasal congestion of such severity that it may impede delivery of the vaccine to the nasopharyngeal mucosa. Administration of the vaccine may be deferred until resolution of illness unless deferral of vaccination may result in the child not being vaccinated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ]. If the child sneezes after LAIV is administered the dose should not be repeated [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Breastfeeding does not adversely affect the immune response to LAIV and is not a contraindication to LAIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     LAIV dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dose for LAIV is 0.2 mL administered intranasally (0.1 mL to each nostril) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Administration with other vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;LAIV can be administered at the same time as other live and inactivated vaccines [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/114\">",
"     114",
"    </a>",
"    ]. However, if it is not administered on the same day as other live vaccines (eg, measles-mumps-rubella, varicella zoster), it should be administered at least four weeks later [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/27,115\">",
"     27,115",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of LAIV has been evaluated in a number of trials including more than 18,000 children younger than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/97\">",
"     97",
"    </a>",
"    ]. Few adverse events occurred in controlled trials in healthy children 12 months to 18 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/97,100,104\">",
"     97,100,104",
"    </a>",
"    ]. In a meta-analysis of three studies [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/100,101,103\">",
"     100,101,103",
"    </a>",
"    ], nasal",
"    <span class=\"nowrap\">",
"     congestion/runny",
"    </span>",
"    nose and fever &gt;100&ordm;F (37.8&ordm;C) occurred in at least 5 percent more of the recipients of vaccine than of placebo after the first dose (58 versus 50 percent and 16 versus 11 percent for congestion and fever, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/97\">",
"     97",
"    </a>",
"    ]. Nasal congestion and low-grade fever typically peak within three to four days after the first dose of LAIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/116\">",
"     116",
"    </a>",
"    ]. In a subsequent meta-analysis, reporting bias of safety outcomes precluded meaningful analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of the effectiveness of a school-based immunization program, students who received LAIV had significantly higher rates of symptoms of influenza-like illness (other than wheezing) and use of nonprescription medicines in the week after immunization than in the week before immunization [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/117\">",
"     117",
"    </a>",
"    ]. However, no significant increases in the use of prescription medications, visits to doctors or clinics, or school days lost by the vaccinated students occurred.",
"   </p>",
"   <p>",
"    During the first two seasons after licensure, approximately 2.5 million individuals received LAIV [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/118\">",
"     118",
"    </a>",
"    ]. No unexpected serious events were identified although a small number of serious adverse events were reported to VAERS: possible anaphylaxis (7), Guillain-Barr&eacute; syndrome (2), Bell's palsy (1), and asthma exacerbation among individuals with a history of asthma (8) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/118\">",
"     118",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Asthma and wheezing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies evaluating the association between LAIV and asthma, wheezing, or respiratory illnesses have had conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85,108,109,119-121\">",
"     85,108,109,119-121",
"    </a>",
"    ]. Among older children, receipt of LAIV has not been associated with an increased frequency of wheezing or asthma-related events [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/108,119,120\">",
"     108,119,120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prelicensure studies identified a possible association between LAIV and episodes of wheezing among children younger than five years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/119,120\">",
"     119,120",
"    </a>",
"    ]. In one of these trials, which took place over four years and did not exclude children with intermittent wheezing, the association was only noted during the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/119\">",
"     119",
"    </a>",
"    ]. Subgroup analysis found no increased risk of medically attended acute respiratory illnesses, including asthma exacerbation, among LAIV recipients with a history of intermittent wheezing during the 42 days after vaccination [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/121\">",
"     121",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A subsequent randomized trial comparing LAIV and IIV among children 6 to 59 months without asthma or history of recent wheezing (ie, within the 42 days before vaccination) failed to confirm an association between LAIV and wheezing for children &gt;24 months [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85\">",
"     85",
"    </a>",
"    ]. However, among children &lt;24 months, medically significant wheezing within 42 days after vaccination was more frequent among LAIV recipients (2.3 versus 1.5 percent), particularly among those 6 to 11 months of age (3.8 versus 2.1 percent). The proportion of children who had wheezing episodes after vaccination who had subsequent episodes of wheezing was similar between groups (32 versus 28 percent for one subsequent episode and 4 versus 5 percent for two or more subsequent episodes in the LAIV and IIV groups, respectively).",
"   </p>",
"   <p>",
"    In post-hoc analyses, rates of hospitalization within 180 days of vaccination were significantly higher among 6- to 11-month-old recipients of LAIV than among 6- to 11-month-old IIV recipients (6.1 versus 2.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/85\">",
"     85",
"    </a>",
"    ]. Higher (but not significantly higher) rates of hospitalization also were observed in children 12 to 47 months of age who had a history of wheezing before entering the study.",
"   </p>",
"   <p>",
"    LAIV is not licensed for use in children younger than two years, nor in children with asthma or risk factors for serious influenza disease. Until additional data are available, the above observations suggest that IIV should continue to be used for children 6 to 24 months of age and young children with a history of wheezing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Viral shedding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viral shedding after immunization with LAIV was evaluated in 344 subjects divided into three groups (5 to 8 years, 9 to 17 years, and 18 to 49 years), with the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/113\">",
"     113",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      5 to 8 years &ndash; Viral shedding occurred in 44 percent, peaked on days 2 to 3, and resolved by 10 days",
"     </li>",
"     <li>",
"      9 to 17 years &ndash; Viral shedding occurred in 27 percent, peaked on days 2 to 3, and resolved by 6 days",
"     </li>",
"     <li>",
"      19 to 49 years &ndash; Viral shedding occurred in 17 percent, peaked on days 2 to 3, and resolved by 6 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transmission of the attenuated influenza strains to unprotected contacts appears to be uncommon, possibly because only low titers of vaccine virus are shed [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/122\">",
"     122",
"    </a>",
"    ]. In a study in which 197 daycare attendees (aged 9 to 36 months) were randomly assigned to receive LAIV or placebo, 80 percent of LAIV recipients shed at least one vaccine strain [",
"    <a class=\"abstract\" href=\"UTD.htm?27/18/27946/abstract/122\">",
"     122",
"    </a>",
"    ]. There was one confirmed case of transmission of a vaccine strain to a placebo recipient who did not develop clinically significant illness. The calculated probability of transmission to a child after contact with a single vaccinated child was 0.58 percent (95% CI 0-1.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/vis/default.htm\">",
"       Vaccine information statement for IIV and LAIV",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.immunize.org/pocketguides/\">",
"       Pocket guide for influenza",
"      </a>",
"      from the National Influenza Vaccine Summit",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       \"Patient information: Flu (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=see_link\">",
"       \"Patient information: Influenza prevention (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=see_link\">",
"       \"Patient information: Influenza symptoms and treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Influenza virus infection is associated with increased rates of hospitalization in children with risk factors for severe or complicated influenza infection, and in otherwise healthy children younger than five years, particularly those younger than two years (",
"      <a class=\"graphic graphic_table graphicRef72029 \" href=\"UTD.htm?32/50/33579\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of seasonal influenza in children\", section on 'Risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Immunization is the major means of influenza prevention. Two types of influenza vaccines are available:",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/21/20824?source=see_link\">",
"       inactivated influenza vaccine",
"      </a>",
"      (IIV), which is administered intramuscularly, and live-attenuated, cold-adapted influenza vaccine (LAIV), which is administered intranasally (",
"      <a class=\"graphic graphic_table graphicRef79474 \" href=\"UTD.htm?41/31/42494\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef60449 \" href=\"UTD.htm?3/34/3630\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Types of vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In accord with the Centers for Disease Control and Prevention (CDC) and American Academy of Pediatrics, we recommend annual influenza immunization for all persons six months of age and older (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). When vaccine supply is limited, immunization efforts should focus on children and adolescents who are at risk for severe or complicated influenza and household contacts and out-of-home caregivers of children 0 to 59 months of age and other individuals who are at increased risk of severe or complicated influenza (",
"      <a class=\"graphic graphic_table graphicRef79334 \" href=\"UTD.htm?28/14/28908\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of vaccine for an individual child depends upon age and risk factors for severe or complicated influenza. IIV is indicated for individuals &ge;6 months, including those who cannot receive LAIV. The following groups should receive IIV, rather than LAIV (",
"      <a class=\"graphic graphic_table graphicRef67562 \" href=\"UTD.htm?5/4/5197\">",
"       table 5",
"      </a>",
"      ):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Children 6 through 23 months of age",
"     </li>",
"     <li>",
"      Children (of any age) with asthma and children two through four years of age with a history of recurrent wheezing",
"     </li>",
"     <li>",
"      Children with medical conditions that increase the risk for severe or complicated influenza infection",
"     </li>",
"     <li>",
"      Children who are close contacts of severely immunocompromised individuals (eg, hematopoietic stem cell transplant recipients)",
"      <br/>",
"      <br/>",
"      (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Choice of vaccine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Contraindications and precautions for LAIV'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Individuals older than 2 years and younger than 50 years who are not among of the categories listed above may receive either IIV or LAIV. Given the potential advantage of broader and more durable immunity with LAIV, we suggest LAIV for such patients if they are not pregnant (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H25\">",
"       'LAIV compared with IIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Annual immunization is necessary even if the previous season&rsquo;s vaccine contained one or more of the antigens to be administered in the current season because immunity declines during the year following vaccination. Immunization should be administered in the fall. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Schedule'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vaccine schedule varies depending upon age and prior history of influenza immunization. The dose of IIV varies depending upon age. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Schedule'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'IIV dose'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24146624\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Caroline Breese Hall, MD, who passed away in December 2012. We wish to acknowledge Dr. Hall&rsquo;s many contributions to UpToDate, in particular her work as an author of this topic.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/1\">",
"      Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/2\">",
"      Louie JK, Gavali S, Acosta M, et al. Children hospitalized with 2009 novel influenza A(H1N1) in California. Arch Pediatr Adolesc Med 2010; 164:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/3\">",
"      Yung M, Slater A, Festa M, et al. Pandemic H1N1 in children requiring intensive care in Australia and New Zealand during winter 2009. Pediatrics 2011; 127:e156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/4\">",
"      Ekstrand JJ, Herbener A, Rawlings J, et al. Heightened neurologic complications in children with pandemic H1N1 influenza. Ann Neurol 2010; 68:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/5\">",
"      Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA 2011; 306:1659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/6\">",
"      Bagdure D, Curtis DJ, Dobyns E, et al. Hospitalized children with 2009 pandemic influenza A (H1N1): comparison to seasonal influenza and risk factors for admission to the ICU. PLoS One 2010; 5:e15173.",
"     </a>",
"    </li>",
"    <li>",
"     Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. Technology Appraisal No. 67. National Institute for Clinical Excellence London, 2003 www.nice.org.uk (Accessed on August 07, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/8\">",
"      Centers for Disease Control and Prevention (CDC). Update: Influenza A (H3N2)v transmission and guidelines - five states, 2011. MMWR Morb Mortal Wkly Rep 2012; 60:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/9\">",
"      Centers for Disease Control and Prevention (CDC). Notes from the field: Outbreak of influenza A (H3N2) virus among persons and swine at a county fair--Indiana, July 2012. MMWR Morb Mortal Wkly Rep 2012; 61:561.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. CDC reports cases 18-29 of H3N2v virus infection; continues to recommend interim precautions when interacting with pigs. file://www.cdc.gov/flu/spotlights/h3n2v_us_cases.htm (Accessed on August 03, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States. MMWR Morb Mortal Wkly Rep 2012; 61:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/12\">",
"      Waalen K, Kilander A, Dudman SG, et al. Age-dependent prevalence of antibodies cross-reactive to the influenza A(H3N2) variant virus in sera collected in Norway in 2011. Euro Surveill 2012; 17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/13\">",
"      Skowronski DM, Janjua NZ, De Serres G, et al. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v). J Infect Dis 2012; 206:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). Interim results: state-specific influenza vaccination coverage--United States, August 2010-February 2011. MMWR Morb Mortal Wkly Rep 2011; 60:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/15\">",
"      Centers for Disease Control and Prevention (CDC). Seasonal influenza vaccination coverage among children aged 6 months-18 years --- eight immunization information system sentinel sites, United States, 2009-10 influenza season. MMWR Morb Mortal Wkly Rep 2010; 59:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/16\">",
"      Early estimates for seasonal influenza vaccine effectiveness--United States, January 2013. MMWR Morb Mortal Wkly Rep 2013; 62.",
"     </a>",
"    </li>",
"    <li>",
"     McMenamin J, Andrews N, Robertson C, et al. Effectiveness of seasonal 2012/13 vaccine in preventing laboratory-confirmed influenza infection in primary care in the United Kindgdom: Mid-season analysis 2012/13. Euro Surveill 2013; 18:pii=20393. www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20393 (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     Skowronski D, Janjua NZ, De Serres, et al. Interim estimates of influenza vaccine effectiveness in 2012/2013 from Canada's sentinel surveillance network, January 2013. Euro Surveill 2013; 18:pii20394. www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20394 (Accessed on February 12, 2013).",
"    </li>",
"    <li>",
"     US Food and Drug Administration News Release. FDA approves first quadrivalent vaccine to prevent seasonal influenza. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294057.htm (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/20\">",
"      Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 2012; 72:2177.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Administration. Approval letter - Fluarix quadrivalent. file://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm332484.htm (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/22\">",
"      Centers for Disease Control and Prevention (CDC). Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13 influenza season. MMWR Morb Mortal Wkly Rep 2012; 61:613.",
"     </a>",
"    </li>",
"    <li>",
"     GlaxoSmithKline. FDA Approves GlaxoSmithKline&rsquo;s four-strain seasonal influenza vaccine for use in the US. file://www.gsk.com/media/press-releases/2012/FDA-pproves-GlaxoSmithKline-four-strain-seasonal-influenza-vaccine-for-use-in-the-US.html (Accessed on December 22, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2012-2013 northern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/201202_recommendation.pdf (Accessed on February 25, 2012).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013 southern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/2013_south/en/index.html (Accessed on February 06, 2013).",
"    </li>",
"    <li>",
"     World Health Organization. Recommended composition of influenza virus vaccines for use in the 2013-14 northern hemisphere influenza season. file://www.who.int/influenza/vaccines/virus/recommendations/2013_14_north/en/index.html (Accessed on March 04, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/27\">",
"      Committee on Infectious Diseases, American Academy of Pediatrics. Recommendations for prevention and control of influenza in children, 2012-2013. Pediatrics 2012; 130:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/28\">",
"      Bernstein HH, Starke JR, American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement--recommendation for mandatory influenza immunization of all health care personnel. Pediatrics 2010; 126:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/29\">",
"      Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006; 24:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/30\">",
"      Glezen WP, Gaglani MJ, Kozinetz CA, Piedra PA. Direct and indirect effectiveness of influenza vaccination delivered to children at school preceding an epidemic caused by 3 new influenza virus variants. J Infect Dis 2010; 202:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/31\">",
"      Bhat N, Wright JG, Broder KR, et al. Influenza-associated deaths among children in the United States, 2003-2004. N Engl J Med 2005; 353:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/32\">",
"      Vesikari T. Emerging data on the safety and efficacy of influenza vaccines in children. Pediatr Infect Dis J 2008; 27:S159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/33\">",
"      Wright PF, Sannella E, Shi JR, et al. Antibody responses after inactivated influenza vaccine in young children. Pediatr Infect Dis J 2008; 27:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/34\">",
"      Ambrose CS, Yi T, Walker RE, Connor EM. Duration of protection provided by live attenuated influenza vaccine in children. Pediatr Infect Dis J 2008; 27:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/35\">",
"      Bateman AC, Kieke BA, Irving SA, et al. Effectiveness of Monovalent 2009 Pandemic Influenza A Virus Subtype H1N1 and 2010-2011 Trivalent Inactivated Influenza Vaccines in Wisconsin During the 2010-2011 Influenza Season. J Infect Dis 2013; 207:1262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/36\">",
"      Ritzwoller DP, Bridges CB, Shetterly S, et al. Effectiveness of the 2003-2004 influenza vaccine among children 6 months to 8 years of age, with 1 vs 2 doses. Pediatrics 2005; 116:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/37\">",
"      Neuzil KM, Jackson LA, Nelson J, et al. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children. J Infect Dis 2006; 194:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/38\">",
"      Englund JA, Walter EB, Gbadebo A, et al. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. Pediatrics 2006; 118:e579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/39\">",
"      Frey SE, Bernstein DI, Gerber MA, et al. Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. J Infect Dis 2012; 206:828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/40\">",
"      Tosh PK, Jacobson RM, Poland GA. Influenza vaccines: from surveillance through production to protection. Mayo Clin Proc 2010; 85:257.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Influenza. In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.439.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/42\">",
"      Loeb M, Russell ML, Moss L, et al. Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA 2010; 303:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/43\">",
"      Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA 2000; 284:1677.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration. FDA approves vaccines for the 2012-2013 influenza season. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm315365.htm (Accessed on August 15, 2012).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves first seasonal influenza vaccine manufactured using cell culture technology. file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm328982.htm (Accessed on November 26, 2012).",
"    </li>",
"    <li>",
"     Flucelvax prescribing information. file://www.novartisvaccinesdirect.com/pdf/Flucelvax_PI.pdf (Accessed on November 28, 2012).",
"    </li>",
"    <li>",
"     FDA news release. FDA approves new seasonal influenza vaccine made using novel technology file://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm335891.htm (Accessed on January 17, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/48\">",
"      Skowronski DM, Masaro C, Kwindt TL, et al. Estimating vaccine effectiveness against laboratory-confirmed influenza using a sentinel physician network: results from the 2005-2006 season of dual A and B vaccine mismatch in Canada. Vaccine 2007; 25:2842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/49\">",
"      Ohmit SE, Victor JC, Rotthoff JR, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355:2513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/50\">",
"      Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008; 26 Suppl 4:D17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/51\">",
"      Giezeman KM, Nauta J, de Bruijn IA, Palache AM. Trivalent inactivated subunit influenza vaccine Influvac: 25-Year experience of safety and immunogenicity. Vaccine 2009; 27:2414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/52\">",
"      Belshe RB, Coelingh K, Ambrose CS, et al. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity. Vaccine 2010; 28:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/53\">",
"      Sambhara S, Stephenson I. Moving influenza vaccines forward. Expert Rev Vaccines 2009; 8:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/54\">",
"      DiazGranados CA, Denis M, Plotkin S. Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: a systematic review with meta-analyses of controlled trials. Vaccine 2012; 31:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/55\">",
"      Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/56\">",
"      Centers for Disease Control and Prevention (CDC). Interim within-season estimate of the effectiveness of trivalent inactivated influenza vaccine--Marshfield, Wisconsin, 2007-08 influenza season. MMWR Morb Mortal Wkly Rep 2008; 57:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/57\">",
"      Szilagyi PG, Fairbrother G, Griffin MR, et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med 2008; 162:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/58\">",
"      Eisenberg KW, Szilagyi PG, Fairbrother G, et al. Vaccine effectiveness against laboratory-confirmed influenza in children 6 to 59 months of age during the 2003-2004 and 2004-2005 influenza seasons. Pediatrics 2008; 122:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/59\">",
"      Jefferson T, Rivetti A, Di Pietrantonj C, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2012; 8:CD004879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/60\">",
"      Hoberman A, Greenberg DP, Paradise JL, et al. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003; 290:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/61\">",
"      Heinonen S, Silvennoinen H, Lehtinen P, et al. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infect Dis 2011; 11:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/62\">",
"      Kelly H, Jacoby P, Dixon GA, et al. Vaccine Effectiveness Against Laboratory-confirmed Influenza in Healthy Young Children: A Case-Control Study. Pediatr Infect Dis J 2011; 30:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/63\">",
"      Mahmud S, Hammond G, Elliott L, et al. Effectiveness of the pandemic H1N1 influenza vaccines against laboratory-confirmed H1N1 infections: population-based case-control study. Vaccine 2011; 29:7975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/64\">",
"      Allison MA, Daley MF, Crane LA, et al. Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 season. J Pediatr 2006; 149:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/65\">",
"      Bueving HJ. Is influenza vaccination in asthmatic children helpful? Clin Exp Allergy 2006; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/66\">",
"      Cates CJ, Rowe BH. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 2013; 2:CD000364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/67\">",
"      Bueving HJ, Bernsen RM, de Jongste JC, et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med 2004; 169:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/68\">",
"      Kramarz P, Destefano F, Gargiullo PM, et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr 2001; 138:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/69\">",
"      Smits AJ, Hak E, Stalman WA, et al. Clinical effectiveness of conventional influenza vaccination in asthmatic children. Epidemiol Infect 2002; 128:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/70\">",
"      Christy C, Aligne CA, Auinger P, et al. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch Dis Child 2004; 89:734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/71\">",
"      Ong BA, Forester J, Fallot A. Does influenza vaccination improve pediatric asthma outcomes? J Asthma 2009; 46:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/72\">",
"      Baxter R, Jeanfreau R, Block SL, et al. A Phase III evaluation of immunogenicity and safety of two trivalent inactivated seasonal influenza vaccines in US children. Pediatr Infect Dis J 2010; 29:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/73\">",
"      Englund JA, Walter E, Black S, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants: a randomized double-blind placebo-controlled study. Pediatr Infect Dis J 2010; 29:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/74\">",
"      Nolan T, McVernon J, Skeljo M, et al. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial. JAMA 2010; 303:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/75\">",
"      Skowronski DM, Hottes TS, Chong M, et al. Randomized controlled trial of dose response to influenza vaccine in children aged 6 to 23 months. Pediatrics 2011; 128:e276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/76\">",
"      D'Angio CT, Heyne RJ, Duara S, et al. Immunogenicity of trivalent influenza vaccine in extremely low-birth-weight, premature versus term infants. Pediatr Infect Dis J 2011; 30:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/77\">",
"      Walter EB, Rajagopal S, Zhu Y, et al. Trivalent inactivated influenza vaccine (TIV) immunogenicity in children 6 through 23 months of age: do children of all ages respond equally? Vaccine 2010; 28:4376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/78\">",
"      Halasa NB, Gerber MA, Chen Q, et al. Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 2008; 197:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/79\">",
"      Walter EB, Englund JA, Blatter M, et al. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study. Pediatr Infect Dis J 2009; 28:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/80\">",
"      Hurwitz ES, Haber M, Chang A, et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection, and clinical effectiveness. J Infect Dis 2000; 182:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/81\">",
"      American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2011-2012. Pediatrics 2011; 128:813.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Febrile seizures associated with TIV &amp; PCV13. file://www.cdc.gov/vaccines/pubs/vis/tiv-pcv-note.htm (Accessed on September 01, 2011).",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. Update on febrile seizures in children following vaccination with influenza vaccines and pneumococcal vaccines file://www.cdc.gov/vaccinesafety/Concerns/FebrileSeizures.html (Accessed on October 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/84\">",
"      Tse A, Tseng HF, Greene SK, et al. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine 2012; 30:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/85\">",
"      Belshe RB, Edwards KM, Vesikari T, et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356:685.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/86\">",
"      Skowronski DM, Jacobsen K, Daigneault J, et al. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics 2006; 117:1963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/87\">",
"      Rosenberg M, Sparks R, McMahon A, et al. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine 2009; 27:4278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/88\">",
"      Ohmit SE, Gross J, Victor JC, Monto AS. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. Vaccine 2009; 27:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/89\">",
"      Jefferson T, Rivetti A, Harnden A, et al. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 2008; :CD004879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/90\">",
"      Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA 2006; 296:1990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/91\">",
"      Greene SK, Kulldorff M, Lewis EM, et al. Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. Am J Epidemiol 2010; 171:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/92\">",
"      Glanz JM, Newcomer SR, Hambidge SJ, et al. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med 2011; 165:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/93\">",
"      McMahon AW, Iskander JK, Haber P, et al. Inactivated influenza vaccine (IIV) in children &lt;2 years of age: examination of selected adverse events reported to the Vaccine Adverse Event Reporting System (VAERS) after thimerosal-free or thimerosal-containing vaccine. Vaccine 2008; 26:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/94\">",
"      Goodman MJ, Nordin JD, Harper P, et al. The safety of trivalent influenza vaccine among healthy children 6 to 24 months of age. Pediatrics 2006; 117:e821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/95\">",
"      Skowronski DM, De Serres G, Hebert J, et al. Skin testing to evaluate oculo-respiratory syndrome (ORS) associated with influenza vaccination during the 2000-2001 season. Vaccine 2002; 20:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/96\">",
"      Phongsamart W, Sirisanthana V, Wittawatmongkol O, et al. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children. Vaccine 2011; 29:8705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/97\">",
"      Ambrose CS, Luke C, Coelingh K. Current status of live attenuated influenza vaccine in the United States for seasonal and pandemic influenza. Influenza Other Respi Viruses 2008; 2:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/98\">",
"      Cha TA, Kao K, Zhao J, et al. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 2000; 38:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/99\">",
"      Buonagurio DA, O'Neill RE, Shutyak L, et al. Genetic and phenotypic stability of cold-adapted influenza viruses in a trivalent vaccine administered to children in a day care setting. Virology 2006; 347:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/100\">",
"      Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998; 338:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/101\">",
"      Tam JS, Capeding MR, Lum LC, et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007; 26:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/102\">",
"      Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J 2009; 28:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/103\">",
"      Belshe RB, Gruber WC, Mendelman PM, et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000; 136:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/104\">",
"      Belshe RB, Ambrose CS, Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008; 26 Suppl 4:D10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/105\">",
"      Halloran ME, Longini IM Jr, Gaglani MJ, et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures. Am J Epidemiol 2003; 158:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/106\">",
"      Mendelman PM, Rappaport R, Cho I, et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 2004; 23:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/107\">",
"      Piedra PA, Gaglani MJ, Kozinetz CA, et al. Trivalent live attenuated intranasal influenza vaccine administered during the 2003-2004 influenza type A (H3N2) outbreak provided immediate, direct, and indirect protection in children. Pediatrics 2007; 120:e553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/108\">",
"      Fleming DM, Crovari P, Wahn U, et al. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J 2006; 25:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/109\">",
"      Ashkenazi S, Vertruyen A, Ar&iacute;stegui J, et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006; 25:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/110\">",
"      Ambrose CS, Wu X, Belshe RB. The efficacy of live attenuated and inactivated influenza vaccines in children as a function of time postvaccination. Pediatr Infect Dis J 2010; 29:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/111\">",
"      Hoft DF, Babusis E, Worku S, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis 2011; 204:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/112\">",
"      Luce BR, Nichol KL, Belshe RB, et al. Cost-effectiveness of live attenuated influenza vaccine versus inactivated influenza vaccine among children aged 24-59 months in the United States. Vaccine 2008; 26:2841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/113\">",
"      Block SL, Yogev R, Hayden FG, et al. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008; 26:4940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/114\">",
"      Nolan T, Bernstein DI, Block SL, et al. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age. Pediatrics 2008; 121:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/115\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Piedra PA, personal communication.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/117\">",
"      King JC Jr, Stoddard JJ, Gaglani MJ, et al. Effectiveness of school-based influenza vaccination. N Engl J Med 2006; 355:2523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/118\">",
"      Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA 2005; 294:2720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/119\">",
"      Piedra PA, Gaglani MJ, Riggs M, et al. Live attenuated influenza vaccine, trivalent, is safe in healthy children 18 months to 4 years, 5 to 9 years, and 10 to 18 years of age in a community-based, nonrandomized, open-label trial. Pediatrics 2005; 116:e397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/120\">",
"      Bergen R, Black S, Shinefield H, et al. Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J 2004; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/121\">",
"      Gaglani MJ, Piedra PA, Riggs M, et al. Safety of the intranasal, trivalent, live attenuated influenza vaccine (LAIV) in children with intermittent wheezing in an open-label field trial. Pediatr Infect Dis J 2008; 27:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?27/18/27946/abstract/122\">",
"      Vesikari T, Karvonen A, Korhonen T, et al. A randomized, double-blind study of the safety, transmissibility and phenotypic and genotypic stability of cold-adapted influenza virus vaccine. Pediatr Infect Dis J 2006; 25:590.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5960 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-D3F1CA963C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27946=[""].join("\n");
var outline_f27_18_27946=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFLUENZA ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Types of vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83326789\">",
"      Effectiveness for 2012-2013 season",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Supply",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Choice of vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Schedule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Schedule in special circumstances",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Immune suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Travelers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H79749360\">",
"      - Children with documented influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Herd immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INACTIVATED INFLUENZA VACCINE (IIV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Efficacy/effectiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Contraindications and precautions for IIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      IIV dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Administration with other vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thimerosal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H349802567\">",
"      Latex",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LIVE-ATTENUATED INFLUENZA VACCINE (LAIV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - LAIV compared with IIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Contraindications and precautions for LAIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      LAIV dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Administration with other vaccines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Asthma and wheezing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Viral shedding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24146624\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5960\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5960|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/3/12349\" title=\"figure 1\">",
"      Peak influenza activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5960|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/50/33579\" title=\"table 1\">",
"      Groups at high risk for influenza complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/31/42494\" title=\"table 2\">",
"      Influenza vaccines summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/34/3630\" title=\"table 3\">",
"      Comparison IIV LAIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/14/28908\" title=\"table 4\">",
"      Priority groups for flu vaccine if supply limited",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/4/5197\" title=\"table 5\">",
"      Choice of influenza vaccine for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42857?source=related_link\">",
"      Acute otitis media in children: Prevention of recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26746?source=related_link\">",
"      Antiviral drugs for the prevention and treatment of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/49/24346?source=related_link\">",
"      Clinical features and diagnosis of seasonal influenza in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15272?source=related_link\">",
"      Epidemiology of influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32602?source=related_link\">",
"      Immunizations during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/25/37273?source=related_link\">",
"      Immunizations in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/30/20967?source=related_link\">",
"      Influenza vaccination in individuals with egg allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/6/40038?source=related_link\">",
"      Pathogenesis of Guillain-Barr&eacute; syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/12/39105?source=related_link\">",
"      Patient information: Influenza prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/12/35013?source=related_link\">",
"      Patient information: Influenza symptoms and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/56/39818?source=related_link\">",
"      Standard immunizations for children and adolescents",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f27_18_27947="Living wills pregnancy";
var content_f27_18_27947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57771&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Twenty-six states in which living wills are not valid if the woman is pregnant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Alabama",
"       </td>",
"       <td>",
"        Arkansas",
"       </td>",
"       <td>",
"        California",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Colorado",
"       </td>",
"       <td>",
"        Connecticut",
"       </td>",
"       <td>",
"        Georgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hawaii",
"       </td>",
"       <td>",
"        Idaho",
"       </td>",
"       <td>",
"        Illinois",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Indiana",
"       </td>",
"       <td>",
"        Iowa",
"       </td>",
"       <td>",
"        Kentucky",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minnesota",
"       </td>",
"       <td>",
"        Missouri",
"       </td>",
"       <td>",
"        North Dakota",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        North Carolina",
"       </td>",
"       <td>",
"        Ohio*",
"       </td>",
"       <td>",
"        Oklahoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pennsylvania",
"       </td>",
"       <td>",
"        Rhode Island*",
"       </td>",
"       <td>",
"        South Dakota",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Texas",
"       </td>",
"       <td>",
"        Utah",
"       </td>",
"       <td>",
"        Washington",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wisconsin",
"       </td>",
"       <td>",
"        Wyoming",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Not valid only if fetus could develop sufficiently for a live birth.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ezekiel Emanuel, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27947=[""].join("\n");
var outline_f27_18_27947=null;
var title_f27_18_27948="Anatomic physiologic classification myoclonus";
var content_f27_18_27948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Anatomic and physiologic classification of common types of myoclonus*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cortical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Asterixis (some cases)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Epilepsia partialis continua",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical reflex myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cortical myoclonus without exaggerated reflex features",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Certain drug-induced and toxic-metabolic etiologies of myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Neurodegenerative disease with cortical involvement:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Alzheimer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Corticobasal degeneration",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Creutzfeldt-Jakob disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Huntington disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        - Parkinson disease and other Lewy body disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Posthypoxic action myoclonus (Lance-Adams myoclonus)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive myoclonic ataxias",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Progressive myoclonic epilepsies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cortical-subcortical",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary generalized epileptic myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary generalized myoclonic seizures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Subcortical-nonsegmental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Essential myoclonus (hereditary)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hyperekplexia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Opsoclonus-myoclonus syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Propriospinal myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reticular reflex myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Segmental",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palatal myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Segmental spinal myoclonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Peripheral",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemifacial spasm",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * More than one mechanism may be operative in an individual patient or disease.",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Caviness, JN, Brown, P. Myoclonus: current concepts and recent advances. Lancet Neurol 2004; 3:598.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27948=[""].join("\n");
var outline_f27_18_27948=null;
var title_f27_18_27949="Choking game risk factors";
var content_f27_18_27949=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Demographic characteristics and risk factors for participation in the \"choking game\" among 8th-grade students: Oregon Healthy Teens survey, 2008",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Characteristic/risk factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        No. (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Prevalence of reported participation in choking game (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        PR (95% CI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        p-value",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Sex",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male",
"       </td>",
"       <td>",
"        3642 (47)",
"       </td>",
"       <td>",
"        6.1",
"       </td>",
"       <td>",
"        Referent",
"       </td>",
"       <td>",
"        0.13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female",
"       </td>",
"       <td>",
"        4115 (53)",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        0.9 (0.6-1.2)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Geography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Urban",
"       </td>",
"       <td>",
"        3944 (55)",
"       </td>",
"       <td>",
"        4.9",
"       </td>",
"       <td>",
"        Referent",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rural",
"       </td>",
"       <td>",
"        3813 (45)",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"       <td>",
"        1.4 (1.0-1.9)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Race/Ethnicity",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        White",
"       </td>",
"       <td>",
"        5298 (66)",
"       </td>",
"       <td>",
"        5.4",
"       </td>",
"       <td>",
"        Referent",
"       </td>",
"       <td>",
"        0.009",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hispanic",
"       </td>",
"       <td>",
"        1184 (16)",
"       </td>",
"       <td>",
"        7.7",
"       </td>",
"       <td>",
"        1.4 (1.0-2.0)",
"       </td>",
"       <td rowspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        American Indian/Alaska Native",
"       </td>",
"       <td>",
"        518 (7)",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        1.4 (1.0-2.0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Black",
"       </td>",
"       <td>",
"        220 (4)",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"       <td>",
"        0.8 (0.5-1.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Native Hawaiian",
"       </td>",
"       <td>",
"        144 (2)",
"       </td>",
"       <td>",
"        3.4",
"       </td>",
"       <td>",
"        0.6 (0.3-1.5)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asian",
"       </td>",
"       <td>",
"        308 (5)",
"       </td>",
"       <td>",
"        2.8",
"       </td>",
"       <td>",
"        0.5 (0.2-1.7)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Mental health or substance use",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        None",
"       </td>",
"       <td>",
"        3525 (45)",
"       </td>",
"       <td>",
"        1.7",
"       </td>",
"       <td>",
"        Referent",
"       </td>",
"       <td>",
"        &lt;0.001",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mental health only",
"       </td>",
"       <td>",
"        1878 (25)",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        2.3 (1.3-4.1)",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Substance use only",
"       </td>",
"       <td>",
"        880 (11)",
"       </td>",
"       <td>",
"        7.9",
"       </td>",
"       <td>",
"        4.6 (2.7-7.8)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Substance use and mental health",
"       </td>",
"       <td>",
"        1456 (19)",
"       </td>",
"       <td>",
"        15.8",
"       </td>",
"       <td>",
"        9.2 (5.8-14.7)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PR: prevalence ratio; CI: confidence interval.",
"     <br>",
"      * Based on response to the following survey item: \"The next question refers to the 'Choking Game', also called Knock Out, Space Monkey, Flatlining, or the Fainting Game. This is an activity that some youth participate in to get a high by cutting off blood and oxygen to the brain with a belt, towel, rope, or other item. Which of the following is true for you? (Please mark all that apply.) a. I have never heard of the Choking Game; b. I've heard of someone participating in the Choking Game; c. I have helped someone else participate in the Choking Game; d. I have participated in the Choking Game myself.",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       Persons identified as white, American Indian/Alaska Native, black, Native Hawaiian, and Asian are all non-Hispanic. Race/ethnicity categories are mutually exclusive.",
"       <br>",
"        &Delta; \"Mental health only\" included youths who answered \"yes\" to at least one of four mental health risk questions: 1) contemplated suicide in past 12 months; 2) self-rated mental health status as \"fair\" or \"poor\" (versus \"excellent\", \"very good\", or \"good\"); 3) had an unmet mental health need in the past 12 months; or 4) gambled for money in the past 12 months. Youths indicating a substance use risk were excluded. \"Substance use only\" included youths who indicated using at least one of four substances in the past 30 days: 1) alcohol; 2) cigarettes; 3) marijuana; or 4) other illegal drugs (eg, stimulants, LSD, ecstasy, cocaine, or heroin). Youths indicating a mental health risk factor were excluded. \"Substance use and mental health\" included youths indicating a mental health risk factor and substance use.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. \"Choking Game\" Awareness and Participation Among 8th Graders - Oregon, 2008. MMWR 2010; 59:3.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27949=[""].join("\n");
var outline_f27_18_27949=null;
var title_f27_18_27950="Nutrition assessment in children";
var content_f27_18_27950=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63820&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Assessment of nutritional factors related to childhood obesity",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Nutritional factor",
"       </td>",
"       <td class=\"subtitle1\">",
"        Contribution to weight gain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Examples of questions for clinical assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        <strong>",
"         Restaurants and fast food",
"        </strong>",
"       </td>",
"       <td rowspan=\"2\">",
"        Meals eaten away from home increase portion size and total energy intake, and are of poorer nutrient quality",
"        <sup>",
"         [1-6]",
"        </sup>",
"        . Increased frequency of eating meals away from home is associated with increased BMI",
"        <sup>",
"         [7,8]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        \"How many times a week does your family get takeout food?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How many meals a week does your family eat at a restaurant or eat fast food?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Sweetened beverages",
"        </strong>",
"       </td>",
"       <td>",
"        High&nbsp;intake of sugar-sweetened beverages is&nbsp;linked to increased prevalence of obesity in children",
"        <sup>",
"         [9-11]",
"        </sup>",
"        , but causality has not been established",
"        <sup>",
"         [12]",
"        </sup>",
"        . Fruit juice also should be considered a sweetened beverage.",
"       </td>",
"       <td>",
"        \"How many times a day, or how many ounces, does your child drink the following: juice, soda, flavored milk, sports drinks, or sweetened tea?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Portion sizes",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Larger portions lead to increased energy intake",
"        <sup>",
"         [13-15]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        \"Are seconds or large portions a challenge for your child?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How many baseball-size servings of pasta, rice, or cereal does your child eat at a meal?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How many decks of cards of meat or protein does your child eat at a meal?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Energy-dense foods",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        An association between energy dense foods and obesity has been established in adults, but not yet in children",
"        <sup>",
"         [15]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        \"How often does your child eat fried foods?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"What does your child typically eat for snacks?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"What type of milk, cheese, cereal, and protein do you have at home?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Fruits and vegetables",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Eating fruits and vegetables may displace more energy dense foods and increase satiety. There is some evidence that low consumption of these foods is associated with&nbsp; obesity",
"        <sup>",
"         [16-18]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        \"What fruits and vegetables do you currently have in your home?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How often does your child eat vegetables at lunch or dinner?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"At which meals or snacks does your child eat fruit?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <strong>",
"         Breakfast",
"        </strong>",
"       </td>",
"       <td rowspan=\"3\">",
"        Skipping breakfast associated with increasing obesity in children despite perceived decrease in daily caloric intake",
"        <sup>",
"         [19-23]",
"        </sup>",
"        , and has adverse effects on school performance",
"        <sup>",
"         [24-26]",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        \"When is the first time your child typically has&nbsp;something to eat or drink after waking up?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Does your child eat breakfast at home or at school?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How often does your child skip breakfast?\"",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Meal frequency and snacking",
"        </strong>",
"       </td>",
"       <td rowspan=\"4\">",
"        Snacking tends to result in increased energy intake and poorer diet quality; a direct association between snacking and obesity in children has not been established.",
"       </td>",
"       <td>",
"        \"When does your child eat meals and snacks at home?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Where does your child eat their snacks?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How long after a meal does your child eat a snack?\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"How many snacks does your child eat on the weekends?\"",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Whitlock EP, O'Connor EA, Williams SB, Beil TL, Lutz KW. Effectiveness of Weight Management Interventions in Children: A Targeted Systematic Review for the USPSTF. Pediatrics 2010.",
"       </li>",
"       <li>",
"        Paeratakul S, Ferdinand DP, Champagne CM, Ryan DH, Bray GA. Fast-food consumption among US adults and children: dietary and nutrient intake profile. J Am Diet Assoc 2003; 103:1332-8.",
"       </li>",
"       <li>",
"        Diliberti N, Bordi PL, Conklin MT, Roe LS, Rolls BJ. Increased portion size leads to increased energy intake in a restaurant meal. Obes Res 2004; 12:562-8.",
"       </li>",
"       <li>",
"        Bowman SA, Gortmaker SL, Ebbeling CB, Pereira MA, Ludwig DS. Effects of fast-food consumption on energy intake and diet quality among children in a national household survey. Pediatrics 2004; 113:112-8.",
"       </li>",
"       <li>",
"        French SA, Story M, Neumark-Sztainer D, Fulkerson JA, Hannan P. Fast food restaurant use among adolescents: associations with nutrient intake, food choices and behavioral and psychosocial variables. Int J Obes Relat Metab Disord 2001; 25:1823-33.",
"       </li>",
"       <li>",
"        Nielsen SJ, Siega-Riz AM, Popkin BM. Trends in food locations and sources among adolescents and young adults. Prev Med 2002; 35:107-13.",
"       </li>",
"       <li>",
"        Schmidt M, Affenito SG, Striegel-Moore R, Khoury PR, Barton B, Crawford P, Kronsberg S, Schreiber G, Obarzanek E, Daniels S. Fast-food intake and diet quality in black and white girls: the National Heart, Lung, and Blood Institute Growth and Health Study. Arch Pediatr Adolesc Med 2005; 159:626-31.",
"       </li>",
"       <li>",
"        Thompson OM, Ballew C, Resnicow K, Must A, Bandini LG, Cyr H, Dietz WH. Food purchased away from home as a predictor of change in BMI z-score among girls. Int J Obes Relat Metab Disord 2004; 28:282-9.",
"       </li>",
"       <li>",
"        Pereira MA, Kartashov AI, Ebbeling CB, Van Horn L, Slattery ML, Jacobs DR Jr, Ludwig DS. Fast-food habits, weight gain, and insulin resistance (the CARDIA study): 15-year prospective analysis. Lancet 2005; 365:36-42.",
"       </li>",
"       <li>",
"        Ludwig DS, Peterson KE, Gortmaker SL. Relation between consumption of sugar-sweetened drinks and childhood obesity: a prospective, observational analysis. Lancet 2001; 357:505-8.",
"       </li>",
"       <li>",
"        Harnack L, Stang J, Story M. Soft drink consumption among US children and adolescents: nutritional consequences. J Am Diet Assoc 1999; 99:436-41.",
"       </li>",
"       <li>",
"        Tordoff MG, Alleva AM. Effect of drinking soda sweetened with aspartame or high-fructose corn syrup on food intake and body weight. Am J Clin Nutr 1990; 51:963-9.",
"       </li>",
"       <li>",
"        Lewis CJ, Park YK, Dexter PB, Yetley EA. Nutrient intakes and body weights of persons consuming high and moderate levels of added sugars. J Am Diet Assoc 1992; 92:708-13. Rolls BJ, Engell D, Birch LL. Serving portion size influences 5-year-old but not 3-year-old children's food intakes. J Am Diet Assoc 2000; 100:232-4.",
"       </li>",
"       <li>",
"        Krebs NF, Himes JH, Jacobson D, Nicklas TA, Guilday P, Styne D. Assessment of child and adolescent overweight and obesity. Pediatrics 2007; 120 Suppl 4:S193-228.",
"       </li>",
"       <li>",
"        Orlet Fisher J, Rolls BJ, Birch LL. Children's bite size and intake of an entree are greater with large portions than with age-appropriate or self-selected portions. Am J Clin Nutr 2003; 77:1164-70.",
"       </li>",
"       <li>",
"        McCrory MA, Fuss PJ, Hays NP, Vinken AG, Greenberg AS, Roberts SB. Overeating in America: association between restaurant food consumption and body fatness in healthy adult men and women ages 19 to 80. Obes Res 1999; 7:564-71.",
"       </li>",
"       <li>",
"        Bazzano LA, He J, Ogden LG, Loria CM, Vupputuri S, Myers L, Whelton PK. Fruit and vegetable intake and risk of cardiovascular disease in US adults: the first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Am J Clin Nutr 2002; 76:93-9.",
"       </li>",
"       <li>",
"        Maskarinec G, Novotny R, Tasaki K. Dietary patterns are associated with body mass index in multiethnic women. J Nutr 2000; 130:3068-72.",
"       </li>",
"       <li>",
"        Wolfe WS, Campbell CC, Frongillo EA Jr, Haas JD, Melnik TA. Overweight schoolchildren in New York State: prevalence and characteristics. Am J Public Health 1994; 84:807-13.",
"       </li>",
"       <li>",
"        Gibson SA, O'Sullivan KR. Breakfast cereal consumption patterns and nutrient intakes of British schoolchildren. J R Soc Health 1995; 115:366-70.",
"       </li>",
"       <li>",
"        Ortega RM, Requejo AM, Lopez-Sobaler AM, Quintas ME, Andres P, Redondo MR, Navia B, Lopez-Bonilla MD, Rivas T. Difference in the breakfast habits of overweight/obese and normal weight schoolchildren. Int J Vitam Nutr Res 1998; 68:125-32.",
"       </li>",
"       <li>",
"        Pastore DR, Fisher M, Friedman SB. Abnormalities in weight status, eating attitudes, and eating behaviors among urban high school students: correlations with self-esteem and anxiety. J Adolesc Health 1996; 18:312-9.",
"       </li>",
"       <li>",
"        Summerbell CD, Moody RC, Shanks J, Stock MJ, Geissler C. Relationship between feeding pattern and body mass index in 220 free-living people in four age groups. Eur J Clin Nutr 1996; 50:513-9.",
"       </li>",
"       <li>",
"        Wyatt HR, Grunwald GK, Mosca CL, Klem ML, Wing RR, Hill JO. Long-term weight loss and breakfast in subjects in the National Weight Control Registry. Obes Res 2002; 10:78-82.",
"       </li>",
"       <li>",
"        Murphy JM, Pagano ME, Nachmani J, Sperling P, Kane S, Kleinman RE. The relationship of school breakfast to psychosocial and academic functioning: cross-sectional and longitudinal observations in an inner-city school sample. Arch Pediatr Adolesc Med 1998; 152:899-907.",
"       </li>",
"       <li>",
"        Ross MM, Kolbash S, Cohen GM, Skelton JA. Multidisciplinary treatment of pediatric obesity: nutrition evaluation and management. Nutr Clin Pract 2010; 25:327-34.",
"       </li>",
"      </ol>",
"      <br>",
"       Data from:",
"       <br>",
"        Krebs NF, et al. Pediatrics 2007; 120:S193.",
"        <br>",
"         Ross MM, et al. Nutr Clin Pract 2010; 25:327.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27950=[""].join("\n");
var outline_f27_18_27950=null;
var title_f27_18_27951="Stone related cystic duct leak";
var content_f27_18_27951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stone-related cystic duct stump leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 266px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrates an incomplete cholecystectomy and cystic duct leak with retained common bile duct stones.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f27_18_27951=[""].join("\n");
var outline_f27_18_27951=null;
